



National
Comprehensive
Cancer
Network®

NCCN Clinical Practice Guidelines in Oncology™

Prevention and Treatment of Cancer- Related Infections

V.1.2008

Continue

www.nccn.org

NCCN Prevention and Treatment of Cancer-Related Infections Panel Members

* Brahm H. Segal, MD/Co-Chair Φ
Roswell Park Cancer Institute

* Lindsey Robert Baden, MD/Co-Chair Φ
Dana-Farber/Brigham and Women's
Cancer Center | Massachusetts General
Hospital Cancer Center

Arthur E. Brown, MD Φ
Memorial Sloan-Kettering Cancer Center

Corey Casper, MD, MPH Φ
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Erik Dubberke, MD Φ
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Alison G. Freifeld, MD Φ ρ
UNMC Eppley Cancer Center at The
Nebraska Medical Center

Michael Gelfand, MD Φ
St. Jude Children's Research
Hospital/University of Tennessee
Cancer Institute

John N. Greene, MD Φ ρ
H. Lee Moffitt Cancer Center &
Research Institute

Michael G. Ison, MD, MS Φ
Robert H. Lurie Comprehensive
Cancer Center at Northwestern
University

James I. Ito, MD Φ
City of Hope

Judith E. Karp, MD \ddagger ρ
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Daniel R. Kaul, MD Φ
University of Michigan Comprehensive
Cancer Centerr

Earl King, MD Ξ
Fox Chase Cancer Cente

Emily Mackler, PharmD Σ
University of Michigan Comprehensive
Cancer Center

Guido Marcucci, MD ρ \dagger
Arthur G. James Cancer Hospital &
Richard J. Solove Research Institute at
The Ohio State University

Jose G. Montoya, MD
Stanford Comprehensive Cancer
Center

Ashley Morris-Engemann, PharmD Σ
Duke Comprehensive Cancer Center

Ken Rolston, MD
The University of Texas M.D. Anderson
Cancer Center

Angelina S. The, MD \dagger ρ
University of Alabama at Birmingham
Comprehensive Cancer Center

Φ Infectious diseases
 \ddagger Hematology/Hematology oncology
 ρ Internal medicine
 Ξ Pulmonary medicine
 \dagger Medical oncology
 Σ Pharmacology
* Writing committee member

Continue

Table of Contents[NCCN Prevention and Treatment of Cancer-Related Infections Panel Members](#)[Antimicrobial Prophylaxis \(INF-1\)](#)[Antibacterial Prophylaxis \(INF-2\)](#)[Antifungal Prophylaxis \(INF-3\)](#)[Antiviral Prophylaxis \(INF-4\)](#)[Antipneumocystis Prophylaxis \(INF-5\)](#)[Prevention of Cytomegalovirus Disease \(INF-6\)](#)[Fever and Neutropenia \(FEV-1\)](#)[Initial Therapy \(FEV-2\)](#)[Initial Risk Assessment for Febrile Neutropenic Patients \(FEV-3\)](#)[Site Specific Evaluation and Therapy:](#)

- [Mouth, Esophagus and Sinus/Nasal \(FEV-4\)](#)
- [Abdominal Pain, Perirectal Pain, Diarrhea, Vascular Access Devices \(FEV-5\)](#)
- [Lung Infiltrates \(FEV-6\)](#)
- [Cellulitis, Wound, Vesicular Lesions, Disseminated Papules or Other Lesions, Urinary Tract Symptoms, Central Nervous System Symptoms \(FEV-7\)](#)

[Principles of Daily Follow-Up \(FEV-8\)](#)[Follow-Up Therapy for Responding Patients \(FEV-9\)](#)[Follow-Up Therapy for Nonresponding Patients \(FEV-12\)](#)[Outpatient Therapy for Low Risk Patients \(FEV-13\)](#)[Antibacterial Agents Table \(FEV-A\)](#)[Antifungal Agents Table \(FEV-B\)](#)[Antiviral Agents Table \(FEV-C\)](#)[Appropriate Use of Vancomycin \(FEV-D\)](#)[Risk Assessment Resources \(FEV-E\)](#)[Adjunctive Therapies \(FEV-F\)](#)[Guidelines Index](#)[Print the Prevention and Treatment of Cancer-Related Infections Guideline](#)**[For help using these documents, please click here](#)**[Manuscript](#)[References](#)

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical_trials/physician.html](#)

NCCN Categories of Consensus: All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations or warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. © 2008.

SUMMARY OF GUIDELINES UPDATES

Prior NCCN guidelines on infections in patients with cancer focused primarily on the management of fever and neutropenia. Reflecting the heterogeneity of immunocompromised conditions in patients with cancer and the spectrum of pathogens to which they are susceptible, the NCCN expanded the scope of our panel to create guidelines on “Prevention and Treatment of Cancer-Related Infections” to expand the “Fever and Neutropenia” guidelines. Although neutropenia remains a key risk factor for infections, other immunocompromised states pose at least equal risk. Allogeneic hematopoietic stem cell transplant (HSCT) recipients with neutrophil recovery who require intensive immunosuppressive therapy for graft-versus-host disease (GVHD) are an example of non-neutropenic patients at great risk for common bacterial and opportunistic infections. We also make new recommendations on other highly immunocompromised patients with cancer such as those receiving high-dose corticosteroids, purine analogues, and alemtuzumab. Indeed, prior NCCN guidelines on fever and neutropenia have addressed infections in the non-neutropenic setting. In the current guidelines, the subject of infections in neutropenic and immunocompromised non-neutropenic patients with cancer are given equal weight.

We expanded the definitions applied to assessment of risk of infections. In patients with neutropenia, the risk of infections is related to the degree and duration of neutropenia. In non-neutropenic, immunocompromised patients, the level of risk may be more difficult to define. For example, in non-neutropenic allogeneic HSCT recipients, the risk of opportunistic fungal and viral infections is strongly related to the degree of GVHD and intensity of immunosuppressive therapy. Therapy with purine analogues and alemtuzumab leads to prolonged suppression of cellular immunity. Host factors were used to stratify the risk for specific infectious complications and were incorporated into new algorithms for prophylaxis, diagnosis, and early therapy in specific patient groups.

We also made modifications related to prophylaxis and early treatment of specific infectious diseases. These modifications were based on the availability of newer antibiotic agents and diagnostics and recent clinical trial data. The new guidelines address the benefits and trade-offs of quinolone prophylaxis in neutropenic patients in light of new data from randomized studies. In addition, the availability of newer broad spectrum antifungal agents with a good safety profile raise the possibility of using mold-active prophylaxis in patients at high risk for invasive fungal infections without the need to empirically modify antifungal therapy solely on persistent neutropenic fever of unknown etiology. Algorithms that include chest CT scans and laboratory surrogates for invasive fungal infections are discussed.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

OVERALL INFECTION RISK IN CANCER PATIENTS ^a	DISEASE / THERAPY EXAMPLES	FEVER & NEUTROPENIA RISK CATEGORY (See FEV-3)	ANTIMICROBIAL PROPHYLAXIS ^{b,c,d,e}
Low	<ul style="list-style-type: none"> • Standard chemotherapy regimens for most solid tumors • Anticipated neutropenia less than 7 d 	Low	<ul style="list-style-type: none"> • Bacterial - None • Fungal - None • Viral - None unless prior HSV episode
Intermediate	<ul style="list-style-type: none"> • Autologous HSCT • Lymphoma • Multiple myeloma • CLL • Purine analog therapy (ie, Fludarabine, 2-CdA) • Anticipated neutropenia 7 to 10 d 	Usually HIGH, but some experts suggest modifications depending on patient status	<ul style="list-style-type: none"> • Bacterial - Consider fluoroquinolone prophylaxis • Fungal - Consider fluconazole during neutropenia and for anticipated mucositis • Viral - During neutropenia and at least 30 d after HSCT
High	<ul style="list-style-type: none"> • Allogeneic HSCT • Acute leukemia <ul style="list-style-type: none"> ➢ Induction ➢ Consolidation • Alemtuzumab therapy • GVHD treated with high dose steroids • Anticipated neutropenia greater than 10 d 	Usually HIGH, but significant variability exists related to duration of neutropenia, immunosuppressive agents, and status of underlying malignancy	<ul style="list-style-type: none"> • Bacterial - Consider fluoroquinolone prophylaxis • Fungal - See INF-3 • Viral - during neutropenia and at least 30 d after HSCT

KEY: 2-CdA = chlorodeoxyadenosine (cladribine), CLL = chronic lymphocytic leukemia, CMV = cytomegalovirus, GVHD = graft versus host disease, HSCT = hematopoietic stem cell transplant, HSV = herpes simplex virus, VZV = varicella zoster virus.

^aGeneral categories based on observational studies, duration of neutropenia, underlying disease, intensity of chemotherapy, and other immunomodulatory therapies.

^bPneumocystis prophylaxis ([See INF-5](#)).


^c[See Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.

^d[See Antifungal Agents \(FEV-B\)](#) for dosing, spectrum and specific comments/cautions.

^e[See Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




^aGeneral categories based on observational studies, duration of neutropenia, underlying disease, intensity of chemotherapy, and other immunomodulatory therapies.

^cSee [Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.

^fAlthough there are data to support levofloxacin prophylaxis for low and intermediate risk patients, the panel discourages this practice in low-risk patients (because of concerns about antimicrobial resistance); however, it can be considered in intermediate-risk patients.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^aGeneral categories based on duration of neutropenia, underlying disease, intensity of chemotherapy, and other immunomodulatory therapies.

^dSee [Antifungal Agents \(FEV-B\)](#) for dosing, spectrum, and specific comments/cautions.

^gConsider antifungal prophylaxis in all patients with GVHD receiving immunosuppressive therapy. See Antifungal Prophylaxis section of the manuscript.

^hSevere mucositis is a risk factor for candidemia in patients with hematologic malignancies and stem cell transplant recipients not receiving antifungal prophylaxis.

ⁱItraconazole, voriconazole, and posaconazole are more potent inhibitors of hepatic cytochrome P450 A isoenzymes than fluconazole and may significantly decrease the clearance of vinca alkaloids.

^jA lipid formulation is generally preferred based on less toxicity.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

OVERALL INFECTION RISK IN CANCER PATIENTS ^a	DISEASE / THERAPY EXAMPLES	VIRUSES	ANTIVIRAL PROPHYLAXIS	DURATION OF ANTIVIRAL PROPHYLAXIS ^e
Low	<ul style="list-style-type: none"> • Standard chemotherapy regimens for solid tumors 	HSV	None unless prior HSV episode	During neutropenia
Intermediate	<ul style="list-style-type: none"> • Autologous HSCT • Lymphoma • Multiple Myeloma • CLL • Purine analog therapy (ie, Fludarabine, 2-CdA) 	HSV VZV	Acyclovir Famciclovir Valacyclovir	During neutropenia and at least 30 d after HSCT
High	<ul style="list-style-type: none"> • Acute leukemia <ul style="list-style-type: none"> ▸ Induction ▸ Consolidation 	HSV	Acyclovir Famciclovir Valacyclovir	During neutropenia
	<ul style="list-style-type: none"> • Alemtuzumab therapy • Allogeneic HSCT 	HSV VZV CMV	Acyclovir Famciclovir ^k or Valacyclovir as HSV prophylaxis ^l (See INF-6) for CMV	HSV prophylaxis ^l <ul style="list-style-type: none"> • Minimum of 2 mo after alemtuzumab and until CD4 ≥ 200 cells/mcL • During neutropenia and at least 30 d after HSCT Pre-emptive therapy for CMV (See INF-6)

KEY: 2-CdA = chlorodeoxyadenosine (cladribine), CLL = chronic lymphocytic leukemia, CMV = cytomegalovirus, GVHD = graft versus host disease, HSCT = hematopoietic stem cell transplant, HSV = herpes simplex virus, VZV = varicella zoster virus.

^aGeneral categories based on observational studies, duration of neutropenia, underlying disease, intensity of chemotherapy, and other immunomodulatory therapies.

^e[See Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.

^kAmong allogeneic HSCT, there is more experience with acyclovir and valacyclovir than famciclovir.

^lAgents used as HSV prophylaxis are also active against VZV, although higher doses may be optimal for VZV prophylaxis ([See FEV-C](#)).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.


INFECTION RISK IN
CANCER PATIENTS^a

DISEASE / THERAPY EXAMPLES

DURATION OF
PROPHYLAXIS

ANTIPNEUMOCYSTIS
PROPHYLAXIS^e

High risk for
Pneumocystis jirovecii
(*Pneumocystis carinii*)



TMP/SMX (preferred)
or
Dapsone, aerosolized
pentamidine, or
atovaquone^o if
TMP/SMX intolerant^o

^aGeneral categories based on duration of neutropenia, underlying disease, intensity of chemotherapy, and other immunomodulatory therapies.

^eSee [Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.

^mRisk of PCP is related to the daily dose and duration of corticosteroid therapy. Prophylaxis against PCP can be considered in patients receiving the prednisone equivalent of 20 mg or more daily for 4 or more weeks.

ⁿPCP prophylaxis should be used when temozolomide is administered concomitantly with radiation therapy and should be continued until recovery from lymphocytopenia.

^oConsider trimethoprim/sulfamethoxazole desensitization or dapsone, aerosolized pentamidine, or atovaquone when *Pneumocystis jirovecii* pneumonia prophylaxis is required, and patients are trimethoprim/sulfamethoxazole intolerant.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PREVENTION OF CYTOMEGALOVIRUS DISEASE

INFECTION RISK IN CANCER PATIENTS ^a	DISEASE / THERAPY EXAMPLES	SURVEILLANCE PERIOD ^p	PRE-EMPTIVE THERAPY ^{e,q}
High risk for Cytomegalovirus disease	Allogeneic stem cell transplant recipients	<ul style="list-style-type: none"> • 1 to 6 months after transplant • GVHD • CD4 < 100 cells/mcL 	Ganciclovir or Foscarnet or Valganciclovir
	Alemtuzumab	For a minimum of 2 mo after alemtuzumab and until CD4 ≥ 100 cells/mcL	

^aGeneral categories based on duration of neutropenia, underlying disease, intensity of chemotherapy, and other immunomodulatory therapies.

^eSee [Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.

^pCMV surveillance consists of at least weekly monitoring of CMV by PCR or antigen testing.

^qDuration of prophylaxis antiviral therapy generally is for at least 2 weeks and until CMV is no longer detected.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CLINICAL PRESENTATION

INITIAL EVALUATION OF
FEVER AND NEUTROPENIA

PRIMARY CULTURES

- Fever:**
- Single temperature $\geq 38.3^{\circ}\text{C}$ orally or $\geq 38.0^{\circ}\text{C}$ over 1 h
- Neutropenia:**
- < 500 neutrophils/mcL or $< 1,000$ neutrophils/mcL and a predicted decline to $\leq 500/\text{mcL}$ over the next 48 h



- Site specific H&P including:**
- Intravascular access device
 - Skin
 - Lungs and sinus
 - Alimentary canal (mouth, pharynx, esophagus, bowel, rectum)
 - Perivaginal/perirectal
- Supplementary historical information:**
- Major comorbid illness
 - Time since last chemotherapy administration
 - History of prior documented infections
 - Recent antibiotic therapy/prophylaxis
 - Medications
 - HIV status
 - Exposures:
 - Others at home with similar symptoms
 - Pets
 - Travel
 - Tuberculosis exposure
 - Recent blood product administration
- Laboratory/radiology assessment:**
- CBC including differential, platelets, BUN, electrolytes, creatinine, and LFTs
 - Consider chest x-ray, urinalysis, pulse oximetry
 - Chest x-ray for all patients with respiratory symptoms



- Blood culture x 2 sets (one set consists of 2 bottles). Options include:
 - One peripheral + one catheter^a or
 - Both peripheral or
 - Both catheter
- Urine (if symptoms, urinary catheter, abnormal urinalysis)
- Site-specific culture:
 - Diarrhea (*Clostridium difficile* assay, enteric pathogen screen)
 - Skin (aspirate/biopsy of skin lesions)
 - Vascular access cutaneous site with inflammation (consider routine/fungal/mycobacteria)
- Viral cultures:
 - Vesicular/ulcerated lesions on skin or mucosa
 - Throat or nasopharynx for respiratory virus symptoms, especially during seasonal outbreaks

[See Initial Therapy \(FEV-2\)](#)

^aPreferred for distinguishing catheter-related infections from secondary sources.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

INITIAL THERAPY FOR FEVER AND NEUTROPENIA^{b,c}

Initial antibiotic therapy should be based on:

- Infection risk assessment ([See FEV-3](#))
- Potential infecting organisms include vancomycin-resistant enterococcus (VRE) and extended spectrum beta-lactamase (ESBL)
- Colonization with or prior infection with methicillin-resistant *S. aureus* (MRSA)
- Site of infection
- Local antibiotic susceptibility patterns
- Organ dysfunction/drug allergy
- Broad spectrum of activity
- Previous antibiotic therapy
- Antipseudomonal coverage
- Bactericidal



- Intravenous antibiotic monotherapy (choose one):
 - ▶ Cefepime (category 1)^d
 - ▶ Ceftazidime^e (category 2B)
 - ▶ Imipenem/cilastatin (category 1)
 - ▶ Meropenem (category 1)
 - ▶ Piperacillin/tazobactam^f (category 1)
- Intravenous antibiotic combination therapy:
 - ▶ Aminoglycoside^g + antipseudomonal penicillin (category 1) ± beta-lactamase inhibitor (category 1)
 - ▶ Aminoglycoside + extended-spectrum cephalosporin (cefepime, ceftazidime)
 - ▶ Ciprofloxacin + antipseudomonal penicillin (category 1)
 - ▶ Use of vancomycin, linezolid, daptomycin or quinupristin/dalfopristin is not routinely recommended^{h,i}
- Oral antibiotic combination therapy for low risk patients:
 - ▶ Ciprofloxacin + amoxicillin/clavulanate (category 1) (for penicillin-allergic patients, may use ciprofloxacin + clindamycin)
 - ▶ Oral antibiotic regimen recommended should not be used if quinolone prophylaxis was used



Site-Specific Evaluation and Therapy:

[Mouth, Esophagus and Sinus/Nasal \(FEV-4\)](#)

[Abdominal Pain, Perirectal Pain, Diarrhea, Vascular Access Devices \(FEV-5\)](#)

[Lung Infiltrates \(FEV-6\)](#)

[Cellulitis, Wound, Vesicular Lesions, Disseminated Papules or other lesions, Urinary Tract Symptoms, Central Nervous System Symptoms \(FEV-7\)](#)

OR

[Follow-up \(FEV-8\)](#)

^bConsider local susceptibility patterns when choosing therapy.

^c[See Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.

^dA recent meta-analysis reported increased mortality associated with cefepime in randomized trials of neutropenic fever (see manuscript).

^eWeak Gram-positive coverage and increased breakthrough infections limit utility.

^fMay interfere with galactomannan measurement.

^gSome authorities recommend avoidance of aminoglycosides because of potential nephrotoxicity, which may be diminished by once-daily administration. Once-a-day aminoglycoside therapy should be avoided for treatment of meningitis or endocarditis.

^hAlthough there are published studies recommending use of these agents; the NCCN panel strongly recommends that these agents should not be used routinely because of concerns about resistance and breakthrough infections.

ⁱ[See Appropriate Use of Vancomycin and Other Agents for Gram-positive Resistant Infections \(FEV-D\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

INITIAL RISK ASSESSMENT FOR FEBRILE NEUTROPENIC PATIENTS^j

SITE OF CARE

TREATMENT OPTIONS

High risk (any factor listed below):

- Inpatient status at time of development of fever
- Significant medical comorbidity or clinically unstable
- Anticipated prolonged severe neutropenia: ≤ 100 cells/mcL and ≥ 7 d
- Hepatic insufficiency (5 times ULN for aminotransferases)
- Renal insufficiency (a creatinine clearance of less than 30 mL/min)
- Uncontrolled/progressive cancer^k
- Pneumonia or other complex infections at clinical presentation
- Alemtuzumab
- Mucositis grade 3-4
- OR
- MASCC Risk Index score of less than 21^j

Low risk (none of the above factors and most of the following):

- Outpatient status at time of development of fever
- No associated acute comorbid illness, independently indicating inpatient treatment or close observation
- Anticipated short duration of severe neutropenia (≤ 100 cells/mcL for < 7 d)
- Good performance status (ECOG 0-1)
- No hepatic insufficiency
- No renal insufficiency
- OR
- A score of 21 or greater on the MASCC Risk Index^j

Initial evaluation

Hospital → IV therapy

Hospital
OR
Consider ambulatory clinic
OR
Home for selected low-risk patients with adequate outpatient infrastructure established

IV therapy or Sequential IV/oral therapy
OR
Oral therapy (category 1)


[See Outpatient Therapy for Low Risk Patients \(FEV-13\)](#)

^jRisk categorization refers to risk of serious complications, including mortality, in patients with neutropenic fever. [See Risk Assessment Resources \(FEV-E\)](#).

^kUncontrolled/progressive cancer is defined as any leukemic patient not in complete remission, or non-leukemic patients with evidence of disease progression after more than 2 courses of chemotherapy.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



See
Follow-up
([FEV-8](#))


^cSee [Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.

^lSee [Antifungal Agents \(FEV-B\)](#) for dosing, spectrum and specific comments/cautions.

^mSee [Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.

ⁿPosaconazole can be considered for salvage therapy or for intolerance to amphotericin B formulations. Posaconazole is not approved by the FDA as either primary or salvage therapy for invasive fungal infections.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^cSee [Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.

ⁱSee [Appropriate Use of Vancomycin and Other Agents for Gram-positive Resistant Infections \(FEV-D\)](#).

^lSee [Antifungal Agents \(FEV-B\)](#) for dosing, spectrum, and specific comments/cautions.

^mSee [Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.


^oSurgical and other subspecialty (eg, gastroenterology, interventional radiology) consultations should be considered for these situations as clinically indicated.

^PLab studies include CMV antigens/PCR and abdominal/pelvic CT.

^qEnterococcal colonization must be differentiated from infection. Vancomycin use must be minimized because of the risk of vancomycin resistance.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^cSee [Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.

^lSee [Antifungal Agents \(FEV-B\)](#) for dosing, spectrum, and specific comments/cautions.

^mSee [Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.


^rOther diagnoses to consider include pulmonary edema, hemorrhage and drug toxicities.

^sAssess for healthcare acquired pneumonia and/or resistant pathogens.

^tSee [Adjunctive Therapies \(FEV-F\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^cSee [Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.

ⁱSee [Appropriate Use of Vancomycin and Other Agents for Gram-positive Resistant Infections \(FEV-D\)](#).


^lSee [Antifungal Agents \(FEV-B\)](#) for dosing, spectrum, and specific comments/cautions.

^mSee [Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF DAILY FOLLOW-UP



^t[See Adjunctive Therapies \(FEV-F\).](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

FOLLOW-UP THERAPY FOR
RESPONDING PATIENTSⁱ[See Appropriate Use of Vancomycin and Other Agents for Gram-positive Resistant Infections \(FEV-D\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

FOLLOW-UP THERAPY FOR
RESPONDING PATIENTS

GENERAL GUIDELINES

SUGGESTED DURATION OF THERAPY FOR DOCUMENTED INFECTION^{c,l,m}


These are general guidelines and may need to be revised for individual patients.

Documented
infection

- Initial antibiotic regimen should generally be continued until neutrophil count is ≥ 500 cells/mcL and increasing
- Duration of antimicrobial therapy may be individualized based upon:
 - ▶ Neutrophil recovery
 - ▶ Rapidity of defervescence
 - ▶ Specific site of infection
 - ▶ Infecting pathogen
 - ▶ Patient's underlying illness

- Skin/soft tissue: 7-14 d
- Bloodstream infection (uncomplicated)
 - ▶ Gram-negative: 10-14 d
 - ▶ Gram-positive: 7-14 d
 - ▶ *S. aureus*: at least 2 weeks after first negative blood culture and normal transthoracic echocardiogram (TTE)^u
 - ▶ Yeast: ≥ 2 wks after first negative blood culture
 - ▶ Consider catheter removal for bloodstream infections with *Candida*, *S. aureus*, *Pseudomonas aeruginosa*, *Corynebacterium jeikeium*, *Acinetobacter*, *Bacillus* organisms, atypical mycobacteria, yeasts, molds, vancomycin-resistant enterococci, and *Stenotrophomonas maltophilia* (category 2B)
- Sinusitis: 10-21 d
- Catheter removal for septic phlebitis, tunnel infection, or port pocket infection
- Bacterial pneumonia: 10-21 d
- Fungal (mold and yeast):
 - ▶ *Candida*: minimum of 2 wks after first negative blood culture
 - ▶ Mold (ie, *Aspergillus*): minimum of 12 wks
- Viral:
 - ▶ HSV/VZV: 7-10 d (category 1); acyclovir, valacyclovir, or famciclovir (uncomplicated, localized disease to the skin)
 - ▶ Influenza: Oseltamivir is approved by FDA for 5 d based on data from ambulatory otherwise healthy individuals with intact immune systems

^cSee [Antibacterial Agents \(FEV-A\)](#) for dosing, spectrum, and specific comments/cautions.^lSee [Antifungal Agents \(FEV-B\)](#) for dosing, spectrum and specific comments/cautions.^mSee [Antiviral Agents \(FEV-C\)](#) for dosing, spectrum and specific comments/cautions.^uA TEE should be considered in all cases of *S. aureus* bacteremia. In patients with conditions that may increase the likelihood of complications (eg, neutropenia, thrombocytopenia, mucositis), a transthoracic echocardiogram (TTE) may be performed initially and, if negative, a TEE should be performed when safe. A TEE is more sensitive and preferred when compared with TTE.**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

FOLLOW-UP THERAPY FOR
RESPONDING PATIENTSSUGGESTED DURATION OF THERAPY
FOR FEVER OF UNKNOWN ORIGIN


^vUse clindamycin for penicillin-allergic patients.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

FOLLOW-UP THERAPY FOR
NONRESPONDING PATIENTS

SUGGESTED DURATION OF THERAPY



^wThe timing to add empirical antifungal therapy varies with the risk of invasive mold infection but generally ranges between 4-7 d of neutropenic fever. In patients at high risk for mold infection (neutropenia > 10 d, allogeneic stem cell transplant recipients, high-dose corticosteroids), the panel recommends adding empirical antifungal therapy after 4 d unless patient is receiving prophylaxis directed against molds. See text for discussion of antifungal prophylaxis versus empirical antifungal therapy.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

OUTPATIENT THERAPY FOR LOW RISK PATIENTS

INDICATION

- Patient determined to be in low risk category on presentation with fever and neutropenia
- Outpatient status at time of development of fever
 - No associated acute comorbid illness, independently indicating inpatient treatment or close observation
 - Anticipated short duration of severe neutropenia (< 7 days)
 - Good performance status (ECOG 0-1)
 - Serum creatinine ≤ 2.0 mg/dL, liver functions ≤ 3x normal
OR
 - A score of 21 or greater on the MASCC Risk Index^j

ASSESSMENT

- Careful examination
- Review lab results: no critical values
- Review social criteria for home therapy
 - ▶ Patient consents to home care
 - ▶ 24 h home caregiver available
 - ▶ Home telephone
 - ▶ Access to emergency facilities
 - ▶ Adequate home environment
 - ▶ Distance within approximately one hour of a medical center or treating physician's office
- Assess for oral antibiotic therapy
 - ▶ No nausea and vomiting
 - ▶ Able to tolerate oral medications
 - ▶ Not on prior fluoroquinolone prophylaxis

MANAGEMENT

- Observation period (2-12 h) (category 2B) in order to:
- Confirm low-risk status and ensure stability of patient
 - Observe and administer first dose of antibiotics and monitor for reaction
 - Organize discharge plans to home and follow-up
 - Patient education
 - Telephone follow-up within 12-24 h

[See Treatment and Follow-up \(FEV-14\)](#)

^jRisk categorization can predict outcome during the febrile episode, including complications/mortality. [See Risk Assessment Resources \(FEV-E\)](#).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

OUTPATIENT THERAPY FOR LOW RISK PATIENTS

TREATMENT OPTIONS

FOLLOW-UP

- IV antibiotics at home
- Daily long-acting intravenous agent ± oral therapy
 - ▶ Home or office
- Oral therapy only^x:
 - ▶ 500 mg every 8 h ciprofloxacin^y plus 500 mg every 8 h amoxicillin/clavulanate^v (category 1)
 - ▶ Other oral regimens are less well-validated (eg, levofloxacin)



- Patient should be monitored daily^z
- Daily examination (clinic or home visit) for the first 72 h to assess response, toxicity, and compliance; if responding, then telephone follow-up daily thereafter.
- Specific reasons to return to clinic:
 - ▶ Any positive culture
 - ▶ New signs/symptoms reported by the patient
 - ▶ Persistent or recurrent fever at days 3-5
 - ▶ Inability to continue prescribed antibiotic regimen (ie, oral intolerance)
 - ▶ Office visit for infusion of IV antibiotics

^vUse clindamycin for penicillin-allergic patients.

^xCriteria for oral antibiotics: no nausea or vomiting, patient able to tolerate oral medications, and patient not on prior fluoroquinolone prophylaxis.

^yThe fluoroquinolone chosen should be based on reliable Gram-negative bacillary activity, local antibacterial susceptibilities, and the use of quinolone prophylaxis of fever and neutropenia.

^zProvider should be individual (eg, MD, RN, PA, NP) who has expertise in the management of patients with neutropenia and fever.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIBACTERIAL AGENTS (References are on page 4)

GRAM-POSITIVE AGENTS ^a	DOSE	SPECTRUM	COMMENTS/CAUTIONS
Vancomycin	15 mg/kg IV every 12 h ^b	Gram-positive organisms with exception of VRE and a number of rare Gram-positive organisms	<ul style="list-style-type: none"> • Should not be considered as routine therapy for neutropenia and fever unless certain risk factors present (See FEV-D)
Linezolid	600 mg PO/IV every 12 h	Gram-positive organisms including VRE	<ul style="list-style-type: none"> • Hematologic toxicity may occur, thrombocytopenia most common (0.3% to 10%) • Serotonin syndrome rare, use cautiously with SSRI's¹ • Not for routine use in fever and neutropenia although does not impair neutrophil recovery • Treatment option for VRE and MRSA • Peripheral/optic neuropathy with long-term use
Daptomycin	4-6 mg/kg IV d ^b	<ul style="list-style-type: none"> • Gram-positive organisms • Has in vitro activity against VRE but is not FDA-approved for this indication 	<ul style="list-style-type: none"> • Equivalent to standard antistaphylococcal agents for <i>Staphylococcus aureus</i> bacteremia at 6 mg/kg dose in non-neutropenic patients² • Weekly CPK to monitor for rhabdomyolysis • Not indicated for pneumonia due to inactivation by pulmonary surfactant • Not studied in patients with fever and neutropenia • Myositis is a potential toxicity
Dalfopristin/ Quinupristin	7.5 mg/kg IV every 8 h	Gram-positive organisms including most VRE (does not have activity against <i>Enterococcus faecalis</i>) or intolerance to vancomycin	<ul style="list-style-type: none"> • Use limited by myalgias/artralgias (up to 47%) • Requires central venous access delivery • Avoid use due to toxicity although coverage is good • Musculoskeletal pain syndrome is a potential toxicity

^a These drugs are not recommended as monotherapy for fever in the setting of neutropenia and should only be added for documented infection with resistant Gram-positive organisms or if certain risk factors are present. ([See FEV-D](#))

^b Requires adjustment in patients with renal insufficiency.

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIBACTERIAL AGENTS (References are on page 4)

BROAD SPECTRUM AGENTS AND COMBINATION THERAPY AGENTS	DOSE	SPECTRUM	COMMENTS/CAUTIONS
Cefepime	2 grams IV every 8 h ^b	<ul style="list-style-type: none"> • Broad spectrum activity against most Gram-positive and Gram-negative organisms • Not active against most anaerobes, MRSA, and <i>Enterococcus spp.</i> 	<ul style="list-style-type: none"> • Use for suspected/proven CNS infection with susceptible organism • Increased frequency of resistance among Gram-negative rod isolates at some centers • Empiric therapy for neutropenic fever
Ceftazidime	2 grams IV every 8 h ^b	<ul style="list-style-type: none"> • Relatively poor Gram-positive activity • Breakthrough streptococcal infections reported • Not active against most anaerobes, MRSA and <i>Enterococcus spp.</i> 	<ul style="list-style-type: none"> • Use for suspected/proven CNS infection with susceptible organism • Increased frequency of resistance among Gram-negative rod isolates at some centers • Empiric therapy for neutropenic fever based on resistance among certain Gram-negative rods (category 2B)
Cilastatin sodium/Imipenem	500 mg IV every 6 h ^b	<ul style="list-style-type: none"> • Broad spectrum activity against most Gram-positive, Gram-negative and anaerobic organisms • Not active against MRSA or VRE 	<ul style="list-style-type: none"> • Use for suspected intra-abdominal source • Meropenem is preferred over imipenem for suspected /proven CNS infection • Imipenem may lower seizure threshold in patients with CNS malignancies or infection or with renal insufficiency • Empiric therapy for neutropenic fever
Meropenem	1 gram IV every 8 h ^b (2 g IV every 8 h for meningitis)		
Piperacillin/Tazobactam	4.5 grams IV every 6 h ^b	<ul style="list-style-type: none"> • Broad spectrum activity against most Gram-positive, Gram-negative and anaerobic organisms • Not active against MRSA or VRE 	<ul style="list-style-type: none"> • Use for suspected intra-abdominal source • Not recommended for meningitis • May result in false positive galactomannan³ • Empiric therapy for neutropenic fever

^bRequires adjustment in patients with renal insufficiency.

[Continued on next page](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIBACTERIAL AGENTS (References are on page 4)

BROAD SPECTRUM AGENTS AND COMBINATION THERAPY AGENTS	DOSE	SPECTRUM	COMMENTS/CAUTIONS
Tigecycline	100 mg load then 50 mg IV every 12 h	<ul style="list-style-type: none"> • Broad spectrum including many Gram-negative organisms, anaerobes, VRE, MRSA • Poor activity against <i>Pseudomonas aeruginosa</i>, and some strains of <i>Proteus</i>, <i>Providencia</i>, and <i>Morganella</i>⁴ 	<ul style="list-style-type: none"> • Not recommended for treatment of bloodstream infections due to poor serum levels • Nausea common • Not studied in patients with neutropenia or significant immune impairment • Effective in skin and soft tissue infections and intra-abdominal infections that do not involve <i>P. aeruginosa</i> • Consider in non-neutropenic patients intolerant of other agents.
Ciprofloxacin	500-750 mg PO every 12 hours or 400 mg IV every 8-12 h ^b	<ul style="list-style-type: none"> • Good activity against Gram-negative and atypical (e.g., <i>Legionella spp.</i>) organisms • Less active than “respiratory” fluoroquinolones against Gram-positive organisms • No activity against anaerobic organisms 	<ul style="list-style-type: none"> • Avoid for empiric therapy if patient recently treated with fluoroquinolone prophylaxis • Increasing Gram-negative resistance in many centers • Oral antibiotic combination therapy in low risk patients (with amoxicillin/clavulanate or clindamycin) • In combination with antipseudomonal penicillin in higher risk patients
Levofloxacin	500-750 mg oral or IV daily ^b	<ul style="list-style-type: none"> • Good activity against Gram-negative and atypical (e.g., <i>Legionella spp.</i>) organisms • Improved Gram-positive activity compared to ciprofloxacin • Limited activity against anaerobes • Prophylaxis in neutropenic patients^{5,6} 	<ul style="list-style-type: none"> • Prophylaxis may increase bacterial resistance and superinfection⁷ • Limited studies as empirical therapy in patients with fever and neutropenia

^bRequires adjustment in patients with renal insufficiency.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued on next page](#)

ANTIBACTERIAL AGENTS

BROAD SPECTRUM AGENTS AND COMBINATION THERAPY AGENTS	DOSE	SPECTRUM	COMMENTS/CAUTIONS
Aminoglycosides <ul style="list-style-type: none"> • Gentamicin • Tobramycin • Amikacin 	Dosing individualized with monitoring of levels ^b	<ul style="list-style-type: none"> • Activity primarily against Gram-negative organisms • Gentamicin is synergistic with beta-lactams against susceptible <i>S. aureus</i> and <i>Enterococcus</i> infections 	<ul style="list-style-type: none"> • Nephrotoxicity and ototoxicity limit use • Combination therapy with anti-pseudomonal penicillin +/- beta-lactamase inhibitor or extended spectrum cephalosporin (see FEV-2)
Trimethoprim/sulfamethoxazole (TMP/SMX)	Single or double strength daily or Double strength 3 times per wk as prophylaxis for <i>P. jirovecii</i>		<ul style="list-style-type: none"> • Highly effective as prophylaxis against <i>P. jirovecii</i> in high risk patients (see INF-5)

REFERENCES

- 1 Boyer EW, Shannon M. Serotonin syndrome. *New England Journal of Medicine* 2005;352:1112-1120.
- 2 Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *New England Journal of Medicine* 2006;355:653-665.
- 3 Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false positive *Aspergillus galactomannan* test results following treatment with beta-lactam antibiotics in patients with hematological disorders. *Journal of Clinical Microbiology* 2006;44(2):389-394.
- 4 Stein GE, Craig WA. Tigecycline: A critical analysis. *Clinical Infectious Disease* 2006;43:518-524.
- 5 Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. *New England Journal of Medicine* 2005;353:977-987.
- 6 Cullen M, Billingham SN, Gaunt C, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. *New England Journal of Medicine* 2005;353:988-998.
- 7 Baden LR. Prophylactic antimicrobial agents and the importance of fitness. *New England Journal of Medicine* 2005;353:1052-1054.

^bRequires adjustment in patients with renal insufficiency.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIFUNGAL AGENTS (References are on page 4)

AZOLES ^a	DOSE	SPECTRUM	COMMENTS/CAUTIONS
Fluconazole	In adults with normal renal function: 400 mg IV/PO daily	<ul style="list-style-type: none"> • Active against <i>Candida</i> species • Active against dimorphic fungi (eg, histoplasmosis, coccidioidomycosis) and <i>C. neoformans</i> 	<ul style="list-style-type: none"> • <i>Candida glabrata</i> is associated with variable resistance in vitro and <i>Candida krusei</i> is always resistant • Inactive against molds (eg, <i>Aspergillus</i> species, Zygomycetes)
Itraconazole	IV 200 mg every 12 h x 4 doses, followed by 200 mg daily; oral 400 mg daily (aim for trough of > 0.25 mcg/mL after 7 d of therapy)	<ul style="list-style-type: none"> • Active against <i>Candida</i>, <i>Aspergillus</i> species and some of the rarer molds • Active against dimorphic fungi and <i>C. neoformans</i> 	<ul style="list-style-type: none"> • Itraconazole has negative inotropic properties and is contraindicated in patients with significant cardiac systolic dysfunction • IV formulation should be used with caution in patients with significant pre-existing renal dysfunction based on potential to worsen azotemia
Voriconazole	IV 6 mg/kg every 12 h x 2 doses, then 4 mg/kg every 12 h; oral 200 mg PO BID (for invasive aspergillosis); ¹ IV 6 mg/kg every 12 h x 2, then 3 mg/kg every 12 h for non-neutropenic patients with candidemia; ²	<ul style="list-style-type: none"> • Active against <i>Candida</i>, <i>Aspergillus</i> species and some of the rarer molds • Active against dimorphic fungi and <i>C. neoformans</i> • Standard of care as primary therapy for invasive aspergillosis (category 1)^{1,3} • Effective in candidemia in non-neutropenic patients² 	<ul style="list-style-type: none"> • Poor activity against Zygomycetes • IV formulation should be used with caution in patients with significant pre-existing renal dysfunction based on potential to worsen azotemia
Posaconazole	<ul style="list-style-type: none"> • Prophylaxis: 200 mg PO TID among high-risk patients (See INF-3) • Salvage therapy: 200 mg PO QID followed by 400 mg PO BID once infection has stabilized 	<ul style="list-style-type: none"> • Effective as prophylaxis in neutropenic patients with myelodysplastic syndrome and acute myelogenous leukemia,⁴ and in HSCT recipients with significant GVHD⁵ • Active against <i>Candida</i>, <i>Aspergillus</i> sp, some Zygomycete sp, and some of the rarer molds • Active against dimorphic fungi and <i>C. neoformans</i> 	<ul style="list-style-type: none"> • Evaluated as salvage therapy (but not FDA-approved) in several invasive fungal diseases. • Data on posaconazole as primary therapy for invasive fungal infections are limited. • Should be administered with a full meal or liquid nutritional supplement. For patients who cannot eat a full meal or tolerate an oral nutritional supplement alternative antifungal therapy should be considered.

^aAzoles inhibit fungal cell membrane synthesis and inhibit cytochrome P450 isoenzymes that may lead to impaired clearance of other drugs metabolized by this pathway. Fluconazole is a less potent inhibitor of cytochrome P450 isoenzymes than the mold-active azoles. Drug-drug interactions are common and need to be closely monitored (consult package inserts for details). Reversible liver enzyme abnormalities are observed.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIFUNGAL AGENTS (References are on page 4)

AMPHOTERICIN B FORMULATIONS ^b	DOSE	SPECTRUM	COMMENTS/CAUTIONS
Amphotericin B desoxycholate (AmB-D)	Varies on indication, generally 0.5 to 1.5 mg/kg/d	Broad spectrum of antifungal activity including <i>Candida</i> , <i>Aspergillus</i> sp (excluding <i>Aspergillus terreus</i>) Zygomycetes, rarer molds, <i>Cryptococcus neoformans</i> , and dimorphic fungi	<ul style="list-style-type: none"> • Substantial infusional and renal toxicity including electrolyte wasting • Saline loading may reduce nephrotoxicity • Infusional toxicity may be managed with anti-pyretics, an anti-histamine, and meperidine (for rigors)
Liposomal amphotericin B (L-AMB)	3 mg/kg/d IV was as effective as, but less toxic than, 10 mg/kg/d as initial therapy for invasive mold infections ^{6,c}		Reduced infusional and renal toxicity compared to AmB-D
Amphotericin B lipid complex (ABLC)	5 mg/kg/d IV for invasive mold infections		Reduced infusional and renal toxicity compared to AmB-D
Amphotericin B colloidal dispersion (ABCD)	5 mg/kg/d IV for invasive mold infections		Substantial infusional toxicity; other lipid formulations of amphotericin B are generally preferred

[Continued on next page](#)

^bBroad spectrum of antifungal activity. Significant infusional and renal toxicity, less so with lipid formulations.

^cThe vast majority of subjects in this trial had invasive aspergillosis; optimal dosing of L-AMB for other mold infections (such as mucormycosis) is unclear.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIFUNGAL AGENTS (References are on page 4)

ECHINOCANDINS ^d	DOSE	SPECTRUM	COMMENTS/CAUTIONS
Caspofungin	<ul style="list-style-type: none"> • 70 mg IV x 1 dose, then 50 mg IV daily; some investigators use 70 mg IV daily as therapy for aspergillosis • 70 mg IV x 1 dose, followed by 35 mg IV daily for patients with moderate liver disease 	Active against <i>Candida</i> and <i>Aspergillus</i> sp. Not reliable or effective against other fungal pathogens.	<ul style="list-style-type: none"> • Primary therapy for candidemia and invasive candidiasis (category 1)⁷ • Salvage therapy for aspergillosis. Similar efficacy compared to AmB-D as primary therapy for candidemia and invasive candidiasis, but significantly less toxic⁷ • 45% success rate as salvage therapy for invasive aspergillosis⁸ • Similar efficacy, but less toxic compared with L-AMB as empirical therapy for persistent neutropenic fever⁷ • Excellent safety profile.
Micafungin	100 mg/d IV for candidemia and 50 mg/d IV as prophylaxis		<ul style="list-style-type: none"> • Primary therapy for candidemia and invasive candidiasis (category 1) • Similar efficacy compared to caspofungin⁹ and compared to L-AMB¹⁰ as primary therapy for candidemia and invasive candidiasis • Superior efficacy compared to fluconazole as prophylaxis during neutropenia in HSCT recipients¹¹ • Excellent safety profile.
Anidulafungin	200 mg IV x 1 dose, then 100 mg/d IV		<ul style="list-style-type: none"> • Primary therapy for candidemia and invasive candidiasis (category 1) • Superior efficacy compared to fluconazole as primary therapy for candidemia and invasive candidiasis¹² • Excellent safety profile.

[Continued on next page](#)

^dA number of centers use combination voriconazole and an echinocandin for invasive aspergillosis based on in vitro, animal, and limited clinical data.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

REFERENCES FOR ANTIFUNGAL AGENTS (page 4 of 4)

- ¹Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 2002;347:408-15.
- ²Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. *Lancet* 2005;366:1435-42.
- ³Walsh TJ et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 2008;46:327-360.
- ⁴Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007;356(4):348-59.
- ⁵Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 2007;356(4):335-47.
- ⁶Cornely O, Maertens J, Bresnik M, et al. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiload Trial). *Clin Infect Dis* 2007;44:1289-97.
- ⁷Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med* 2002;347:2020-9.
- ⁸Maertens J, Raad I, Petrikos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. *Clin Infect Dis* 2004;39:1563-71. Epub 2004 Nov 9.
- ⁹Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clin Infect Dis* 2007;45:883-93.
- ¹⁰Kuse ER, Chetchotisakd P, Da Cunha CA, et al. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double blind trial. *Lancet* 2007;369:1519-27.
- ¹¹van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. *Clin Infect Dis*. 2004 Nov 15;39(10):1407-16.
- ¹²Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin Study Group. Anidulafungin vs. fluconazole for invasive candidiasis. *N Engl J Med* 2007;356:2472-82.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIVIRAL AGENTS (References are on page 4)

Agent	Treatment	Spectrum	Comments/Cautions
Acyclovir	Prophylaxis ^a : HSV (400 mg PO TID to QID) ¹ ; VZV in allogeneic HSCT recipients (800 mg PO BID) ² ; CMV in allogeneic HSCT recipients (800 mg PO QID) ^{b,3} Treatment: significant mucocutaneous HSV (5 mg/kg IV every 8H for 7-10 days); single dermatomal VZV (800 mg PO 5 times daily or 5 mg/kg IV every 8H for 7-10 days); disseminated HSV or VZV (10-12 mg/kg IV every 8H) ⁴	HSV, VZV, CMV	Hydration to avoid crystal nephropathy with high dose
Valacyclovir	Prophylaxis ^a : HSV or VZV (500 mg PO BID or TID) ¹ CMV in allogeneic HSCT recipients (2gm PO QID) ^{b,5} Treatment: HSV or VZV (Valacyclovir 1 gm PO TID) ⁴	HSV, VZV	
Famciclovir	Prophylaxis: HSV or VZV (250 mg PO BID) Treatment: HSV (250 mg PO TID) or VZV (500 mg PO TID) ^{6,7}	HSV, VZV	No data for oncologic related prophylaxis
Ganciclovir	Prophylaxis for CMV: 5-6 mg/kg IV every day for 5 days/week from engraftment until day 100 after HSCT ^{c,1,8} Pre-emptive therapy for CMV: 5 mg/kg every 12H for 2 weeks; if CMV remains detectable, treat with additional 2 weeks of ganciclovir 6 mg/kg daily 5 days per week. Therapy: CMV disease (5 mg/kg every 12H for 2 weeks followed by 5 to 6 mg/kg daily for at least an additional 2 weeks). Add IVIG for CMV pneumonia, and consider adding IVIG for CMV disease at other sites. Formulations and dosages of IVIG vary in different series; 500 mg/kg every other day for the first week is a reasonable regimen.	CMV	May cause bone marrow suppression
Valganciclovir	Prophylaxis: CMV (900 mg every day) ^c Pre-emptive therapy for CMV: 900 mg PO BID for 2 weeks; consider additional 900 mg PO daily for at least 7 days after a negative test	CMV	May cause bone marrow suppression

^aAntiviral prophylaxis should be targeted to specific high-risk patients (see INF-4). In non-transplant high-risk patients, prophylaxis should be administered to patients seropositive for HSV or VZV (or with a history of chicken pox). In HSCT recipients, prophylaxis is only indicated if either the donor or recipient is seropositive for the virus in question. The indicated doses for antiviral agents are for adults with normal renal function; consult package insert for dose modification in pediatrics and in patients with renal impairment. Prophylactic antiviral doses may be higher than those routinely used in immunocompetent persons (for example, for recurrent cold sores); there is substantial variability in the prophylactic doses of acyclovir used in different clinical trials in patients with hematologic malignancies and HSCT recipients.

^bHigh dose acyclovir and valacyclovir have been used as prophylaxis for CMV. Because these agents have weak activity against CMV, a strategy of CMV surveillance and pre-emptive therapy with ganciclovir, valganciclovir, or foscarnet is required among patients at high risk for CMV disease.

^cIn general, the strategy of CMV surveillance testing by antigenemia or PCR followed by pre-emptive anti-CMV therapy for a positive result is favored over universal long-term prophylaxis in allogeneic HSCT patients.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIVIRAL AGENTS (References are on page 4)

Agent	Treatment	Spectrum	Comments/Cautions
Foscarnet	Prophylaxis for CMV: 60 mg/kg TID ¹ or 60 mg/kg IV every 12H for 7 days, followed by 90-120 mg/kg IV every day until day 100 after HSCT. ^{c,8,9} Pre-emptive therapy for CMV: 60 mg/kg every 12H for 2 weeks; if CMV remains detectable, treat with additional 2 weeks of foscarnet, 90 mg/kg daily 5 days per week. Therapy: Acyclovir-resistant HSV (40 mg/kg every 8H for 7-10 days); CMV disease (90 mg/kg every 12H for 2 weeks followed by 120 mg/kg daily for at least an additional 2 weeks). Add IVIG for CMV pneumonia, and consider adding IVIG for CMV disease at other sites.	HSV, VZV, CMV	Drug of choice for acyclovir resistant HSV and VZV and ganciclovir resistant CMV; nephrotoxic; monitor electrolytes
Cidofovir	Prophylaxis for CMV: Cidofovir 5 mg/kg IV every other week with probenecid 2 gm PO 3H before the dose, followed by 1 gm PO 2H after the dose and 1 gm PO 8H after the dose and IV hydration Treatment: Cidofovir 5 mg/kg IV every week for 2 weeks, followed by cidofovir 5 mg/kg every 2 weeks with probenecid 2 gm PO 3H before the dose, followed by 1 gm PO 2H after the dose and 1 gm PO 8H after the dose and IV hydration	CMV	Nephrotoxicity, ocular toxicity, bone marrow toxicity, hydration and probenecid required to reduce nephrotoxicity
Oseltamivir	Prophylaxis: 75 mg PO every day ^{d,10} Treatment: 75 mg BID	Influenza A & B	May cause nausea (improved when taken with food)
Zanamivir	Prophylaxis: 2 oral inhalations (5 mg/inhalation) daily Treatment: 2 oral inhalations (5 mg/inhalation) BID	Influenza A & B	Duration influenced by nature of exposure (ongoing vs. time limited); may cause bronchospasm
Amantadine		Influenza A	Not currently recommended secondary to resistance
Rimantadine		Influenza A	Not currently recommended secondary to resistance

^cIn general, the strategy of CMV surveillance testing by antigenemia or PCR followed by pre-emptive anti-CMV therapy for a positive result is favored over universal long-term prophylaxis in allogeneic HSCT patients.

^dProphylaxis among highly immunocompromised persons during community and nosocomial outbreaks of influenza A should be considered.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIVIRAL AGENTS (References are on page 4)

Agent	Treatment	Spectrum	Comments/Cautions
Pegylated Interferon-alpha (or peginterferon alfa-2a)	Treatment for HCV: Pegylated Interferon-alpha 1.5 mcg/kg (or peginterferon alfa-2a 180 mcg) SC weekly plus ribavirin orally (dosing based on weight: if less than 75 kg, 400 mg in the morning and 600 mg in the evening; if greater than 75 kg, 600 mg twice daily)	HCV	
Intravenous immune globulin (IVIG)	Doses of IVIG vary among different studies and different viral illnesses. A dose of 400 mg/kg administered daily for 5 days is common for parvovirus B19-associated disease. ¹¹ For CMV and RSV disease, adjunctive IVIG (400mg/kg) every other day for 3 to 5 doses is commonly administered	RSV, Parvovirus B19, CMV	
Palivizumab	Prophylaxis: 15 mg/kg IM monthly during RSV season ^{f,12}	RSV	Data predominantly in pediatric population; inadequate database to judge efficacy in RSV disease in patients with hematologic malignancies and stem cell transplant recipients
Ribavirin	Treatment for RSV disease ^e : (6 gm administered by continuous inhalation via SPAG-2 nebulizer every 12-18H daily for 7 days); may be paired with IVIG (500 mg/kg every other day) or palivizumab ¹³	RSV	
Lamivudine	100 mg PO every day ¹	HBV	Concerns with resistant virus emerging when monotherapy utilized
Adefovir	10 mg PO every day (May consider using tenofovir)	HBV	Limited data in oncologic populations. Data extrapolated from non-immunocompromised patients
Entecavir	0.5 mg PO every day	HBV	Limited data in oncologic populations. Data extrapolated from non-immunocompromised patients

^eInhaled ribavirin is only FDA approved for hospitalized infants and young children with severe lower respiratory tract RSV disease. The experience in immunocompromised adults with RSV disease is limited, but should be considered given the potential morbidity and mortality associated with RSV infection. Ribvirin is teratogenic and precautions are required during administration (see Package insert).

^fPalivizumab is an RSV-specific monoclonal abody that has principally been evaluated in the pediatric population; there are inadequate data to judge efficacy in RSV disease in patients with hematologic malignancies and stem cell transplant recipients.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ANTIVIRAL AGENTS – REFERENCES

- ¹ Sandherr M, Einsele H, Hebart H, et al. Infectious Diseases Working Party, German Society for Hematology and Oncology. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). *Ann Oncol* 2006;17(7):1051-1059.
- ² Boeckh M, Kim HW, Flowers MED, Meyers JD and Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation -- a randomized double-blind placebo-controlled study. *Blood* 2006;107:1800-1805.
- ³ Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2002;29(8):633-638.
- ⁴ Gilbert DN, Moellering RC, Sande MA. *The Sanford Guide to Antimicrobial Therapy* (37th ed.). Hyde Park, VT: Jeb E. Sanford Publishers. 2007
- ⁵ Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. *Blood* 2002;99:3050-3056.
- ⁶ Frechette G, Romanowski B. Efficacy and safety of famciclovir for the treatment of HSV infection in HIV+ patients. *Can J Infect Dis* 1997; 8(Suppl A):44A.
- ⁷ Schacker T, Hu H, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: A double-blind, placebo-controlled trial. *Ann Intern Med* 1998;128:21-28.
- ⁸ Centers for Disease Control and Prevention. Infectious Disease Society of America. American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *MMWR Recomm Rep* 2000;49(RR-10):1-125, CE1-7.
- ⁹ Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. *Blood* 2002;99:1159-1164.
- ¹⁰ Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. *Clin Infect Dis* 2007;45(2):187-193.
- ¹¹ Heegaard Ed, Brown KE. Human parvovirus B19. *Clin Microbiol Rev* 2002;15:485-505
- ¹² Boeckh M, Berrey MM, Bowden RA, et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. *J Infect Dis* 2001;184(3):350-354. Epub 2001 Jun 28.
- ¹³ Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. *Bone Marrow Transplant* 1995;16:393-399.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

APPROPRIATE USE OF VANCOMYCIN AND OTHER AGENTS FOR Gram-positive RESISTANT INFECTIONS

- Vancomycin should not be considered as a routine component of initial therapy for fever and neutropenia. Because of the emergence of vancomycin-resistant organisms, empiric vancomycin should be avoided except for serious infections associated with the following clinical situations:
 - ▶ Clinically apparent, serious, catheter-related infection
 - ▶ Blood culture positive for Gram-positive bacterium prior to final identification and susceptibility testing
 - ▶ Known colonization with penicillin/cephalosporin-resistant pneumococci or methicillin-resistant *Staphylococcus aureus*
 - ▶ Hypotension or septic shock without an identified pathogen (ie, clinically unstable)
 - ▶ Soft tissue infection
 - ▶ Risk factors for viridans group streptococcal, bacteremia (category 2B): severe mucositis (eg, associated with high-dose cytarabine) and prophylaxis with quinolones or TMP-SMX (see manuscript)^a
- Vancomycin should be discontinued in 2-3 days if a resistant Gram-positive infection (eg, MRSA) is not identified and if clinically appropriate.
- Linezolid, quinupristin/dalfopristin, and daptomycin may be used specifically for infections caused by documented vancomycin-resistant organisms (eg, VRE) or in patients for whom vancomycin is not an option. Linezolid should be considered for ventilator associated MRSA pneumonia.
(See FEV-A 1 of 4)

^aRecent studies have shown that addition of vancomycin is likely to be unnecessary solely on the basis of neutropenic fever and mucositis when broad spectrum beta-lactam agents with activity against oral flora (eg, piperacillin/tazobactam or imipenem/cilastatin) are used.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

RISK ASSESSMENT RESOURCES

USING THE MASCC RISK-INDEX SCORE

- Using the visual analogue score, estimate the patient's burden of illness at the time of initial clinical evaluation. No signs or symptoms or mild signs or symptoms are scored as 5 points, moderate signs or symptoms are scored as 3 points. These are mutually exclusive. No points are scored for severe signs or symptoms or moribund.
- Based upon the patients age, past medical history, present clinical features and site of care (inpt/outpt when febrile episode occurred), score the other factors in the model and sum them.

TALCOTT RISK ASSESSMENT²

High Risk:

Group 1- Patients hospitalized at onset of fever and neutropenia

Group 2- Outpatients with a concurrent comorbidity at presentation (hemodynamic instability, clinical bleeding, respiratory failure, altered mental status or new neurologic symptoms, dehydration)


Group 3- Outpatients with uncontrolled cancer at presentation (newly treated tumors, newly relapsed, refractory or persistent leukemia, or progressive disease)

Low Risk:

Group 4- Outpatients with comorbidity or uncontrolled cancer at presentation

BURDEN OF ILLNESS

How sick is the patient at presentation?



No signs or symptoms Mild signs or symptoms Moderate signs or symptoms Severe signs or symptoms Moribund

Estimate the burden of illness considering all comorbid conditions

MASCC RISK-INDEX SCORE/MODEL¹

Characteristic	Weight
• Burden of illness	
> No or mild symptoms	5
> Moderate symptoms	3
• No hypotension	5
• No COPD	4
• Solid tumor or hemotologic malignancy with no previous fungal infection	4
• No dehydration	3
• Outpatient status	3
• Age <60 years	2

¹Klastersky J, Paesmans M, Rubenstein EJ et al. The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients. J Clin Oncol 2000;18(16):3038-51.

²Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Arch Intern Med 1988;148:2561-68.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

ADJUNCTIVE THERAPIES

Limited or anecdotal data are available to suggest that these interventions may be beneficial:

- **G-CSF or GM-CSF should be considered in neutropenic patients with serious infectious complications, such as the following (category 2B):**
 - ▶ **Pneumonia**
 - ▶ **Invasive fungal infection**
 - ▶ **Progressive infection (any type)**
- **Granulocyte transfusions (category 2B)**
 - ▶ **Invasive fungal infection**
 - ▶ **Gram-negative rod infection unresponsive to appropriate antimicrobial therapy**
- **Intravenous immunoglobulin**
 - ▶ **Should be used in combination with ganciclovir for CMV pneumonia**
 - ▶ **Consider IV IgG for patients with profound hypogammaglobulinemia (category 2B)**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Manuscript

NCCN Categories of Evidence and Consensus

Category 1: There is uniform NCCN consensus, based on high-level evidence, that the recommendation is appropriate.

Category 2A: There is uniform NCCN consensus, based on lower-level evidence including clinical experience, that the recommendation is appropriate.

Category 2B: There is nonuniform NCCN consensus (but no major disagreement), based on lower-level evidence including clinical experience, that the recommendation is appropriate.

Category 3: There is major NCCN disagreement that the recommendation is appropriate.

All recommendations are category 2A unless otherwise noted.

Overview

Infectious diseases are important causes of morbidity and mortality in patients with cancer. In certain instances, the malignancy itself can predispose patients to severe or recurrent infections. Neutropenia has been recognized for many decades as a major risk factor for the development of infections in cancer patients undergoing chemotherapy. Effective strategies to anticipate, prevent, and manage infectious complications in neutropenic cancer patients have led to improved outcomes.¹⁻¹³ Due to advances in antimicrobial therapy, it is now uncommon for patients with acute leukemia or those undergoing stem cell transplantation to die from infections during the neutropenic period.

Previous NCCN guidelines on infections in patients with cancer focused primarily on the management of fever and neutropenia. Reflecting the heterogeneity of immunocompromised conditions in patients with

cancer and the spectrum of pathogens to which they are susceptible, the NCCN expanded the scope of our panel in 2007 to create guidelines on “Prevention and Treatment of Cancer-Related Infections.” These revised guidelines replace the previous NCCN guidelines on “Fever and Neutropenia.”

We characterize the major categories of immunologic deficits in persons with cancer and the major pathogens to which they are susceptible. Specific guidelines are provided on the prevention, diagnosis, and treatment of the major common and opportunistic infections that afflict patients with cancer. These NCCN guidelines should be applied in conjunction with careful, individual patient evaluation and with an understanding of host factors that predispose patients to specific infectious diseases and with an understanding of antimicrobial susceptibility patterns.

Scope of the Problem

Although neutropenia remains a key risk factor for infections, other immunocompromised states pose at least equal risk. Allogeneic hematopoietic stem cell transplant (HSCT) recipients with neutrophil recovery who require intensive immunosuppressive therapy for graft-versus-host disease (GVHD) are an example of non-neutropenic patients at great risk for common bacterial, viral, and opportunistic infections. Indeed, previous NCCN guidelines on fever and neutropenia have addressed infections in the non-neutropenic setting. In the current guidelines, infections in neutropenic and immunocompromised non-neutropenic patients with cancer are given equal weight.

Another reason for expanding the scope of the NCCN guidelines is that the diagnostic evaluation and antibacterial therapy for neutropenic fever have remained relatively constant over the past several years. The spectrum of infectious diseases in allogeneic HSCT recipients with GVHD is distinct from neutropenia, and the standards of care are not as

clearly established. In addition, the last set of authoritative U.S. guidelines, specifically related to preventing infections in allogeneic HSCT recipients, were established several years ago.¹⁴ We therefore believe that an updated set of guidelines related to this patient population addresses an important need. Our scope also includes other highly immunocompromised patients with cancer (such as those receiving high-dose corticosteroids, purine analogues, or alemtuzumab).

Organization

The guidelines are divided into 4 sections. The first section discusses the major host factors that predispose patients to infectious diseases. The second section addresses management of neutropenic fever. This section is similar to the previous NCCN guidelines on “Fever and Neutropenia” and contains updated recommendations based on new clinical trial data. The third section addresses site-specific infections (for example, pneumonia, abdominal infections, catheter-associated infections), with a focus on patients who have neutropenia or who are otherwise significantly immunocompromised (for example, HSCT recipients). The fourth section addresses prevention of infectious complications, including immunization and targeted antimicrobial prophylaxis.

Host Factors That Predispose Patients to Infectious Complications

Immunodeficiencies Associated With Primary Malignancy

Certain malignancies are inherently associated with immune deficits. Patients with hematologic malignancies and myelodysplastic syndrome (MDS) may be leukopenic due to replacement of the marrow with malignant cells or due to a dysfunctional marrow. Patients with chronic lymphocytic leukemia (CLL) frequently have hypogammaglobulinemia leading to increased susceptibility to encapsulated bacteria, principally *Streptococcus pneumoniae*.¹⁵ Such patients may have recurrent

sinopulmonary infections and septicemia. Patients with multiple myeloma are often functionally hypogammaglobulinemic; the total level of immunoglobulin production may be elevated, but the repertoire of antibody production is restricted. Savage and colleagues¹⁶ noted a biphasic pattern of infection among patients with multiple myeloma. Infections by *S.pneumoniae* and *Haemophilus influenzae* occurred early in the disease and in patients responding to chemotherapy, whereas infections by *Staphylococcus aureus* and Gram-negative pathogens occurred more commonly in advanced disease and during neutropenia.

Patients with advanced or refractory malignancy have a greater risk of infectious complications than those who respond to therapy. Refractory hematologic malignancies can be associated with marrow failure from disease and from multiple cycles of chemotherapy. Solid tumors may predispose patients to infection because of anatomic factors. Tumors that overgrow their blood supply become necrotic, thus forming a nidus for infection. Endobronchial tumors may cause recurrent postobstructive pneumonias. Abdominal tumors may obstruct the genitourinary or hepatobiliary tracts, predisposing patients to pyelonephritis and cholangitis, respectively. Direct invasion through the colonic mucosa is associated with local abscess formation and sepsis by enteric flora. Patients undergoing surgery for malignancies may be at high risk for infectious complications as a result of the type of surgery (for example, esophagectomy and hepatobiliary reconstruction are surgeries associated with a high risk for infection), extent of tumor burden, preoperative performance status, and previous surgery, chemotherapy, and radiation therapy. Patients with advanced malignancy are also commonly malnourished, which further increases the risk of infection.

Neutropenia

The absence of granulocytes, the disruption of the integumentary, mucosal, and mucociliary barriers, and inherent microbial flora shifts that accompany severe illness and antimicrobial usage predispose the neutropenic patient to infection. The signs and symptoms of infection are often absent or muted in the absence of neutrophils, but fever remains an early, although nonspecific, sign.¹ Approximately 48% to 60% or more of the patients who become febrile have an established or occult infection.¹⁷ Roughly 10% to 20% or more of patients with neutrophil counts less than 100/mcL will develop a bloodstream infection.² Primary sites of infection are the alimentary tract (that is, mouth, pharynx, esophagus, large and small bowel, and rectum), sinuses, lungs, and skin.

The pathogens responsible for initial infections early in the course of fever and neutropenia are primarily bacteria, whereas antibiotic-resistant bacteria, yeast, other fungi, and viruses are common causes of subsequent infections. Coagulase-negative staphylococci, *S.aureus*, viridans group streptococci, and enterococci are the major Gram-positive pathogens. Coliforms (for example, *Escherichia coli*, *Klebsiella*, *Enterobacter* species) and *Pseudomonas aeruginosa* are the most common Gram-negative infections complicating neutropenia. Herpes simplex virus (HSV), respiratory syncytial virus (RSV), parainfluenza, and influenza A and B are also occasionally initial pathogens. Infections due to *Candida* species may occur later in the course of neutropenia, particularly as a consequence of gastrointestinal (GI) mucositis. *Aspergillus* species and other filamentous fungi are an important cause of morbidity and mortality in patients with severe and prolonged neutropenia.¹⁸ Deaths resulting from infections identified at the onset of fever during neutropenia remain uncommon, and most infection-associated deaths result from subsequent infections during the course of neutropenia.¹⁹

Studies from more than 4 decades ago have shown that as the neutrophil count decreases below 500/mcL (defined as *neutropenia*), the susceptibility to infection increases.^{2,20} The frequency and severity of infection are inversely proportional to the neutrophil count; the risks of severe infection and bloodstream infection are greatest when the neutrophil count is less than 100/mcL. The rate of decline of the neutrophil count and the duration of neutropenia are also critical factors. These latter 2 aspects are a measure of bone marrow reserve and are highly correlated with severity of infection and clinical outcome.

Disruption of Mucosal Barriers

The mucosal linings of the GI, sinopulmonary, and genitourinary tracts constitute the first line of host defense against a variety of pathogens. Chemotherapy and radiation therapy impair mucosal immunity at several different levels. When the physical protective barrier conferred by the epithelial lining is compromised, local flora may invade. Neutropenia and loss of the epithelial cell anatomic barrier may predispose patients to typhlitis (neutropenic enterocolitis). Chemotherapy-related GI mucositis predisposes patients to blood stream infections by viridans group streptococci,²¹⁻²⁴ Gram-negative rods, and *Candida* species.²⁵

Splenectomy and Functional Asplenia

In the spleen, rapid antigen presentation occurs, which leads to the production of opsonizing antibodies by B-cells. The removal of non-opsonized bacteria protects against encapsulated bacteria to which the patient is not yet immune. Splenic irradiation results in functional asplenia, which predisposes patients to pneumococcal sepsis. Functional asplenia is also a late complication of severe GVHD.²⁶ Thus, in allogeneic HSCT recipients, fever in the late transplant period must be evaluated promptly (similar to patients with asplenia) because of the risk of overwhelming infection by encapsulated pathogens.

Asplenic patients are principally at risk for overwhelming sepsis by encapsulated bacteria. The most common pathogen is *S.pneumoniae*, but other pathogens include *H.influenzae* and *Neisseria meningitidis*. The Advisory Committee on Immunization Practices (ACIP) for the Centers for Disease Control and Prevention (CDC) recommends that asplenic persons be immunized with the pneumococcal polysaccharide and meningococcal vaccines

(<http://www.cdc.gov/mmwr/pdf/wk/mm5641-1immunization.pdf>). The conjugated meningococcal vaccine is preferred in adults 55 years of age or younger, because it confers longer lasting immunity than the polysaccharide vaccine. Immunization of adults with the pediatric *H.influenzae* type B (Hib) vaccine is considered optional because of lack of data on efficacy in older children and adults, although studies suggest good immunogenicity in immunocompromised patients. Immunization is ideally performed at least 2 weeks in advance of splenectomy. If this is not feasible, immunization is still advisable after splenectomy, because such patients are still capable of mounting a protective antibody response. One-time reimmunization with the pneumococcal vaccine is advised in asplenic persons 5 years after the time of initial vaccination. Penicillin prophylaxis is advised in asplenic patients to prevent pneumococcal disease (see section on “Prophylaxis Against Pneumococcal Infection”).

Corticosteroids and Other Lymphotoxic Agents

High-dose corticosteroids have profound effects on the distribution and function of neutrophils, monocytes, and lymphocytes. In patients with cancer, corticosteroids are seldom the only immunosuppressive agents being administered, and it is therefore difficult to delineate the degree of impairment in host defense elicited by the corticosteroid regimen alone. The risk of infections is a function of the dose and duration of corticosteroids as well as other co-existing immunodeficiencies (such as neutropenia) and other immunosuppressive agents. Corticosteroids blunt fever and local signs of infection, such as peritonitis.

Lymphocyte-depleting agents increase the risk of common and opportunistic infectious diseases. Fludarabine is a fluorinated analogue of adenine that has been used in a variety of hematologic malignancies. Fludarabine is a lymphotoxic compound, primarily affecting CD4+ lymphocytes. The combination of fludarabine and corticosteroids is more immunosuppressive than either agent alone.²⁷ Fludarabine plus prednisone results in a uniform depression of CD4+ cells that may persist for several months after completion of therapy.²⁸ In one series, 14 of 264 patients (5%) with CLL developed either *Pneumocystis jirovecii* (previously *Pneumocystis carinii*) pneumonia (PCP) or listeriosis, and 3 cases occurred more than 1 year after therapy in patients who were in remission. Patients with hematologic malignancies and allogeneic HSCT recipients are being treated with increasing frequency with novel monoclonal antibodies that cause a depletion of lymphocyte subsets. The extent of immunosuppression and risk of infections associated with these novel agents merit further study.

Alemtuzumab (Campath-1H) is a humanized monoclonal antibody that targets CD52, which is abundantly expressed on most normal lymphocytes. This agent has been used most extensively in patients with CLL who have failed fludarabine therapy. Alemtuzumab causes prolonged and severe lymphopenia in all patients; it causes grade 3 or 4 neutropenia in 70% of patients. Four weeks after initiation of alemtuzumab, the median CD4+ count was 0/mcL and 6 months after discontinuation, the count was 238/mcL in previously untreated patients (<http://www.fda.gov/cder/foi/label/2007/103948s5070lbl.pdf>). The CD8+ counts also changed in a similar manner. In some patients, CD4+ and CD8+ counts did not reach baseline levels until more than 1 year after alemtuzumab therapy. Infections are a substantial cause of morbidity and mortality in alemtuzumab recipients; most infections occurred in patients with CLL refractory to alemtuzumab.²⁹ Bacterial, viral, fungal, mycobacterial, and *P.jirovecii* infections are observed. Prophylaxis with trimethoprim/sulfamethoxazole (TMP/SMX) and with an antiviral agent

active against HSV (acyclovir, famciclovir, or valacyclovir) should be administered from the time of alemtuzumab initiation until at least 2 months after completion of therapy or until the CD4 count is 200/mcL or more, whichever occurs later.

Cytomegalovirus (CMV) reactivation occurs in a substantial number of alemtuzumab recipients (range, 10%-50%) and occurs most commonly between 3 and 6 weeks after initiation of therapy when T-cell counts reach a nadir. The NCCN panel recommends surveillance for CMV reactivation using polymerase chain reaction (PCR) or antigen-based methods in alemtuzumab recipients from the time of initiation until at least 2 months after completion of therapy or until the CD4 count is 100/mcL or more, whichever occurs later. This CD4 count was selected based on the experience in patients with advanced acquired immunodeficiency syndrome (AIDS) where CMV disease is uncommon with a CD4 count greater than 100/mcL.³⁰ Pre-emptive anti-CMV therapy is recommended in those who demonstrate reactivation of the virus by surveillance methods. The Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) does not recommend CMV surveillance in alemtuzumab recipients.³¹

Hematopoietic Stem Cell Transplantation

Autologous HSCT recipients have fewer infectious complications than allogeneic recipients. Most infections in autologous HSCT recipients occur during neutropenia or within the first few months after transplantation before reconstitution of cellular immunity. However, CD34 enrichment of autografts leads to a substantial reduction in T-cells, natural killer cells, and monocytes, compared with unmanipulated autografts, which delays immune reconstitution. Recipients of CD34-enriched autografts appear to be at a similar level of risk as allogeneic HSCT recipients for CMV and other opportunistic infections.³²

The spectrum of pathogens to which allogeneic HSCT recipients are most susceptible follows a time line corresponding to the predominant immune defects. In the first month after HSCT, neutropenia is the principal host defense defect, which predisposes patients to bacterial, fungal, and viral infections. After myeloid engraftment, qualitative dysfunction of phagocytes persists due to corticosteroid and other immunosuppressive agents. The risk of infection by opportunistic viruses and filamentous fungi (molds) during this period is strongly associated with the severity of GVHD and with the requirement for potent immunosuppressive regimens.

Defects in cell-mediated immunity persist for several months even in uncomplicated allogeneic HSCT recipients, predisposing them to common bacterial and viral infections and to multiple opportunistic infections (for example, candidiasis, invasive mold infections, *P.jirovecii*, *Cryptococcus neoformans*, dimorphic fungal infections [such as, histoplasmosis and coccidioidomycosis], HSV, CMV, herpes zoster, Epstein-Barr virus-associated lymphoproliferative disease, community respiratory viruses, legionellosis, listeriosis, nocardiosis, toxoplasmosis, and mycobacterial diseases). Whereas mature and cooperative T- and B-cell functions are usually reconstituted by 1 to 2 years after engraftment, chronic GVHD is associated with persistently depressed cell-mediated and humoral immunity.

Defective reconstitution of humoral immunity is a major factor contributing to increased infection susceptibility in the late transplant period. Winston and colleagues³³ noted a high frequency of pneumococcal infections between 7 and 36 months after transplantation, associated with serum opsonic deficiency for *S.pneumoniae*. Kulkarni and colleagues³⁴ reported that pneumococcal sepsis occurred a median of 10 months after transplant (range, 3 to 187 months) and was significantly more frequent in patients with chronic GVHD. Guidelines from the CDC recommend that allogeneic bone

marrow transplant recipients with severe hypogammaglobulinemia (IgG < 400 mg/dL) and with recurrent infections receive intravenous immunoglobulin (IVIG) prophylaxis; IVIG is not recommended in other patient groups or in autologous HSCT recipients routinely.³⁵ The CDC has published guidelines on vaccination of HSCT recipients and household members to prevent infections following transplantation.¹⁴

Allografts from human leukocyte antigen (HLA)–matched unrelated donors, partially mismatched related donors, and cord blood are associated with a higher risk of GVHD. T-cell depletion delays immune reconstitution and, consequently, carries a greater risk of infectious complications, most notably opportunistic viral³⁶ and fungal³⁷ pathogens. Cord blood transplant recipients may have a higher risk of infections than other allograft recipients during the early transplant period because of slower myeloid engraftment.

Management of Neutropenic Patients With Fever

The definitions of fever and neutropenia in these NCCN clinical guidelines are consistent with those developed by the Infectious Diseases Society of America (IDSA) and the U.S. Food and Drug Administration (FDA) for evaluating antimicrobial therapy for fever and neutropenia.³ *Fever* is defined as a single temperature 38.3°C or more orally or 38.0°C or more over 1 hour in the absence of an obvious cause. Although uncommon, a patient with neutropenia and signs or symptoms of infection (that is, abdominal pain, severe mucositis, perirectal pain) without fever should be considered to have an active infection. The concomitant administration of corticosteroids may also blunt the fever response as well as any localizing signs of infection. The NCCN guidelines define *neutropenia* as either 1) an absolute neutrophil count (ANC) less than 500/mcL, or 2) an ANC less than 1000/mcL and a predicted decline to 500/mcL or less over the next 48 hours.

Initial Evaluation

The initial evaluation should focus on determining the potential sites and causative organisms of infection and on assessing the patient's risk of developing an infection-related complication (see [FEV-1](#)). A site-specific history and physical examination should be performed promptly, cultures should be obtained, and empiric antibiotics started soon after the time of presentation. The common sites of infection for patients with fever and neutropenia (such as the alimentary tract, groin, skin, lungs, sinus, ears, perivagina, perirectum, and intravascular access device sites) should be thoroughly assessed. Other important historical features to consider include major comorbid illness, medications, time since last chemotherapy administration, recent antibiotic therapy, and exposure to infections from household members.

Initial laboratory/radiology evaluation should include a complete blood count with differential analysis, platelets, blood urea nitrogen, creatinine, electrolytes, total serum bilirubin, liver-associated enzymes, and renal function tests. Oxygen saturation and urinalysis should be considered, depending on symptoms. Chest radiographs should be done for all patients with respiratory signs or symptoms; however, radiographic findings may be absent in neutropenic patients with pulmonary infection.³⁸

Cultures

Culture specimens should be collected during or immediately after completing the examination. Two blood samples should be cultured. When obtaining blood cultures, there are 3 options: 1) one set can be obtained peripherally and one can be obtained from a central venous catheter (if present); 2) both sets can be obtained peripherally; or 3) both sets can be obtained through the catheter (see [FEV-1](#)). The positive predictive value of a catheter culture is less than a peripheral culture. The approach of obtaining blood for culture from both the central catheter and peripherally may help determine whether the

venous access device (VAD) is the source of bloodstream infection based on the differential time to positivity.³⁹ However, some experts recommend that only blood from the VAD needs to be obtained for culture, without the requirement for a peripheral vein blood culture.³⁹ A meta-analysis has shown little clinical use for 2-site culturing in patients with cancer who have a VAD, and poor patient acceptance of peripheral venipunctures when a VAD is in place.⁴⁰ The panel consensus is that the volume of blood for culture is the most important aspect of blood culturing, but the need for the performance of cultures from both peripheral and central sites remains unclear.

In the absence of lesions or clinical signs and symptoms, routine cultures of the anterior nares, oropharynx, urine, stool, and rectum are rarely helpful. Diarrheal stools felt to be infectious should be tested for the presence of *Clostridium difficile*. In patients with diarrhea, consider testing for rotavirus and norovirus in winter months and during outbreaks. Symptoms of urinary tract infection should be evaluated with a urinalysis and culture. Vascular access site inflammation or drainage should be cultured. Biopsy with microbiologic and pathologic evaluation should be considered for new or undiagnosed skin lesions. Viral cultures of mucosal or cutaneous lesions may identify HSV infections. In patients with symptoms of respiratory viral infection, viral cultures and rapid viral antigen testing of the nasopharyngeal secretions can be useful in winter months and during local outbreaks of such infections.^{41,42}

Initial Empiric Antibiotic Therapy

The foundation of infection management is to administer empiric antibiotics in patients with fever and neutropenia. This is necessary, because currently available diagnostic tests are not sufficiently rapid, sensitive, or specific to identify or exclude microbial causes of fever from other noninfectious causes. All neutropenic patients should be treated empirically with broad spectrum antibiotics promptly at the first

sign of infection (that is, fever). This is done to avoid the mortality associated with a delay in treatment in those patients who have a serious infection.^{3,19} Many highly effective antibiotic regimens are available, and those that are recommended are supported by randomized clinical trial evidence.

The selection of initial therapy should take into consideration the following factors (see [FEV-2](#)):

- The patient's infection risk assessment (see [FEV-3](#))
- The antimicrobial susceptibilities of pathogens isolated locally
- The most common potentially infecting organisms, including antibiotic-resistant pathogens, such as extended spectrum beta-lactamase-producing Gram-negative rods, vancomycin-resistant enterococcus (VRE), and colonization with or previous infection with methicillin-resistant *S.aureus* (MRSA).
- The potential sites of infection
- The importance of a broad spectrum bactericidal antibiotic regimen that includes antipseudomonal coverage
- Clinical instability (for example, hypotension, organ dysfunction)
- Drug allergy
- Recent antibiotic use (including prophylaxis)

Recommended Approaches

The panel considers each of the following approaches to initial empiric management of febrile neutropenia to be appropriate based on the results of large, randomized controlled clinical trials.^{1,3,19}

The first approach is intravenous antibiotic monotherapy (all category 1 except where noted) with either imipenem/cilastatin, meropenem, an extended-spectrum antipseudomonal cephalosporin (cefepime or ceftazidime [category 2B]), or piperacillin/tazobactam.^{4,43-46} Local institutional bacterial susceptibilities should be considered when selecting empiric antibiotic therapy.

A meta-analysis of randomized trials involving cefepime reported that cefepime was associated with increased all-cause mortality when used for empiric therapy for neutropenic fever, although no increase in infection-related mortality was noted.^{47,48} Additionally, the vast majority of the individual randomized trials showed no significant difference in mortality between cefepime and comparators. No convincing explanations exist for why cefepime would cause increased mortality, assuming this finding is true. The majority of NCCN panel members consider cefepime to be an appropriate option as empiric therapy for neutropenic fever based on the historical experience, randomized clinical trial database, and inherent limitations associated with meta-analyses. Two panel members had significant reservations about cefepime use based on the uncertainty of the benefit versus risk raised by the meta-analysis and on the availability of alternative regimens for neutropenic fever. There was agreement that further studies and evaluation of this data are warranted before changes in recommendations can be firmly made. Note that the FDA is currently doing a safety review of cefepime (http://www.fda.gov/cder/drug/early_comm/cefepime.htm).

The second approach is intravenous antibiotic combination therapy using 3 options: (1) an aminoglycoside plus an antipseudomonal penicillin (with or without a beta-lactamase inhibitor) (category 1); (2) ciprofloxacin plus an antipseudomonal penicillin (category 1)⁴⁹; or (3) an aminoglycoside plus an extended-spectrum antipseudomonal cephalosporin (ceftazidime or cefepime).⁴⁹⁻⁵¹

Aminoglycoside use carries the inherent risk of renal and otic toxicity. Avoiding these toxicities requires careful monitoring and necessitates frequent reassessment, but once-daily aminoglycoside dosing is associated with less renal toxicity than shorter interval dosing.⁵² Once-daily aminoglycoside dosing should probably not be used for treating meningitis or endocarditis based on inadequate clinical data.

For patients at high risk for *Pseudomonas* infections (such as, history of previous *Pseudomonas* infections or presence of ecthyma gangrenosum), initial combination therapy with the most active antipseudomonal agents available in the local setting should be considered.

The third approach is the addition of intravenous vancomycin for specific indications either to intravenous monotherapy or to combination therapy (see section on “Empiric Vancomycin Therapy”). Support for the judicious use of vancomycin has developed because of the increased frequency of beta-lactam-resistant Gram-positive infections caused by MRSA, most coagulase-negative staphylococci, penicillin-resistant viridans group streptococci and enterococci, and *Corynebacterium jeikeium*. However, vancomycin should be reserved for specific indications and should not be considered as a routine component of initial therapy for fever and neutropenia (see [FEV-D](#)).

Empiric Addition of Vancomycin

There is considerable debate about the use of empiric vancomycin in patients with fever and neutropenia. The clinical concern has been that a portion of infections caused by Gram-positive pathogens can be fulminant and lead to rapid death in patients who are not treated promptly with appropriate antibiotics. However, a large, prospective, randomized trial from the European Organization for Research and Treatment of Cancer failed to show true clinical advantages for empiric vancomycin in adults.⁵³ This study reported that empiric vancomycin decreased the number of days the patients had fever but did not improve survival. The study also showed that empiric vancomycin was associated with an increased incidence of nephrotoxicity and hepatotoxicity. A prospective randomized trial of fever and neutropenia in children has reported benefit for empiric vancomycin;⁵⁴ however, another randomized study in children failed to show a benefit for the addition of vancomycin.⁵⁵

The major concern surrounding the uncontrolled use of vancomycin has been the emergence of vancomycin-resistant organisms, especially enterococci.⁵⁶ Reports of vancomycin-resistant and vancomycin-intermediate sensitive *S.aureus* are currently rare but are of key concern, and they underscore the need for judicious vancomycin use.⁵⁷ The increase in vancomycin resistance generally has been associated with excessive use of vancomycin among hospitalized patients. The guidelines panel advises practitioners to adopt the recommendation of the Hospital Infection Control Practices Advisory Committee (HICPAC) of the CDC for preventing the spread of vancomycin resistance.⁵⁸ Because of the increased risk of vancomycin-resistant organisms, empiric vancomycin use should be considered only in patients at high risk for serious Gram-positive infection, and should not be considered as a routine component of initial therapy for fever and neutropenia. Vancomycin should be considered in the following clinical situations (see [FEV-D](#)):

- Clinically apparent, serious, intravenous catheter-related infections. Many of these infections are caused by coagulase-negative staphylococcal isolates, which are usually beta-lactam antibiotic resistant.⁵⁹
- The patient's blood cultures are positive for Gram-positive bacteria before final identification and susceptibility testing.
- Known colonization with penicillin/cephalosporin-resistant pneumococci or MRSA
- Hypotension or septic shock develops in the patient without an identified pathogen (that is, clinically unstable).
- Soft tissue infection
- Risk factors for viridans group streptococcal bacteremia (category 2B): severe mucositis (for example, associated with cytarabine) and prophylaxis with ciprofloxacin or TMP/SMX.

If empiric vancomycin is initiated in any of these situations, its use should be reassessed within 2 to 3 days of initiation. If a resistant Gram-positive pathogen cannot be identified and if clinically appropriate, empiric vancomycin therapy should then be discontinued.

In patients with acute leukemia receiving mucotoxic regimens, prophylaxis with ciprofloxacin and TMP/SMX have been associated with an increased risk of viridans group streptococcal infections.⁶⁰⁻⁶² The broad spectrum, Gram-negative bacillary coverage and limited Gram-positive pathogen activity of these drugs likely predispose to GI colonization and subsequent infection with such organisms.^{63,64} It is unknown whether prophylaxis with newer generation fluoroquinolones (for example, levofloxacin), which have increased activity against Gram-positive bacteria compared to ciprofloxacin, will increase the risk of breakthrough viridans group streptococcal infections.

Although bloodstream infections by viridans group streptococci resistant to all beta-lactams are observed in patients with cancer, cefepime, imipenem/cilastatin, meropenem, and piperacillin-tazobactam have more reliable activity than ceftazidime against viridans group streptococci.⁶⁵ Addition of vancomycin produced no benefit compared to placebo with regard to defervescence, episodes of Gram-positive bacteremia, or use of empiric antifungal therapy in patients with hematologic malignancies and in HSCT recipients with neutropenic fever of unknown etiology that persisted for 48 to 60 hours after initial empiric piperacillin-tazobactam.^{66,67} A smaller randomized, placebo-controlled study did not show any advantage after adding teicoplanin (a glycopeptide antibiotic similar to vancomycin) in patients with neutropenic fever that persisted after 3 to 4 days of empiric imipenem.⁶⁸ In patients with neutropenic fever and severe mucositis who are receiving imipenem, meropenem, or piperacillin-tazobactam (that is, antibiotics with activity against oral flora), it does not appear that the addition of vancomycin is advantageous. Thus, the NCCN panel

recommends that vancomycin should not be routinely added to an empiric regimen solely based on persistent neutropenic fever of unknown etiology.

Agents With Broad Spectrum Activity Against Gram-Positive Pathogens

Linezolid, daptomycin, quinupristin/dalfopristin, and tigecycline are active against many Gram-positive organisms, including beta-lactam vancomycin-resistant pathogens.^{69,70} The panel recommends that the use of these drugs be limited to specific situations involving infections caused by antibiotic-resistant organisms (see [FEV-D](#)). Although there are published studies of some of these agents in patients with neutropenia, the NCCN panel strongly recommends that these agents not be used routinely as empiric therapy for neutropenic fever because of concerns about emergence of resistance and toxicity.

Resistance of Gram-positive organisms to linezolid is infrequent, but this agent needs to be used cautiously in patients with compromised bone marrow function because of the marrow toxicity associated with long-term use of linezolid. Thrombocytopenia is most common (0.3% to 10%) and increases with the duration of use. In neutropenic patients with cancer, myeloid recovery does not seem to be delayed with short courses of linezolid;^{71,72} however, experience with long durations of therapy (for example, more than 14 days) is limited in cancer patients. Linezolid should be considered for treatment of MRSA pneumonia in ventilated patients.⁷³

Recently, the FDA issued an alert about linezolid indicating that it is not approved for treatment of catheter-related infections, catheter-site infections, or Gram-negative infections (<http://www.fda.gov/cder/drug/InfoSheets/HCP/linezolidHCP.htm>). In an open-label randomized study, patients treated with linezolid had a higher chance of death compared with those receiving vancomycin, oxacillin, or dicloxacillin for intravascular catheter-related infections with 1) Gram-negative agents alone; 2) both Gram-positive and Gram-

negative organisms; or 3) no infection. No mortality difference by treatment was found among those who had Gram-positive infections alone.

Daptomycin is effective against most Gram-positive pathogens, but it should not be used for treatment of pneumonia, because it is inactivated by surfactant. Daptomycin is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of certain Gram-positive microorganisms.^{74,75} A recent randomized study showed similar efficacy of daptomycin compared with vancomycin or anti-staphylococcal beta-lactams as therapy for *S.aureus* bacteremia and endocarditis.⁷⁶

Quinupristin/dalfopristin is active against *S.aureus* (including MRSA) and *Enterococcus faecium* (including vancomycin-resistant strains) but is inactive against *Enterococcus faecalis*. Use of quinupristin/dalfopristin has been limited because of the high frequency of substantial musculoskeletal symptoms.⁷⁷

Optimal therapy for VRE infections is not well defined. Linezolid, quinupristin-dalfopristin (active against *E. faecium*, but not *E. faecalis*), and daptomycin have been used in VRE bloodstream infections in patients with cancer with variable success rates.^{71,77,78} Removal of an infected catheter should always be strongly considered. In the absence of more definitive data, therapy with one of these agents is advised for VRE bacteremia.

Tigecycline has activity against clinically relevant resistant Gram-positive (including VRE and MRSA) and Gram-negative infections, but is not active against *P.aeruginosa*. It is effective in complicated skin infections, soft tissue infections, and intraabdominal infections that do not involve *P.aeruginosa*. There are no published clinical trial data on tigecycline as therapy for bacteremia or pneumonia, and experience in cancer patients is lacking; tigecycline has not been studied in patients

with neutropenia or significant immune impairment. Tigecycline is not recommended as first-line therapy in cancer patients but can be considered in non-neutropenic patients intolerant of other agents. Other antibiotics (for example, dalbavancin, telavancin, oritavancin, ceftobiprole [a cephalosporin]) with broad spectrum activity against Gram-positive bacteria (including MRSA) are in clinical development.

Initial Empiric Therapy for Patients Who Are Clinically Unstable

Sepsis is suggested by signs of clinical instability including hypotension, tachypnea, new or worsening tachycardia, mental status changes, decreased urine output, and organ dysfunction. Initial therapy for sepsis should broadly cover pathogens that are likely to cause sepsis while minimizing the potential for inadequate treatment. Unlike the stable patient with neutropenic fever, modifying antibiotics based on culture data may not be possible for the patient with sepsis if the initial regimen does not provide adequate coverage. The antibiotic regimen should be modified, if necessary, after culture results and susceptibility are known.

The initial empiric regimen for the neutropenic patient with clinical instability may include a broad spectrum beta-lactam (for example, imipenem, meropenem, or piperacillin-tazobactam) plus an aminoglycoside and vancomycin. Addition of fluconazole or an echinocandin should be strongly considered in patients not receiving antifungal prophylaxis. Local susceptibility patterns and recent antibiotic use should be taken into account when devising the antibiotic regimen. Some experts also suggest that patients who have a history of *P.aeruginosa* colonization or of invasive disease should receive combination therapy with an antipseudomonal beta-lactam plus an aminoglycoside or ciprofloxacin.

In septic shock, rapid interventions need to be made. Fluid resuscitation, oxygen, invasive hemodynamic monitoring, and vasopressor agents may be required. Stress doses of hydrocortisone

(intravenous 50 mg every 6 hours with or without fludrocortisone oral 50 mcg daily) have been associated with decreased mortality in patients with septic shock and with insufficient adrenal reserve. Stress-dose steroids are recommended for patients with septic shock who require vasopressor support (see “Surviving Sepsis Campaign guidelines”).⁷⁹⁻⁸³ High-dose steroids may be detrimental and should not be given.

In patients with severe sepsis, drotrecogin alfa (Xigris), or recombinant human activated protein C (APC), may provide a modest survival advantage for those at highest risk of death (APACHE II score, 25 or more), but this agent did not benefit lower risk patients or pediatric patients with shock.⁸⁴⁻⁸⁶ Bleeding is the major adverse effect of drotrecogin alfa; it has not been evaluated in neutropenic patients who may have an increased risk of bleeding from concomitant thrombocytopenia. The data are currently inadequate to make a recommendation about the efficacy or safety of this agent in neutropenic patients, or more generally, in patients receiving treatment for cancer.

Prognostic Factors in Patients With Bacteremia

Elting and colleagues have developed a classification system for bacteremias in febrile neutropenic patients based on size and presence of associated tissue involvement.⁸⁷ Complex bacteremias are associated with the lung, liver and spleen, kidney, colon, bone and joints, veins and heart, meninges, soft tissues with necrosis, or skin/soft tissue/wound/cellulitis greater than 5 cm. Simple bacteremias are associated with less tissue involvement (bacteruria, otitis, pharyngitis, soft tissue <5 cm). Complex infections associated with bacteremia decrease survival and, thus, have prognostic significance. At 21 days, 20% of patients with complex infections were dead compared to only 5% of patients with simple bacteremias ($P<.0001$). Profoundly neutropenic patients with simple bacteremias had a much higher response rate to antibiotics (94% versus 70%, $P<.0001$) compared to

patients with complex bacteremias. Response to the initial antibiotic regimen and ultimate outcome were decreased in leukemia patients (those who presented with shock or patients with serum albumin <3.5 g/dL). The median time to defervescence for patients with simple bacteremias was 50% of that observed for patients with complex bacteremias (2.5 versus 5.3 days, $P<.0001$).⁸⁷ Based on these and other studies, clinical criteria can be used to stratify patients with bacteremia into high- and low-risk strata shortly after the onset of the febrile neutropenic episode. These criteria in one combination or another have been used to select patients for risk-adjusted clinical trials of empiric antibiotic therapy.^{5-8,10,88-94}

Empiric Antifungal Therapy in Persistent Neutropenic Fever

Empiric antifungal therapy for persistent febrile neutropenia unresponsive to broad spectrum antibacterial agents is used, because neutropenic patients are known to be at risk for invasive fungal infections, and because clinical examination and collection of cultures are not sufficiently sensitive for early detection of those infections.⁹⁵ Traditionally, empiric antifungal therapy is initiated after 4-7 days of empiric antibiotic therapy for fever and neutropenia, in patients who have remained febrile or have recrudescence fever. The concept of using empiric antifungal therapy was established in the 1970s and 1980s when about 20% of patients being treated for acute leukemia or undergoing HSCT would develop an invasive fungal infection due to *Candida* or *Aspergillus* species by day 20 of neutropenia.⁹⁶ The toxicity of amphotericin B limited its use as routine prophylaxis, which would entail exposing more patients to a toxic drug over a prolonged period than does empiric therapy. With the widespread use of fluconazole prophylaxis in the 1990s among high-risk patients with acute leukemia and in HSCT recipients, the incidence of invasive candidiasis in these patients decreased substantially, although breakthrough candidemia by fluconazole-resistant strains occurred.⁹⁷ Empiric antifungal therapy for neutropenic fever principally involved switching from fluconazole to

amphotericin B to broaden the antifungal spectrum to include molds such as *Aspergillus*. Subsequently, liposomal amphotericin B (L-AMB) proved to be safer than and as effective as conventional amphotericin B for empiric antifungal therapy.⁹⁸

Based on the toxicity of amphotericin B products and the availability of safer and equally effective alternative agents, amphotericin B products were considered a category 2B recommendation for prophylaxis and empirical antifungal therapy for persistent or recurrent neutropenic fever of unknown etiology. In cases in which there is a stronger clinical suspicion of mold infection than neutropenic fever alone (for example, a new pulmonary nodule in a patient with fever and prolonged neutropenia), then use of an amphotericin B formulation (or a mold-active azole or an echinocandin) should be considered pending additional diagnostic evaluation. In general, lipid formulations of amphotericin B are generally preferred over the conventional formulation, because they are less toxic.⁹⁹ This recommendation is stronger in patients with risk factors for acute renal failure, such as pre-existing renal disease, HSCT recipients, and co-administration of nephrotoxic agents.¹⁰⁰⁻¹⁰²

Fluconazole has been used successfully as empiric therapy for neutropenic fever^{103,104} in patients not receiving prophylaxis but is limited by lack of activity against molds. Intravenous followed by oral itraconazole solution was as effective as, but less toxic than, conventional amphotericin B when used as empiric therapy in an open, randomized study;¹⁰⁵ these results led to FDA approval of itraconazole solution for this indication. Itraconazole in the capsule formulation has erratic oral bioavailability and is therefore not suitable as empiric antifungal therapy. Itraconazole has negative inotropic effects and is contraindicated in patients with compromised cardiac function.

Voriconazole was compared with liposomal amphotericin B (L-AMB) in an open, randomized study of empiric antifungal therapy (n=837

patients, 72% with hematologic malignancies).¹⁰⁶ The overall success rates for preventing invasive fungal infections were 26% with voriconazole and 31% with L-AMB. Empiric voriconazole was associated with fewer breakthrough fungal infections (1.9% versus 5.0%), with the greatest protective benefit occurring in pre-specified high-risk patients (relapsed acute leukemia and allogeneic HSCT). Because the noninferiority of voriconazole versus L-AMB was not demonstrated in this study based on prespecified criteria, voriconazole did not receive FDA approval for use as empiric therapy. However, most panel members consider voriconazole to be an acceptable option as empiric therapy in patients at high risk for invasive mold infection.

Echinocandins are active against *Candida* and *Aspergillus* species but have unreliable activity against most other opportunistic fungi. Caspofungin was compared with L-AMB as empiric therapy for fungal infections in a randomized double-blind study of 1095 patients.¹⁰⁷ The overall success rates were 34% in both caspofungin and in L-AMB recipients. The proportion of patients who survived at least 7 days after therapy was greater in the caspofungin group (92.6% versus 89.2%, $P=.05$). The rates of breakthrough fungal infections and resolution of fever during neutropenia were similar in the 2 groups. In patients with a baseline invasive fungal infection, mortality was 11% in caspofungin and 44% in L-AMB recipients, respectively ($P<.01$). Drug-related toxicities and premature withdrawals because of drug-related adverse events were significantly lower in caspofungin recipients. This study strongly supports caspofungin as an option for empiric antifungal therapy. The other echinocandins, anidulafungin and micafungin, have not been studied specifically for empiric antifungal therapy; however, some panel members would consider them to likely be effective, based on the data for caspofungin.

Newer azoles, such as voriconazole and posaconazole, and echinocandins are increasingly being used as prophylaxis against

molds and *Candida* in high-risk patients.¹⁰⁸⁻¹¹⁰ It is unclear whether patients who are already receiving mold-active prophylaxis should subsequently receive empiric antifungal therapy with an additional or different antifungal solely based on persistent neutropenic fever.¹¹¹ One approach has been to evaluate such patients with a high resolution computed tomography (CT) scan of the chest, in search of lesions suspicious for invasive fungal disease. CT scanning in this setting has not been validated but it is a reasonable approach, along with careful physical examination and blood cultures, in an effort to identify a source of persistent unexplained fever in the neutropenic patient. Laboratory markers (such as serum galactomannan and beta-glucan) have important limitations, including falsely negative results in some patients already receiving prophylactic or empiric antifungals^{112,113} (see “Early Diagnosis of Invasive Fungal Infections”). A recent meta-analysis showed the sensitivity of the galactomannan test for proven aspergillosis to be only 70% among patients with hematologic malignancies and 82% among stem cell transplant recipients.¹¹⁴ However, these antigen-based assays have a high negative predictive value in the absence of mold-active antifungal therapy.

In patients receiving only yeast-active prophylaxis with fluconazole or no antifungal prophylaxis, empiric antifungal trials have shown that approximately 5% have baseline invasive fungal infections at the time of enrollment.^{106,107} Empiric antifungal therapy with anti-mold activity would be expected to benefit these few patients without incurring greater risk of toxicity.

Pre-emptive antifungal therapy is a newly introduced concept that involves using characteristic changes in chest or sinus CT scans, laboratory markers, or both to trigger modification of the antifungal regimen, rather than provide empiric antifungals to all persistently febrile neutropenic patients. Maertens and colleagues¹¹⁵ evaluated the strategy of fluconazole prophylaxis in high-risk neutropenic patients

followed by switching to L-AMB based on such pre-specified triggers, including serially positive serum galactomannan tests, a bronchoalveolar lavage (BAL) showing mold, and/or suggestive chest CT in patients with persistent fever or with signs of invasive fungal infection. Directed antifungal therapy was given to 7.7% (9/117) of patients rather than up to one third of patients who might have received it on the basis of fever alone. Although this approach was successful in identifying early invasive aspergillosis and in avoiding empiric antifungal therapy in most patients with persistent neutropenic fever, the panel considers the evidence supporting pre-emptive antifungal therapy to be too preliminary to support its routine use.

Follow-up of Patients With Neutropenic Fever

Daily evaluation by a health care professional who is experienced in treating patients with fever and neutropenia is essential (see [FEV-8](#)). The daily examination should focus on a site-specific assessment, and an infectious disease consultation should be considered for all complicated cases or progressive infections. Time to defervescence ranges from 2 to 7 days (median, 5 days) for febrile cancer patients with neutropenia who receive appropriate initial antibiotic therapy.¹¹⁶ This rate of fever response should be considered when assessing the need to adjust initial antibiotics; random additions or changes for persistent fever are discouraged in the absence of additional clinical or microbiologic evidence. The expected slow defervescence of fever also complicates decisions regarding the need for repeat blood cultures. Although some experts recommend daily blood cultures until the patient becomes afebrile, there is increasing evidence that daily blood cultures are unnecessary in stable neutropenic patients with persistent fever of unknown etiology.¹¹⁷

Current bacterial blood culture systems (such as the BACTEC[™] continuous-monitoring culture system) can detect 90% to 100% of bacterial bloodstream pathogens within 48 hours of culture. For this

reason, ordering additional cultures routinely before obtaining the results from the initial series is discouraged. Daily review of previously obtained cultures is critical, and the panel recommends documenting clearance of bloodstream bacterial or fungal infections with repeat blood cultures.¹¹⁸

Evaluation of Response and Duration of Therapy

The duration of antimicrobial therapy, in general, is dictated by the underlying site of infection, causative organism(s), the patient's clinical condition along with response to treatment and recovery of neutrophils. It is generally recommended that antibiotics be continued until the ANC is 500 or more cells/mcL in cases of fever of unknown etiology. Documented infections are usually treated according to the site, pathogen, and at least until ANC recovery. The panel is limited by a lack of recent high-level evidence to formulate consensus about duration of treatment for all situations; however, general recommendations are given.

Patients With Documented Infection Sites or Pathogens

Most experts recommend continuing antimicrobial therapy for documented infections at least until a patient's ANC recovers to 500/mcL or more (see [FEV-10](#)) but also recommend using a defined course of therapy appropriate for the specific infection. Thus, the duration of antimicrobial therapy may be longer than the duration of neutropenia in these patients. For example, most uncomplicated skin and alimentary tract mucosal infections can be treated with 7 to 14 days of therapy. For most bacterial bloodstream infections, 7 to 14 days of therapy is usually adequate, with longer durations (10-14 days) recommended for Gram-negative bacteremias. A longer duration (10-21 days) of treatment is also usually indicated for infections of the lungs or sinuses and for bacteremias.⁸⁷ Complex intra-abdominal infections, such as typhlitis, should be treated until all evidence of infection has resolved, and there has been recovery from neutropenia.

For all *S.aureus* bloodstream infections, a transesophageal echocardiogram (TEE) is recommended to help define the absence or presence of heart valve vegetations, and thus, to help define the duration of therapy as short (2 weeks after first negative blood culture) or long (4 to 6 weeks).¹¹⁹⁻¹²² A TEE is more sensitive and preferred when compared with a transthoracic echocardiogram (TTE).¹²³ In patients with conditions that may increase the likelihood of complications (for example, neutropenia, thrombocytopenia, mucositis), a TTE may be performed initially and, if negative, a TEE should be performed when safe. If a TEE is not feasible, a minimum 4-week course of intravenous antibiotics should be considered for *S.aureus* bloodstream infections.

The duration of treatment for HSV (uncomplicated, localized disease to the skin) and varicella zoster virus (VZV; uncomplicated, localized disease to a single dermatome) infections is 7 to 10 days (category 1).¹²⁴ Life-threatening infections, such as invasive fungi or CMV, require individualized courses of therapy that are often prolonged. The duration of anti-infective therapy may need to be extended if further chemotherapy is required while treating a significant infection. This may occur with infections that complicate leukemia or lymphoma treatments in which multiple cycles of intensive chemotherapy are required.

Patients with documented infections who become afebrile after the initiation of the empiric antibiotic regimen and who are at low risk for complications associated with infection may be candidates for outpatient antibiotic therapy. The regimen, whether oral or intravenous, should be appropriate for neutropenic fever and have activity against the specific infection.

Severe or Refractory Infections

Patients with documented infection sites or pathogens who do not respond to initial antimicrobial therapy pose a difficult management challenge and are at increased risk of infection-associated morbidity

and mortality. The panel strongly recommends that an infectious disease expert be consulted for all such patients. The lack of response may suggest an infection with a pathogen resistant to the antimicrobial therapy being used, inadequate serum or tissue levels of the antibiotic(s), infection at a vascular site (that is, catheter or “closed space” infection), or emergence of a second infection. Some documented infections fail to respond to appropriate therapy because of associated profound neutropenia. If possible, treatment should be optimized using broad spectrum antibiotic combinations that minimize other organ toxicity.

Both the American Society of Clinical Oncology¹²⁵ and the NCCN have guidelines for the use of prophylactic colony-stimulating factors (CSF) in neutropenic patients (see [NCCN Myeloid Growth Factors Guidelines](#)). It is not clear whether these agents are useful as adjunctive therapy for established infectious diseases. Although the data supporting their use are limited, adjunctive therapy with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) should be considered in neutropenic patients with significant infectious complications (category 2B) such as pneumonia, invasive fungal infections, or any type of progressive infection. Granulocyte transfusions may be considered in neutropenic patients with serious infectious complications, such as invasive fungal infections (category 2B). The panel notes that the benefit versus toxicity balance associated with granulocyte transfusions has not been established.

Patients With Persistent Neutropenia and Fever of Unknown Etiology
A critical component of treating patients with fever of unknown etiology is daily clinical evaluation. Careful, daily, site-specific examinations should be performed by a health care professional who has experience and expertise in managing neutropenia and fever. Reassessment should include a review of all previous cultures and radiographs. If

patients receive vancomycin as part of their initial empiric therapy, but they do not have a pathogen recovered or a site of infection identified justifying such treatment, then vancomycin should be discontinued.

Patients with fever of unknown origin who become afebrile soon after starting empiric therapy may have empiric antibiotics discontinued with ANC recovery (500 or more neutrophils/mcL) as long as the neutrophil count is likely to continue to increase (patients are often receiving a growth factor). This recommendation assumes that the patient is clinically well and afebrile for at least 24 hours before antibiotic discontinuation. Patients who become afebrile but remain persistently neutropenic (500 neutrophils or less/mcL) should receive a more prolonged course of antibiotic therapy until the neutropenia resolves (see [FEV-11](#)). Lower risk patients can also be switched to oral antibiotics until their neutropenia resolves (that is, 500 mg ciprofloxacin every 8 hours plus 500 mg of amoxicillin/potassium clavulanate every 8 hours). Patients with recurrent fever should be reassessed promptly to determine the need for a change in their antibiotic regimen or for addition of antifungal therapy. In stable patients who fail to have neutrophil count recovery, have no documented focus of infection, and have been afebrile for more than 7 to 14 days, some panel members support discontinuing empiric antimicrobial therapy (category 2B).

Patients with a fever persisting beyond 4 days of initial antimicrobial therapy and with an unidentified source of infection should undergo reassessment of their antimicrobial therapy (see [FEV-12](#)). The need for a change in therapy should be based on the patient's clinical status and likelihood of imminent bone marrow recovery.

The clinically stable patient with persistent fever of unknown etiology may be safely watched without altering the initial antimicrobial therapy. Modifications of initial empiric antibiotic therapy should be based on specific new clinical findings and/or new microbiologic results; fever alone should not prompt changes in antimicrobial therapy. The major

exception is the initiation of empiric antifungal therapy in patients who have persistent or recurrent fever after 4 to 7 days of empiric antibacterial therapy and who are not receiving mold-active prophylaxis (see "Empiric Antifungal Therapy"). Most experts advise continuing empiric antibiotic therapy until the absolute neutrophil count recovers.

Although fever resolution may be slow during neutropenia, persistent fever may result from a noninfectious etiology, such as drug fever. Persistent fever may also represent an inadequately treated infectious process, such as a nonbacterial infection (fungal or viral), a bacterial infection that is resistant to empiric antibiotics, a venous access or closed space infection, or inadequate antimicrobial serum levels. It is important to recognize that documented deep tissue infections may take longer than fever of unknown etiology to respond to antimicrobial therapy. In these cases, daily assessment of clinical improvement or failure depends on radiographic, culture and clinical examination data, as well as on the fever trends. Unusual infections (for example, toxoplasmosis) may complicate neutropenia, particularly if immunosuppressive agents (for example, high-dose corticosteroids) are also used. The panel strongly recommends an infectious disease consultation for these patients.

Development of Clinical Instability While Receiving Antibacterial Therapy

It is essential to recognize the early signs of breakthrough infections after the initiation of antibacterial therapy. Although persistent neutropenic fever alone is not an indication to modify the antibacterial regimen, signs of breakthrough infection should prompt additional evaluation and consideration to modify therapy.

New findings suggestive of sepsis (for example, hypotension, tachycardia, mental status changes, organ dysfunction) require the following: 1) repeat physical examination to identify a source of infection; 2) repeat blood cultures; 3) consideration of radiologic

studies; and 4) empiric modification of antimicrobial therapy pending culture results. Information about the previous use of antibiotics and local sensitivity patterns of Gram-negative pathogens should guide empiric changes. Empiric addition of vancomycin is warranted in the unstable patient (see [FEV-A](#), [FEV-D](#)). In patients receiving ceftazidime, the possibility of breakthrough infections (either from extended spectrum beta-lactamase-producing or from cephalosporinase-producing Gram-negative rods) should be considered and switching to imipenem or meropenem is appropriate pending culture results.

Stenotrophomonas maltophilia or carbapenem-resistant *P.aeruginosa* may cause breakthrough sepsis in patients receiving imipenem or meropenem; consider empiric modification to a regimen containing piperacillin-tazobactam, an aminoglycoside, and TMP/SMX. In patients not receiving a systemic antifungal agent, addition of fluconazole or an echinocandin should be strongly considered for possible candidemia. The antibiotic regimen should then be tailored based on culture and radiologic results.

Outpatient Management of Patients With Neutropenic Fever

Initial Evaluation of Risk

Patients with neutropenia may be categorized into either a high- or low-risk group^{10-13,88,89,126,127} using criteria that are derived either from validated clinical prediction rules based on risk models or from clinical trials eligibility criteria (see [FEV-3](#) and [FEV-E](#)).^{6,10,11,13,23,88,89,126,127} Risk assessment attempts to predict the probability that a neutropenic patient will experience serious complications during a febrile episode; risk assessment also helps determine whether the patient who is at low risk for serious complications could safely receive treatment outside of the hospital and receive initial empiric therapy with oral antibiotics.

Prospective trials have indicated that febrile neutropenic patients can be initially evaluated in the hospital, ambulatory clinic, or home and then treated effectively with broad spectrum intravenous, sequential

intravenous/oral, or oral therapy.⁸⁸⁻⁹⁰ Only centers with the necessary infrastructure should treat low-risk patients in an outpatient setting, preferably in an investigational context.

Risk assessment should be performed as part of the initial evaluation (see [FEV-3](#)). The most accurate and recently validated prediction rule to assess risk is from the Multinational Association of Supportive Care in Cancer (MASCC) (see [FEV-E](#)).^{128,129} It is also acceptable to employ risk assessment criteria that have been identified in large clinical trials to distinguish between patients at low and high risk for complications during the course of neutropenia.

The MASCC prediction rule does not consider the duration of neutropenia to be a deciding factor that influences the clinical course during the febrile episode; however, the panel acknowledges that some consideration of the duration of anticipated neutropenia may be helpful in risk assessment.

Duration of Neutropenia and Risk

For decades clinicians have regarded depth and duration of neutropenia as critical determinants of a patient's risk for infection. Once the relationship between the ANC and incidence of infections was demonstrated, the importance of increased neutrophil counts on outcomes was evident. In Bodey's original work, the fatality rate was highest (80%) in patients who initially started with neutrophil counts less than 100/mcL that did not change during the first week of infection compared to the lower rate (27%) in those patients who started out with neutrophil counts less than 1000/mcL, which then rose to greater than 1000/mcL.²⁰ Many clinical trials since then have reported that response rates to antibiotic regimens are highly influenced by trends in the neutrophil count during febrile episodes. In one study, the overall response rate was 73% if the initial neutrophil count increased compared to 43% if it decreased or remained unchanged ($P<.00001$).¹³⁰ The response rate in patients who were initially

profoundly neutropenic (that is, ANC<100/mcL) but who recovered from neutropenia was 67%, compared to only 32% in patients who remained profoundly neutropenic ($P<.0001$). In 1988, Rubin and colleagues published a study from the National Cancer Institute examining the influence of the duration of neutropenia on the response to empiric antimicrobial therapy and other important clinical outcomes in patients with fever of undetermined origin.¹³¹ Patients with less than 7 days of neutropenia had response rates to initial antimicrobial therapy of 95%, compared to only 32% in patients with more than 14 days of neutropenia ($P<.001$); however, patients with intermediate durations of neutropenia between 7 and 14 days had response rates of 79%.¹³¹

Clearly bone marrow recovery is a very important factor that influences outcome during the febrile neutropenic episode. Delayed bone marrow recovery might be anticipated in certain patient subsets (for example, those who have received multiple cycles of myelosuppressive chemotherapy; patients with known bone marrow metastases; or patients who have received radiation therapy to the pelvis, spine, or long bones). Most patients with solid tumors have neutropenia lasting less than 7 days and are at much lower risk. Several studies have demonstrated the ability of clinicians to predict anticipated duration of neutropenia. In prospective randomized trials of oral versus intravenous antibiotics for patients at low risk, the predicted expected further duration of neutropenia was used as an eligibility criteria and clinicians were accurate more than 80% of the time.^{88,91} The duration of neutropenia can be one of a number of factors in selecting patients for outpatient management of neutropenic fever.

Evaluation of Patients for Outpatient Therapy for Neutropenic Fever

Outpatient therapy has become a common practice in low-risk patients with neutropenic fever. Several single-center clinical trials generally support the shift in care for low-risk patients to the outpatient setting

and believe that the hospital is not necessarily a safer place for low-risk patients, given the hazards of hospitalization that have been documented by the Institute of Medicine.¹³² It is also clear that not all centers are equipped to attempt such outpatient treatment, nor are all patients with fever appropriate candidates. Early success with this type of therapy has been predicated on the ability to accurately determine an individual patient's risk of developing complications associated with infection and on the presence of an adequate center infrastructure for the treatment and monitoring of such patients (see "Risk Assessment").

Once a patient's level of risk has been identified (see [FEV-13](#) and [FEV-E](#) and "Risk Assessment"), it can then be used to determine the appropriate site of care and route of administration of broad spectrum antibiotics. The panel recommends that all high-risk patients receive hospital care with broad spectrum intravenous therapy. Low-risk patients may be treated in the hospital with oral or intravenous antibiotics, in an ambulatory clinic, or at home if adequate follow-up care can be provided (that is, 24 hours per day, 7 days per week). Outpatient therapy should be considered only for low-risk patients who consent to home care, have a telephone, have access to emergency facilities, have an adequate and supportive home environment, and are within 1 hour's travel time of a medical center or physician's office. Outpatient therapy requires a period of early monitored assessment and an observation period of 2 to 12 hours (category 2B) (see [FEV-13](#)). The assessment requires a careful examination, review of laboratory results, review of social criteria for home therapy (as previously described), and assessment of whether oral antibiotics are feasible. The observation period is used to confirm the patient is low risk, to observe and administer the first dose of antibiotics as well as monitor for reaction, to ensure the stability of the patient, to organize discharge plans to home and follow-up, to educate the patient, and to perform telephone follow-up within 12 to 24 hours. This assessment and observation can be performed during a short hospital stay or in an

ambulatory facility or office staffed with qualified health care professionals. Providers who perform the early assessment and follow-up should be well trained (for example, a physician, nurse, physician assistant, and/or nurse practitioner) as well as have experience and expertise in managing neutropenia and fever.

Outpatient Regimens

Outpatient antimicrobial treatment may consist of broad spectrum antibiotics given at home or in the clinic, or an oral regimen for carefully selected patients. For low-risk patients who are considered appropriate for oral therapy, the combination of ciprofloxacin with amoxicillin/clavulanate (both at 500 mg every 8 hours) is considered the regimen of choice based on multiple, well-designed randomized trials (category 1) (see [FEV-14](#)). Although some of these trials were performed in an inpatient setting, they provide evidence of the efficacy of the oral combination compared with standard intravenous therapy in the low-risk population.^{5,88} Ciprofloxacin plus clindamycin is an acceptable alternative for penicillin-allergic patients.⁶ However, ciprofloxacin monotherapy is not considered by the panel to be an adequate broad spectrum agent because of the potential for serious breakthrough infections caused by viridans group streptococci.¹³³ Nonetheless, several small studies have used high-dose oral ciprofloxacin alone in low-risk patients with fever and neutropenia.^{9,134,135}

Oral ofloxacin has been demonstrated to be safe as an oral regimen in several smaller studies. Presumably, levofloxacin (which is the L-isomer of ofloxacin) may be used as well. Other newer generation fluoroquinolones (for example, moxifloxacin, gemifloxacin) have not been studied as empiric therapy for low-risk fever and neutropenia, and may have inadequate Gram-negative rod activity. The panel feels that outpatient therapy with a fluoroquinolone should be based on reliable Gram-negative bacillary activity of the antibiotic that includes

P.aeruginosa and local antibacterial susceptibilities. Fluoroquinolones should not be used as initial outpatient therapy for patients who have received prophylaxis with a fluoroquinolone. Until better levels of evidence are available, the panel cannot recommend oral monotherapy with a fluoroquinolone for low-risk patients considering the strength of the evidence for combination therapy with ciprofloxacin plus amoxicillin/clavulanate. Intravenous therapy may also be used for outpatient treatment of low-risk patients with fever and neutropenia with treatment given either in the home or day clinic setting. Several intravenous outpatient regimens for low-risk patients have been studied in nonrandomized or small open trials, including intravenous ceftazidime, imipenem/cilastatin, and aztreonam plus clindamycin.^{6,89,90}

Once-daily ceftriaxone has been used for empiric antibiotic therapy in a few noncomparative studies in centers where *Pseudomonas* is not a common pathogen.⁹⁴ However, most *P.aeruginosa* isolates are resistant to ceftriaxone. Although ceftriaxone combined with a once-daily aminoglycoside is a convenient regimen for outpatient intravenous administration, an aminoglycoside without an antipseudomonal beta-lactam may not be effective against *P.aeruginosa*, which remains an infrequent but often lethal pathogen. Therefore, the panel cannot recommend ceftriaxone with or without an aminoglycoside as empiric therapy for neutropenic fever. If this regimen is used, it should be restricted to low-risk patients at centers where *P.aeruginosa* infection is uncommonly observed. In addition to antimicrobial spectrum, other factors to consider in the choice of an outpatient regimen include stability of the reconstituted drugs, ability to manage intravenous infusions, and vascular access devices.

Follow-Up of Outpatients With Fever and Neutropenia

Follow-up management can be performed at the patient's home or in the physician's office or clinic. The panel recommends that patients be assessed daily while febrile, although some experts feel that less

frequent follow-up may be appropriate after fever defervescence (see [FEV-14](#)). A return to the clinic is recommended for any positive culture, for persistent or recurrent fever at 3-5 days, if serious subsequent infections or adverse events develop, or if the patient is unable to continue the prescribed antibiotic regimen (for example, because of oral intolerance).

Site-Specific Evaluation and Treatment of Infectious Diseases

The NCCN guidelines provide recommendations for site-specific evaluation and therapy for infections of the mouth and esophagus, sinuses, liver, abdomen, rectum, vascular access sites, lungs, skin/soft tissue, urinary tract, and central nervous system (CNS). This section is tailored to patients with neutropenia or those who are otherwise significantly immunocompromised (for example, HSCT recipients).

Mouth and Esophageal Infections

The mouth and esophagus are common sites of infection in patients with fever and neutropenia. This site predilection occurs because of the propensity of the mouth and alimentary tract mucosa to be disrupted by cytotoxic therapy, which can cause mucositis. Unfortunately, the characteristics of this disruption are not etiology specific, and important viral and fungal pathogens often can be distinguished only by microbiologic culture. Empiric antibiotic therapy must consider the endogenous anaerobic flora and the shift in oral flora, which occurs with serious illness or antibiotic use (see [FEV-4](#)). The increased frequency of HSV reactivation and severity of these infections in cancer patients are well known and preventable. The incidence of HSV reactivation in immunocompromised patients may approach 50% to 75%, but it is nearly zero in those who receive prophylaxis with appropriate antiviral agents.¹²⁴ Herpes simplex virus infections are associated with more extensive mucosal damage, increased secondary infections, and significantly prolonged healing time. Baglin and associates reported

that patients with fever and neutropenia who experienced concomitant HSV reactivation and were treated with appropriate antiviral therapy had a significant decrease in the number of days with fever.¹³⁶

Systemic or topical antifungal agents can be used to treat thrush. Because of the risk of candidemia, systemic antifungal therapy is advised in neutropenic patients. Fluconazole is recommended as first-line therapy for thrush. If patients do not respond, the dose of fluconazole can be increased to as high as 800 mg daily (in adults with normal renal function).¹³⁷ Although cross-resistance among azoles may occur, oral voriconazole or posaconazole are reasonable oral options for thrush that is refractory to fluconazole. Echinocandins (such as, caspofungin, micafungin, or anidulafungin) can be used for patients with azole-refractory mucosal candidiasis. Amphotericin B formulations are also effective but are limited by toxicity.

Thrush along with retrosternal burning, chronic nausea, or odynophagia should raise suspicion for *Candida* esophagitis. However, *Candida* esophagitis may occur in the absence of oral thrush, especially in patients receiving oral topical antifungal agents. Definitive diagnosis of esophageal candidiasis is made by endoscopy. Empiric systemic antifungal therapy is often used to treat presumed *Candida* esophagitis.

The presence of thrush favors esophageal candidiasis in patients with symptoms compatible with esophagitis, although the symptoms of HSV and *Candida* esophagitis are similar. Other causes of esophagitis (for example, radiation esophagitis, GVHD of the esophagus or stomach) also produce similar symptoms. A trial of fluconazole and acyclovir (5 mg/kg every 8 hours in patients with normal renal function) should be considered in neutropenic patients and other highly immunocompromised persons with symptoms that suggest esophagitis. Cytomegalovirus esophagitis is a rare complication of chemotherapy-induced neutropenia and is most commonly observed in allogeneic HSCT recipients with GVHD. Negative CMV surveillance results from

antigenemia or PCR studies would make CMV disease very unlikely. Ganciclovir or foscarnet may be considered for patients at high risk for CMV disease with symptoms suggestive of esophagitis.

For patients with esophagitis who do not respond to empiric therapy with these agents, careful upper endoscopy with platelet support (if required) may be considered to obtain cultures. Tissue biopsies are the gold standard of diagnosis of invasive esophageal infections. However, there may be substantial morbidity associated with endoscopy and biopsy in patients who are profoundly neutropenic and/or thrombocytopenic; therefore, the procedure should be done cautiously. Radiographic procedures, such as barium studies, are insensitive and add little clinically significant information; therefore, these procedures are not recommended.

Sinus or Nasal Infections

The sinuses are a common site of bacterial infection. Patients with severe and prolonged neutropenia (for example, more than 10 days) and allogeneic HSCT recipients with GVHD are particularly predisposed to invasive mold infections. Cytotoxic therapy disrupts the natural cleansing mechanisms in the nasal passages and increases colonization. A preceding chronic infection may also become active in the setting of neutropenia. Sinusitis during the early neutropenic period (less than 7 days) is principally caused by respiratory and Gram-negative bacterial pathogens. In patients with longer duration neutropenia or in those receiving concomitant high-dose corticosteroid therapy, invasive mold infections are an important concern.

Initial symptoms of sinusitis may be mild. A high-resolution CT scan of the sinuses is the radiographic procedure of choice to evaluate patients with pain or tenderness of the sinuses, nasal erosions, unilateral facial swelling, unilateral eye tearing, or epistaxis. An MRI that includes evaluation of the orbit and cavernous sinuses is useful to evaluate

proptosis of the eye or cranial nerve abnormalities. Bony erosion on CT scan suggests invasive fungal disease. Ear, nose, and throat (ENT) and ophthalmologic examinations should be performed for symptomatic patients with abnormalities on CT scan, with biopsy and culture of any abnormal tissues. Broad spectrum coverage for aerobes and anaerobes is appropriate for neutropenic and otherwise highly immunocompromised patients with sinus infections. Vancomycin (or another anti-Gram-positive agent) should be added for periorbital cellulitis, which is frequently caused by *S.aureus*.

Sinus endoscopy with biopsy and culture are often required to definitively establish the diagnosis and should be pursued aggressively in patients at high risk for mold infection. Invasive fungal sinusitis in patients with hematologic malignancies and with prolonged neutropenia is principally caused by *Aspergillus* species (*A.flavus* and *A.fumigatus*) and Zygomycetes. In a case-control study of invasive aspergillosis and zygomycosis in patients with acute leukemia and in allogeneic HSCT recipients, fungal sinusitis and use of voriconazole each favored a diagnosis of zygomycosis.¹³⁸ A lipid formulation of amphotericin B should be used for suspected or confirmed invasive sinus mold infection, pending definitive histology and culture results (see [FEV-B](#)). Posaconazole can be considered for salvage therapy or for intolerance to amphotericin B formulations; posaconazole is not approved by the U.S. FDA as either primary or salvage therapy for invasive fungal infections. Voriconazole (category 1) is the drug of choice for invasive aspergillosis.¹³⁹ Urgent debridement of necrotic tissue should be performed, when feasible.

Abdominal, Rectal, and Liver Infections

Most infections in the abdomen, rectum, or liver are discovered because of a combination of clinical signs and symptoms (for example, abdominal pain, perirectal pain, and diarrhea) as well as biochemical abnormalities (for example, abnormal liver function tests) (see [FEV-5](#)).

These infections are usually diagnosed and managed based on the radiologic, GI, and surgical expertise of the treating oncology center. Improved imaging techniques (including ultrasonography, CT scans, magnetic resonance imaging [MRI], and radionuclide and endoscopic procedures) have decreased the need for surgical intervention. The choice of diagnostic studies should be based on the clinical presentation and on relative clinical benefit.

Antimicrobial therapy for GI infections must take into account the high likelihood of polymicrobial pathogens and the presence of the endogenous anaerobic GI flora. Acceptable therapeutic options in this setting include monotherapy with a carbapenem (imipenem/cilastatin, meropenem, or ertapenem), piperacillin/tazobactam, or pairing ceftriaxone with metronidazole. In neutropenic patients, the antibiotic regimen should have antipseudomonal activity.

Percutaneous aspiration and drainage should be performed, if feasible, for suspicious infected collections. Cholangitis may complicate obstructive tumors or previous hepatobiliary surgery. If cholangitis is suspected (patients have fever with or without abdominal tenderness and liver enzyme abnormalities compatible with obstruction), a CT scan should be performed to evaluate for biliary tract dilatation and for abscess or infected collections. An endoscopic cholangiogram is useful to document the level of obstruction; if present, endoscopic stent placement may resolve the obstruction, which is a key component in managing cholangitis.

The GI tract and central venous catheters are the principal portals of entry of systemic candidiasis. *Candida* species are components of the colonic flora in 30% to 60% of normal adults. Patients are susceptible to candidal bloodstream infection because of the mucosal damage induced with cytotoxic therapy and neutropenia.²⁵ Breaches in the GI tract after anastomotic leaks also predispose patients to candidal

peritonitis and bloodstream infections.¹⁴⁰ Prophylaxis with fluconazole should be considered in these high-risk patients.

Clostridium difficile colitis is principally a complication of antibiotic therapy and hospitalization; *C. difficile* colitis is also a complication of neutropenia, occurring in about 7% of patients.¹⁴¹ Diarrhea should be evaluated with at least 2 stool *C. difficile* toxin screens. The rate and severity of *C. difficile* colitis in the United States may be increasing, partly because of the emergence of a more virulent strain of *C. difficile*. Recently, multi-institutional outbreaks of *C. difficile* colitis have been reported that were associated with high morbidity and mortality; these outbreaks were caused by a distinct strain with variations in toxin genes and with resistance to fluoroquinolones.^{142,143} Early reports suggested that metronidazole cured nearly 90% of cases of *C. difficile* colitis, and the rate of recurrence was low. Recently, a much lower response rate of *C. difficile* colitis to metronidazole was reported. Musher and colleagues¹⁴⁴ reported that of 207 patients treated with metronidazole for *C. difficile* colitis, only 50% were cured and had no recurrence of disease. The panel recommends initial oral metronidazole for *C. difficile* colitis that is not severe. Oral vancomycin is not advised as routine initial therapy for *C. difficile* colitis because of the risk of selection for VRE and because of the substantial expense. Oral vancomycin should be considered for more complicated cases, such as severe diarrhea, dehydration, clinical instability, significant co-morbidities, or recurrent or refractory *C. difficile* colitis. Efforts should be made to deliver vancomycin by the nasogastric route in patients with severe *C. difficile* colitis. There are limited data to suggest that intravenous metronidazole may be useful in this setting, and it is best used as an adjunct to oral vancomycin.^{145,146} Intravenous vancomycin is of no value in this setting because of inadequate luminal levels. Subtotal colectomy, diverting ileostomy, or colostomy may be required in cases involving toxic dilatation or perforation of the colon. Newer therapies, including the oral agents rifaximin and nitazoxanide, are under investigation. Multiple

recurrences of *C.difficile* are a challenging problem in the cancer patient and may respond to a prolonged, tapering oral vancomycin dose over several weeks.¹⁴⁷

Neutropenic enterocolitis is a serious, potentially life-threatening disease characterized by fever, diarrhea, and abdominal pain. When it occurs in the cecum, it is commonly referred to as typhlitis. The cecum is more vulnerable because of its size and shape, but any or all of the colon may be involved. CT scanning is the diagnostic study of choice and usually demonstrates thickening of the bowel wall. This illness has frequently been associated with acute leukemia, neutropenia, and intensive cytotoxic therapy. The differential diagnosis for this syndrome includes *C.difficile* colitis, CMV enteritis (most common in allogeneic HSCT recipients), and GI tract GVHD. Bloodstream infections and sepsis (frequently polymicrobial), bowel perforation, and hemorrhage may occur. The natural history of typhlitis is quite variable, but all patients should be assessed for *C.difficile* infection and should be treated with bowel rest and broad spectrum antibiotics, including coverage for *C.difficile* and aerobic as well as anaerobic pathogens. Parenteral nutrition should be considered if clinical signs and symptoms do not resolve promptly. Approximately 5% of patients with typhlitis develop complications requiring surgical intervention (for example, perforation, uncontrolled sepsis or rectal bleeding).¹⁴⁸ Consequently, the panel recommends that surgical and other subspecialty consultations be obtained early in the course of treatment.

Vascular Access Device Infections

Vascular access device infections are common as a consequence of the ubiquity of VADs in patients undergoing intensive or cyclic chemotherapy. The risk of infection varies with the device used (long-term implanted catheters versus short-term central catheters), duration of placement, and extent of the patient's immunosuppression. Short-term central catheters impregnated with minocycline and rifampin or

silver-chlorhexidine have been associated with fewer device-related bacterial infections.¹⁴⁹⁻¹⁵² However, no studies have shown the value of these coatings for preventing infections in long-term, indwelling devices.¹⁵³ A meta-analysis of prospective, randomized studies showed that use of a vancomycin lock solution in patients being treated with long-term central VADs reduced the risk of bloodstream infection.¹⁵⁴ The panel does not currently endorse this practice because of concerns about the emergence of bacterial resistance if this approach were widely employed. The CDC has published guidelines on the prevention of intravenous catheter-associated infections.¹⁵⁵

Vascular access device infections are categorized as entry or exit site infections, tunnel or port pocket infections, septic phlebitis, or catheter-associated bloodstream infections (see [FEV-5](#)). The majority of these infections are caused by Gram-positive pathogens, with coagulase-negative staphylococci recovered most frequently. Accordingly, intravenous vancomycin is recommended for those infections that are serious and clinically obvious.

Most VAD exit site infections can be treated effectively with appropriate antimicrobial therapy without the need for catheter removal. If clinical signs of catheter infection are present, a skin swab for culture from the exit site and blood cultures should be obtained. In a patient with neutropenic fever and clinical signs of a VAD-associated infection, an appropriate initial regimen would consist of an agent recommended for neutropenic fever (see [FEV-2](#)) and vancomycin (see [FEV-5](#)). Linezolid is not advised as routine therapy for catheter-related infections nor is it FDA-approved for this indication (see FDA alert: <http://www.fda.gov/cder/drug/InfoSheets/HCP/linezolidHCP.htm>). If there is a clinically apparent, serious, catheter-related infection (such as a tunnel or port pocket infection, or septic phlebitis), catheter removal should be performed immediately.

Determining the role of the catheter in bloodstream infections is frequently difficult if there is no evidence of local catheter inflammation. Differential time to positivity method (DTP) is a useful diagnostic tool for detecting VAD infections. Early positivity of central venous blood cultures predicts catheter-related bacteremia and may be used to avoid unnecessary catheter removal in critically ill patients. It was shown that DTP between centrally and peripherally drawn blood cultures of 120 minutes or more is highly sensitive and specific for diagnosing catheter-related bacteremia.¹⁵⁶⁻¹⁶⁰ It should be noted that these studies were only performed in patients with removable catheters, not implanted catheters (for example, Hickman or Mediport) that are frequently used in patients undergoing cancer treatment.

Most catheter-associated bloodstream infections respond to antimicrobial therapy alone without catheter removal, but immediate catheter removal is advisable for patients with bloodstream infections caused by fungi (yeasts or molds) or nontuberculosis mycobacteria (for example, *Mycobacterium chelonae*, *Mycobacterium abscessus*, *Mycobacterium fortuitum*). Bloodstream infections caused by *Bacillus* organisms, *Candida*, *S.aureus*, *Acinetobacter*, *C.jejikeium*, *P.aeruginosa*, *S.maltophilia*, and vancomycin-resistant enterococci may be difficult to eradicate with antimicrobial therapy alone; therefore, catheter removal should be considered as part of initial therapy (category 2B). In patients with mucositis, the bowel is likely to be the portal of entry for bloodstream infection by GI flora such as *Candida* sp. and enterococci;²⁵ DTP may be useful to distinguish whether bloodstream infection by these organisms is catheter-related and to guide whether catheter removal should be performed. If not removed initially, catheter removal is advised for known or suspected VAD-associated bloodstream infections if the organism is recovered from blood obtained 48 hours after initiation of appropriate antibiotic therapy. In patients with VAD infection and clinical instability, removal of the infected catheter should be performed immediately.

In patients with catheter-associated bloodstream infections caused by *S.aureus*, a TEE should be considered to rule out otherwise unidentified endocarditis (see “Patients With Documented Infection Sites or Pathogens” and [FEV-10](#)). Removal of the catheter should be considered to avoid a persistent nidus of infections that may predispose patients to recurrent bacteremia.

The panel recognizes that certain conditions may preclude the ability to immediately replace intravenous catheters, such as limited options for intravenous access and thrombocytopenia refractory to platelet products. Administering antibiotics through each lumen of the involved catheter has been suggested to avoid treatment failure caused by microbial sequestration. Some experts believe supplemental urokinase infusions can be helpful in patients with catheter-related infections.¹⁶¹ However, the panel believes data are insufficient to recommend either of these approaches.

Lung Infections

Pulmonary infiltrates pose a difficult diagnostic challenge in patients with cancer. Noninfectious causes of pulmonary infiltrates include congestive heart failure, pulmonary hemorrhage, infarction, drug-induced pneumonitis, radiation injury, tumor, bronchiolitis obliterans, and acute respiratory distress syndrome. Common processes can have atypical radiographic appearances, and 2 or more pulmonary processes can exist simultaneously. A careful history should include the time course of respiratory symptoms, sick contacts (for example, community respiratory viral infections, tuberculosis), recent hospitalization, travel, exposure to animals, and exposure to droplets from water distribution systems (*Legionella*). Community outbreaks of specific pathogens (for example, influenza, pertussis) should be considered in the differential diagnosis and should guide initial therapy.

Community-Acquired Pneumonia in the Absence of Neutropenia and Immunosuppressive Therapy

The diagnostic evaluation and initial therapy for community-acquired pneumonia must consider host factors and previous use of antibiotics. The IDSA has published guidelines on community-acquired pneumonia.¹⁶² If feasible, sputum and blood cultures should be collected before starting therapy. In patients who are not neutropenic, not receiving immunosuppressive therapy, and not requiring hospital admission (based on a validated pneumonia severity index), therapy includes either 1) a respiratory fluoroquinolone (levofloxacin 750 mg/day, moxifloxacin, or gemifloxacin); or 2) a beta-lactam (for example, high-dose amoxicillin or amoxicillin-clavulanate) plus a macrolide (for example, azithromycin).¹⁶² These regimens will treat most of the common community-acquired pathogens, including “atypical” pneumonia (*Chlamydia*, *Mycoplasma*, and *Legionella* species).

In patients requiring hospital admission, monotherapy with a respiratory fluoroquinolone or combination therapy with a macrolide plus either ceftriaxone, cefotaxime, or ertapenem) is recommended. Ertapenem has Gram-positive, Gram-negative (excluding *P.aeruginosa* and *Acinetobacter* species), and anaerobic activity useful for suspected aspiration or postobstructive pneumonia. In patients with severe community-acquired pneumonia (for example, who require admission to an intensive care unit), we advise broad spectrum coverage with an antipseudomonal beta-lactam plus either a respiratory fluoroquinolone or azithromycin. In patients with previous MRSA infection or known colonization with MRSA, addition of vancomycin or linezolid should be considered for pneumonia requiring hospitalization. A nasopharyngeal wash for influenza virus and initiation of empiric oseltamivir should be considered during the winter, early spring, and especially during community outbreaks of influenza. A parapneumonic effusion should be

aspirated and submitted for Gram stain, bacterial culture, protein, lactate dehydrogenase, and pH.

Community respiratory viral infections (such as, influenza, parainfluenza, RSV, adenovirus, rhinoviruses, metapneumoviruses) have a seasonal pattern (generally November through April); however, parainfluenza viral infections can occur throughout the year. During the influenza season, consider empiric oseltamivir (effective against influenza A and B) for patients within 48 hours after symptoms develop that are suggestive of influenza (such as, high fever, coryza, myalgia, and dry cough), especially during community outbreaks. Although it may cause bronchospasm, zanamivir can also be considered. Rimantadine or amantadine (only effective against influenza A) are not currently recommended for use because of resistance.

Hospital-Acquired Pneumonia

Guidelines on the management of adults with hospital-acquired pneumonia from the American Thoracic Society (ATS) emphasize that the time of onset of pneumonia is an important risk factor for specific pathogens that may be resistant to antibiotics.¹⁶³ Early-onset hospital-acquired pneumonia (occurring within the first 4 days of hospitalization) is likely to be caused by antibiotic-sensitive bacteria and usually carries a better prognosis. Late-onset hospital-acquired pneumonia (occurring after 5 days or more of hospitalization) is more likely caused by multidrug-resistant pathogens, and is associated with greater morbidity and mortality. The population of multidrug resistant bacteria (notably, MRSA and antibiotic-resistant Gram-negative pathogens) varies among different hospitals and geographic distributions. Therefore, the selection of initial therapy for hospital-acquired pneumonia requires knowledge of the local patterns of antibiotic susceptibility.

Cancer patients with early-onset hospital-acquired pneumonia who have received antibiotics within the past 90 days, have had a recent hospitalization, or are from healthcare-associated facilities (eg, nursing

home, dialysis center) are at risk for colonization with multidrug resistant pathogens. These patients should be treated with broad spectrum regimens that include an antipseudomonal beta-lactam (eg, ceftazidime, cefepime, imipenem, meropenem, or piperacillin/tazobactam) plus an antipseudomonal fluoroquinolone (eg, ciprofloxacin or levofloxacin) or aminoglycoside, plus either linezolid or vancomycin (aim for trough vancomycin level of 15-20 mcg/mL).¹⁶³ The antibiotic regimen can be subsequently tailored based on culture results.

Pulmonary Infiltrates in Neutropenic Patients

In patients with neutropenia for less than 1 week, pulmonary infections are likely to be caused by Enterobacteriaceae (for example, *E.coli*, *Klebsiella* sp.), *P.aeruginosa*, and *S.aureus* as well as pathogens encountered in non-immunocompromised persons (as previously described). Because of the neutropenia, consolidation and sputum production may be absent. Blood cultures, a chest radiograph, and, if possible, a sputum sample for Gram stain and culture should be obtained. In suspected acute bacterial pneumonia, appropriate empiric antibiotic therapy must be initiated promptly and the response must be closely monitored in an inpatient setting. The therapeutic regimen depends on several variables, including recent use of antibiotics, community or nosocomial pneumonia, and the local antibiotic sensitivity data.

If community-acquired pneumonia is suspected (that is, pneumonia present before admission or developing within 3 to 4 days of hospitalization), addition of a macrolide or fluoroquinolone to an antipseudomonal beta-lactam is warranted to treat atypical pathogens. For nosocomial pneumonia, therapy with an antipseudomonal beta-lactam is advised, and addition of an aminoglycoside or fluoroquinolone should be considered. For cases of nosocomial pneumonia in which hospital-acquired legionellosis is suspected, empiric addition of a

macrolide or fluoroquinolone is also warranted. Vancomycin or linezolid should be added for pneumonia in patients colonized with MRSA and for nosocomial pneumonia at centers in which MRSA is common. Community respiratory viruses should also be considered, especially during winter months. Respiratory syncytial virus, parainfluenza, and influenza are significant pathogens during neutropenia in patients receiving chemotherapy for acute leukemia and in HSCT recipients.

If clinical improvement occurs within 48 to 72 hours of therapy, no further diagnostic measures are necessary; antibiotic therapy should be continued until neutropenia resolves and for at least 10 to 14 days. Once neutropenia resolves, an appropriate oral antibiotic regimen can be administered for the remainder of the course.

In cases of refractory pneumonia, bacterial infection resistant to the initial antibiotic regimen and nonbacterial pathogens should be considered, particularly filamentous fungi. A CT scan of the chest is useful in defining the location and morphology of the lesions, and in guiding diagnostic procedures. A “halo sign” in a persistently febrile neutropenic patient is highly suggestive of invasive aspergillosis;¹⁶⁴ however, angioinvasive infections including other filamentous fungi and *P.aeruginosa* may produce similar findings.

A new or progressive infiltrate developing in patients with prolonged neutropenia (for example, more than 10 days) receiving broad spectrum antibacterial agents suggests invasive aspergillosis or infection with other molds. Consider adding voriconazole or a lipid formulation of amphotericin B while waiting for diagnostic results. Empiric modification of the antibacterial regimen based on the predominant local hospital pathogens (for example, MRSA, antibiotic-resistant Gram-negative bacteria) is also warranted in patients with a rapidly progressive pneumonia.

Pulmonary Infiltrates in Patients With Impaired Cellular Immunity

Patients with impaired cellular immunity are at increased risk for common bacterial infections and opportunistic infections, including fungi (*Aspergillus* and other filamentous fungi, *Cryptococcus neoformans*, dimorphic fungi), *Legionella*, *P.jirovecii*, *M.tuberculosis*, nontuberculous mycobacteria, *Nocardia* species, and viral pathogens.

In patients with clinical and radiographic findings suggestive of acute bacterial pneumonia (for example, acute onset fever, respiratory symptoms, and a focal infiltrate), the diagnosis and management are similar to that for neutropenic patients. An antipseudomonal beta-lactam plus either a respiratory quinolone or azithromycin is a reasonable initial regimen in patients with pneumonia requiring hospitalization. In allogeneic HSCT recipients with GVHD not receiving mold-active prophylaxis, addition of a mold-active drug (for example, voriconazole) should be considered. Particularly among the most highly immunocompromised patients (for example, significant GVHD), the differential diagnosis is very broad, and an initial empiric regimen cannot have activity against all possible pathogens. We emphasize the need to establish a definitive diagnosis in patients with negative diagnostic results who are deteriorating clinically after a 2 to 3 day trial of broad spectrum antibiotics.

Diffuse infiltrates have a broad differential diagnosis, including PCP, viral infections, hemorrhage, and drug-induced pneumonitis. A diagnosis of PCP should be considered in patients with significantly impaired cellular immunity not receiving PCP prophylaxis who present with diffuse pulmonary infiltrates. Bronchoalveolar lavage is the standard approach for diagnosing PCP. In patients with substantial respiratory disease (eg, labored breathing, requiring supplemental oxygen), empiric therapy should be initiated before BAL. Pending BAL results, an initial regimen can include a respiratory fluoroquinolone against community-acquired pathogens and TMP-SMX (TMP

component: 5 mg/kg every 8 hours) against possible PCP. In patients with suspected PCP and with room air PaO₂ of 75 torr or less, corticosteroids (initially prednisone 40 mg twice daily, then tapered) should be added based on studies of patients with AIDS-associated PCP.¹⁶⁵

Patients at the highest risk for CMV pneumonia include allogeneic HSCT recipients post-engraftment (particularly those receiving immunosuppressive therapy for GVHD) and alemtuzumab recipients. Negative CMV surveillance testing (antigenemia or peripheral blood PCR) makes CMV pneumonia very unlikely. Cytomegalovirus pneumonia is uncommonly observed in non-transplanted patients receiving therapy for leukemia.¹⁶⁶ Community respiratory viruses can cause severe pulmonary infection in neutropenic patients and in non-neutropenic patients with impaired cellular immunity. Noninfectious etiologies must also be considered, as previously stated. Bronchoalveolar lavage is sensitive in diagnosing bacterial and viral pneumonia and PCP, and is often the initial invasive diagnostic procedure (described below).

Non-Invasive Diagnosis of Pneumonia

In patients with suspected pneumonia, routine sputum and blood cultures should be obtained, ideally before antibiotics are initiated or modified. Sputum cultures for *Legionella* species are sensitive if obtained before initiating antibiotics; however, specific culture conditions are required. Legionellosis can also be diagnosed based on urine antigen testing, which only detects *Legionella pneumophila* type I, the cause of most (but not all) cases of *Legionella* pneumonia. A nasopharyngeal wash is useful to diagnose community respiratory viral infections. The rapid test for influenza A and B may be performed using a throat or nasopharyngeal swab. Rapid antigen detection methods can provide a diagnosis within hours; however, if results are negative, shell vial culture takes about 5 days.

Fungal pneumonia is suggested by the following: host factors predisposing the patient to invasive aspergillosis, appropriate symptoms or signs of infection, a compatible pulmonary lesion, and a positive serum galactomannan or beta-glucan assay. Host factors indicative of high risk for invasive aspergillosis include neutropenia for more than 10 days, receipt of an allogeneic HSCT, prolonged use of high-dose systemic corticosteroids, or treatment with T-cell suppressants. The galactomannan assay is specific for invasive aspergillosis, whereas the beta-glucan assay detects aspergillosis and other invasive fungal infections (including invasive candidiasis, PCP, and fusariosis).¹⁶⁷⁻¹⁶⁹ Zygomycosis yields negative serum galactomannan or beta-glucan test results.

Antigen-based detection systems have advantages and limitations. A recent meta-analysis showed that the galactomannan assay had a sensitivity of 70% and specificity of 89% for proven invasive aspergillosis, and that the accuracy of the test varied.¹¹⁴ The lack of consistent results likely relates to different cut-off values for a positive result, differences in patient populations, and possibly use of mold-active prophylaxis. Several variables can affect the performance of the galactomannan assay,^{170,171} which may account for the different results. The sensitivity of the assay is significantly reduced by concomitant mold-active antifungal agents.^{112,172} False-positive results may be more common in children and in allogeneic HSCT recipients.¹⁷³ Concomitant piperacillin/tazobactam causes false-positive galactomannan results.^{174,175} False-positive beta-glucan results have been reported in patients with surgical packing who are receiving immunoglobulin therapy and in patients receiving intravenous amoxicillin-clavulanate.^{176,177} Despite these limitations, a patient at high risk for invasive aspergillosis (for example, prolonged neutropenia or allogeneic HSCT recipient) with clinical and radiological findings (for example, a new pulmonary nodule of 1 cm or greater or infiltrate) compatible with invasive aspergillosis and with a positive serum galactomannan is likely

to have invasive aspergillosis, and a mold-active agent (voriconazole is preferred) should be added.

The assay for serum or urine *Histoplasma* antigen is a sensitive and specific test in patients with disseminated histoplasmosis (histoplasmosis is endemic in the central United States). Coccidioidomycosis is endemic in the southwestern United States. Disseminated coccidioidomycosis can be diagnosed based on appropriate symptoms and signs of infection and on positive serum titers. Bronchoalveolar lavage is the diagnostic gold standard for PCP. In a small series, sputum induction with hypertonic saline was diagnostic of PCP in non-HIV-infected patients in about 60% of cases.¹⁷⁸ A BAL should be performed if sputum induction is attempted, and the results are negative.

Invasive Diagnostic Procedures for Pulmonary Infiltrates

Invasive diagnostic procedures may be required in the following situations: 1) the clinical course does not suggest an acute bacterial process, 2) the patient has not responded to initial antibiotic therapy, and/or 3) noninvasive testing yields negative results. Bronchoalveolar lavage has a high diagnostic yield in alveolar infiltrates, such as pneumonia caused by *P.jirovecii*, *M.tuberculosis*, and respiratory viruses. The sensitivity of BAL for focal lesions (such as nodules) is variable. In lesions more than 2 cm, the sensitivity of BAL ranges from 50% to 80%; however, in smaller lesions, the diagnostic yield is usually about 15%.¹⁷⁹ Quantitative cultures from BAL or from a protected brush catheter may increase the specificity in the diagnosis of bacterial pneumonia as distinguished from upper airway colonization in ventilated patients.

Bronchoalveolar lavage only detects about 50% of cases; therefore, it is relatively insensitive for diagnosing aspergillosis.¹⁸⁰ However, there are encouraging preliminary data from other immunosuppressed populations indicating that the galactomannan test performed on

bronchoalveolar washings has high diagnostic sensitivity and specificity.^{181,182} In patients with focal peripheral lesions, percutaneous biopsy may increase the diagnostic yield; however, in thrombocytopenic patients, the risk of bleeding may be unacceptably high. The microbiologic evaluation should take into account the clinical manifestations and nature of immunocompromise. In the highly immunocompromised (for example, those receiving chemotherapy for acute leukemia, HSCT recipients), the following studies on BAL and lung biopsies should be considered: culture and stains for bacteria, fungi, *Legionella*, mycobacteria, *Nocardia*, HSV, CMV, community respiratory viruses (both rapid antigen and shell vial culture), and cytology or immunofluorescent studies for *P.jirovecii*. In a patient with compatible host factors and radiologic findings, a positive galactomannan result from BAL is also indicative of probable invasive aspergillosis.^{181,182}

For nondiagnostic BAL or percutaneous lung biopsy results, a thoracoscopic lung biopsy should be considered if an adequate platelet count is achievable. The thoracoscopic approach has less morbidity than an open lung biopsy and generally provides adequate tissue samples for diagnosis of most infectious and noninfectious etiologies. This invasive procedure may identify the causative pathogen or the presence of a noninfectious etiology (for example, treatment-associated lung toxicity, hemorrhage, or bronchiolitis obliterans–organizing pneumonia [BOOP]), which may allow one to eliminate potentially toxic or unnecessary antimicrobial therapies. Thoracoscopic and open lung biopsies sometimes do not provide a definitive diagnosis, either due to sampling error or nonspecific pathologic findings.

Skin and Soft Tissue Infections

The evaluation and recommended empiric therapy for skin and soft tissue infections in neutropenic patients are discussed in the algorithm (see [FEV-7](#)). When evaluating the potential for a skin/soft tissue

infection, careful examination of all line sites and perineal areas are essential. Antimicrobial therapy should be tailored to the probable organism(s): Staphylococci and streptococci for catheter-associated processes as well as Gram-negative and anaerobic organisms for perineal processes, respectively. Vancomycin may be considered for cellulitis, disseminated papules/lesions, and wound infections (see [FEV-7](#)). Acyclovir, famciclovir, or valacyclovir should be considered for vesicular lesions after appropriate diagnostic tests (scraping base of vesicle for HSV or VZV, direct fluorescent antibody tests, herpesvirus culture) have been done.

Skin lesions can be manifestations of systemic infection. Ecthyma gangrenosum is the most characteristic skin lesion associated with systemic *P.aeruginosa* infection. Similar lesions can be caused by *S.aureus*, enteric Gram-negative bacilli infection, and filamentous fungi (including *Aspergillus*, *Zygomycetes*, and *Fusarium* species). A rapidly progressive deep soft tissue infection with gas formation suggests clostridial myonecrosis (or polymicrobial necrotizing fasciitis). Broad spectrum antibiotics and surgical debridement may be life saving if initiated early. Hematogenously disseminated candidiasis with skin involvement manifests as fever and erythematous cutaneous papules; blood cultures are expected to be positive for *Candida* species.

In the highly immunocompromised patient with cancer, the differential diagnosis of skin lesions is often broad and includes noninfectious etiologies such as drug reactions, Sweet's syndrome, erythema multiforme leukemia cutis, and (in the case of allogeneic HSCT recipients) GVHD. Biopsy of skin lesions for histology and culture is recommended. In allogeneic HSCT recipients, the differential diagnosis of infectious etiologies is particularly broad, and cultures from skin biopsies for bacteria, fungi, viruses, and mycobacteria should be considered when infection is suspected.

Central Nervous System Infections

CNS Infections Related to Neurosurgery

CNS infections in patients with cancer can be divided into surgical and nonsurgical complications. The IDSA has published guidelines on the management of bacterial meningitis.¹⁸³ The most common organisms infecting intraventricular devices are coagulase-negative staphylococci, *S.aureus*, and *Propionibacterium acnes*. Enterobacteriaceae and *P.aeruginosa* account for only 10% of these infections. Coagulase-negative staphylococci and *P.acnes* usually cause indolent late postoperative infections. Therapy with systemic antibiotics and removal of the entire device are the most effective approaches to eradicate infection. Use of parenteral and intraventricular instillation of antibiotics without removal of the device may not be effective, and recrudescence of infection is common. Antibiotic therapy should be tailored to the specific pathogen isolated from cerebrospinal fluid. In an acutely ill patient with suspected meningitis related to previous neurosurgery, empiric therapy can include parenteral vancomycin (which has activity against *Staphylococcus*, *Streptococcus*, and *Propionibacterium* species; dose 15 mg/kg every 8 to 12 hours to maintain serum trough concentration of 15-20 mcg/mL) in combination with ceftazidime (2 g every 8 hours), cefepime (2 g every 8 hours), or meropenem (2 g every 8 hours) (which have activity against Enterobacteriaceae and *P.aeruginosa*); these doses apply to adults with normal renal function.¹⁸³

CNS Infections Unrelated to Neurosurgery

CNS infections unrelated to neurosurgery are relatively uncommon in patients with cancer. Initial evaluation generally involves a head CT scan to rule out intracranial bleeding and a lumbar puncture (assuming there are no contraindications). Cerebrospinal fluid studies should be tailored to specific host factors, epidemiologic exposures (for example, travel history), and clinical presentation. At a minimum, cell counts with differential, glucose and protein levels, and bacterial culture and Gram

stain should be obtained. In patients with impaired cellular immunity, cryptococcal antigen and fungal culture on cerebrospinal fluid should be obtained. Noninfectious causes of meningitis include nonsteroidal anti-inflammatory agents, TMP/SMX, carcinomatous meningitis, and serum sickness (for example, associated with anti-lymphocyte immunoglobulin preparations).

A reasonable empiric regimen for suspected bacterial meningitis in patients with cancer is ceftriaxone (2 g every 12 hours in adults) plus ampicillin (2 g every 4 hours in adults with normal renal function) plus vancomycin (15 mg/kg every 8 to 12 hours in adults with normal renal function; maintain serum trough of 15 to 20 mcg/mL). This regimen has activity against the common causes of bacterial meningitis, including penicillin-resistant pneumococci and listeriosis. In patients at risk for *P.aeruginosa* meningitis (eg, neutropenia, neurosurgery within the past 2 months, allogeneic HSCT, history of *P.aeruginosa* infection), use of cefepime (2 g every 8 hours in adults with normal renal function) or meropenem (2 g every 8 hours in adults with normal renal function) instead of ceftriaxone in the initial empiric regimen is advised. The antibiotic regimen should be tailored based on culture results.

In patients with suspected encephalitis (fever, mental status changes, cerebrospinal fluid pleocytosis), intravenous acyclovir (10-12 mg/kg every 8 hours in patients with normal renal function) should be considered as empiric therapy for HSV in addition to an appropriate antibacterial regimen. An MRI and cerebrospinal fluid studies should be performed as previously described and should include PCR for HSV and cerebrospinal fluid cytology. Polymerase chain reaction for arboviruses should be considered in patients with exposure to endemic areas. Culture and PCR for tuberculosis should be considered in patients with known or suspected exposure to tuberculosis (for example, residence in an endemic area, shelter, or prison, previous positive PPD [purified protein derivative]). In patients with severe

impairment of cellular immunity (for example, allogeneic HSCT recipients, advanced AIDS), additional cerebrospinal fluid studies should be considered (such as PCR for CMV, VZV, human herpes virus–6 [HHV-6], and toxoplasmosis).

Brain abscesses usually manifest with headache, focal neurologic findings, or seizures. An MRI typically shows single or multiple lesions with edema and ring enhancement. Bacterial abscesses in non-immunocompromised patients are typically caused by dental flora. In patients with prolonged neutropenia and in allogeneic HSCT recipients, CNS aspergillosis must be considered. A chest CT showing a new nodule or infiltrate and a positive serum galactomannan result in this setting are highly suggestive of pulmonary aspergillosis with CNS dissemination. In patients with impaired cellular immunity, other causes of CNS abscesses include toxoplasmosis, nocardiosis, cryptococcosis, and mycobacterial infections. Noninfectious etiologies in patients with impaired cellular immunity include CNS malignancies (such as secondary lymphomas) and Epstein-Barr virus (EBV)–associated post-transplantation lymphoproliferative disorder (PTLD). Given the broad differential diagnosis of new CNS lesions in highly immunocompromised patients, a brain biopsy is strongly recommended (if feasible) with material submitted for histology and culture. Cultures and stains should include bacteria, fungi, mycobacteria, and *Nocardia* species.

In non-immunocompromised patients with a bacterial brain abscess, initial therapy with ceftriaxone (2 g every 12 hours in adults) plus metronidazole (7.5 mg/kg every 6 hours in adults with normal renal function) is advised. In patients with prolonged neutropenia without corticosteroids or lymphocyte-depleting agents, a reasonable initial regimen consists of combination cefepime, metronidazole, and voriconazole (intravenous 6 mg/kg every 12 hours for 2 doses followed by 4 mg/kg every 12 hours); note potential for intravenous voriconazole

to worsen renal disease in patients with pre-existing renal impairment (see [FEV-B](#)). Voriconazole (as well as itraconazole and posaconazole) has important drug-drug interactions with certain antiseizure agents (for example, phenytoin); therefore, the voriconazole package insert should be reviewed to guide dosing of these agents (<http://www.fda.gov/cder/foi/label/2006/021266s019,021267s021,021630s011lbl.pdf>). In allogeneic HSCT recipients and other patients with severe T-cell impairment, addition of high-dose TMP/SMX (trimethoprim component: 5 mg/kg every 8 hours) should be considered to cover toxoplasmosis and nocardiosis, pending a definitive diagnosis. An Infectious Diseases consultation is advised in all cases of suspected or documented CNS infections.

Therapy for Invasive Fungal Infections

Invasive Candidiasis

Candida species are the fourth most common cause of nosocomial bloodstream infections in the United States.¹⁸⁴ The crude mortality of candidemia ranges from 23% to greater than 50%. This variable mortality rate reflects serious comorbidities (such as malignancy, neutropenia) and illness requiring prolonged periods in the intensive care unit. *Candida albicans* is the most common *Candida* species isolated from the blood. The proportion of non-*albicans* *Candida* species varies among different centers, but accounts for approximately 50% of blood stream isolates. *Candida krusei* is always resistant to fluconazole, and *Candida glabrata* has a broad range of minimum inhibitory concentrations (MICs). *Candida parapsilosis* is mostly associated with vascular catheters and lipid formulations used for total parenteral nutrition.

A randomized study comparing intravenous fluconazole (400 mg daily) with amphotericin B as therapy for candidemia in non-neutropenic patients found both regimens equally effective, but fluconazole had less toxicity.¹⁸⁵ In a subsequent study of non-neutropenic patients with

candidemia, combination therapy with a higher dose of fluconazole (800 mg daily) and amphotericin B led to improved clearance of candidemia compared with fluconazole alone, but the combination regimen was associated with significantly more nephrotoxicity and with no survival benefit.¹³⁷ Voriconazole was equally effective as, but less nephrotoxic than, a strategy of amphotericin B followed by fluconazole in non-neutropenic patients with invasive candidiasis.¹⁸⁶ In trials of “invasive candidiasis,” most patients had candidemia, but those with deep organ involvement (for example, peritoneal, hepatic, or renal candidiasis) without positive blood cultures were also eligible for enrollment.

Four phase III randomized trials have been performed evaluating echinocandins as initial therapy for invasive candidiasis.¹⁸⁷⁻¹⁸⁹ When caspofungin was compared with conventional amphotericin B, there was a trend to a higher favorable response rate in the caspofungin arm (73% and 62%, respectively) in the modified intent-to-treat analysis.¹⁸⁷ Among patients who met eligibility criteria and received at least 5 days of study drug, caspofungin was statistically superior to amphotericin B (81% versus 65% successful outcome, respectively). Caspofungin was less toxic than amphotericin B. Micafungin was as effective as liposomal amphotericin B as therapy for invasive candidiasis.¹⁸⁸ There were fewer treatment-related adverse events, including those that led to treatment discontinuation, with micafungin than with liposomal amphotericin B. Anidulafungin was not inferior to fluconazole as therapy for invasive candidiasis and was possibly more efficacious.¹⁹⁰ At the end of intravenous therapy (the primary endpoint), treatment was successful in 75.6% of patients treated with anidulafungin, as compared with 60.2% of those treated with fluconazole (95% confidence interval, 3.9 to 27.0). Finally, caspofungin and micafungin were equally safe and effective as therapy for invasive candidiasis.¹⁸⁹

Taken together, the panel believes that these trials establish a lead role for the echinocandins as a class as initial therapy for candidemia and other forms of invasive candidiasis in non-neutropenic patients. Azoles (fluconazole and voriconazole) also have an important role as step-down oral agents or as initial therapy in certain patients at lower risk for mortality and serious complications. Given the availability of safer alternatives, the panel does not recommend amphotericin B products routinely for candidemia, although such agents may be considered in unusual complicated cases, such as meningitis and endocarditis. Because most studies evaluating echinocandins have included very small numbers of neutropenic patients, the optimal therapy for invasive candidiasis in this population is not definitive.

Invasive Aspergillosis

Voriconazole has become a new standard of care for invasive aspergillosis (see [FEV-B](#)). In an open-label, multicenter randomized trial of primary therapy for invasive aspergillosis, voriconazole was more effective than amphotericin B (53% versus 32% of subjects had a complete or partial response) and was associated with improved survival at 12 weeks (71% versus 58%, respectively).¹³⁹ Among neutropenic patients, the success rate in the voriconazole arm was 51%, which was superior to the amphotericin B arm.¹³⁹ In a retrospective analysis of 86 patients with CNS aspergillosis treated with voriconazole either as primary or salvage therapy, 35% had a complete or partial response.¹⁹¹ This success rate compares very favorably to previous series in which the frequency of successful responses to amphotericin B was almost nil.¹⁹² Based on the strength of this database, the panel recommends voriconazole as first-line therapy for invasive aspergillosis.

It is not clear what the optimal therapy is for breakthrough invasive aspergillosis in patients receiving mold-active prophylaxis. Breakthrough invasive aspergillosis in a patient receiving oral

posaconazole prophylaxis may be caused by inadequate oral bioavailability due to mucositis or poor oral intake, or possibly resistance. Some experts would advise changing to a different class of antifungals (such as a lipid formulation of amphotericin B, with or without an echinocandin). Others would use intravenous voriconazole with or without an echinocandin.

Lipid formulations of amphotericin B have at least comparable efficacy and reduced renal toxicity compared to conventional amphotericin B deoxycholate (AmB-D). Some investigators have persuasively argued that lipid formulations of amphotericin B should be considered suitable replacements for AmB-D for primary therapy for many invasive fungal infections.⁹⁹ Amphotericin B colloidal dispersion (ABCD) was equally effective as, but less nephrotoxic than, AmB-D as primary therapy for invasive aspergillosis.¹⁹³ Amphotericin B lipid complex (ABLC) was safe and effective as therapy for invasive aspergillosis based on an open label data registry.¹⁹⁴

A randomized study compared liposomal amphotericin B (L-AMB) at either 3 or 10 mg/kg per day for 14 days, followed by 3 mg/kg per day as therapy for invasive mold infections.¹⁹⁵ When compared with the 10 mg/kg/day dose, the 3 mg/kg/day dose was as effective as, but less nephrotoxic, and was associated with a trend toward superior 12-week survival (72% and 59%, respectively; 95% confidence interval, -0.2% to 26%). Because 97% of enrolled patients had invasive aspergillosis, this study does not permit conclusions about optimal L-AMB dosing in patients with other mold infections (such as zygomycosis).

Echinocandins have not been evaluated as initial monotherapy for invasive aspergillosis in clinical trials. Caspofungin as salvage therapy in patients with invasive aspergillosis led to a favorable response in 37 (45%) of 83 patients.¹⁹⁶ It might be possible to use combination antifungal therapy pairing an echinocandin with either an amphotericin B preparation or an azole with activity against *Aspergillus* species. The

rationale is that echinocandins target a unique site (the beta-glucan constituent of the fungal cell wall), which is distinct from the polyenes and azoles that target the fungal cell membrane. The combination of an echinocandin with an azole or amphotericin B has shown neutral to synergistic activity in vitro. Enhanced efficacy of combination regimens pairing an echinocandin with either an azole or an amphotericin B formulation was observed in some animal models of invasive aspergillosis¹⁹⁷⁻²⁰⁰ but not in others.²⁰¹⁻²⁰³

In small retrospective series, the combination of caspofungin and liposomal amphotericin B as salvage therapy led to a favorable outcome in approximately 40% to 60% of patients with invasive aspergillosis, although these series included cases of “possible” aspergillosis.^{204,205} Marr and colleagues²⁰⁶ reported a survival advantage of voriconazole plus caspofungin compared to voriconazole alone in a retrospective analysis of salvage therapy for invasive aspergillosis. This database, although encouraging, involved small numbers of patients and the 2 groups of patients evaluated were noncontemporaneous; therefore, other host and infection-related factors may have influenced the outcome. A noncomparative study of caspofungin combined with other mold-active drugs as salvage therapy for invasive aspergillosis resulted in a success rate of 49% (25/51) at 12 weeks after initiation of combination therapy,²⁰⁷ which was similar to caspofungin monotherapy. In an open-label study of invasive aspergillosis, micafungin combined with other antifungals led to a successful response in 5/17 (29%) and 60/174 (35%) of the primary and salvage treatment groups, respectively.²⁰⁸ The number of patients in the micafungin monotherapy arms was too small to permit comparisons. The initial micafungin dose (75 mg/day) used in this study was low by today’s standards.

Although combination antifungal therapy is commonly used as therapy for invasive aspergillosis, the clinical database is inadequate to make

conclusions about whether any combination regimen is more effective than voriconazole alone, which is the current gold standard. A randomized, prospective study is required to definitively assess the benefit of combination antifungal therapy in invasive aspergillosis.

Posaconazole has been effective as salvage therapy against a broad spectrum of invasive fungal infections.²⁰⁹⁻²¹² Of patients with invasive aspergillosis that was refractory or who had intolerance to standard antifungal therapy, 42% had a complete or partial response with posaconazole.²¹³ Posaconazole has been approved in the European Union for treatment of invasive aspergillosis and certain other invasive fungal infections refractory to standard antifungal agents. In the United States, posaconazole is not FDA-approved as primary or salvage therapy for invasive fungal disease.

Zygomycosis and Other Invasive Mold Infections

The frequency of zygomycosis (also referred to as “mucormycosis”) has increased at some centers in the setting of more frequent voriconazole usage.^{138,214,215} In a case-control study of invasive aspergillosis and zygomycosis in patients with acute leukemia and allogeneic HSCT recipients, use of voriconazole and fungal sinusitis each favored a diagnosis of zygomycosis.¹³⁸ However, some transplant centers reported an increased frequency of zygomycosis that pre-dated the availability of voriconazole,^{216,217} a finding that likely reflects a greater proportion of patients with severe host defense impairment. Zygomycosis typically manifests as rhinocerebral or pulmonary disease. Histopathology showing broad aseptate or hyposeptate hyphae with 90-degree branching is suggestive of zygomycosis, although culture is required for confirmation.

There are no randomized studies of therapy for zygomycosis and other uncommon invasive mold infections. Recommendations for therapy are based on a limited number of patients from retrospective analyses, data registries, and open-label salvage therapy antifungal trials. Treatment

of zygomycosis involves amphotericin B (a lipid formulation is advised) plus early and aggressive surgical debridement. There is a gap in knowledge regarding optimal dosing of lipid formulations of amphotericin B for invasive non-*Aspergillus* mold infections; an initial dose of 5 mg/kg/day is commonly used, but higher doses have been well tolerated and may be beneficial. Posaconazole, a second generation antifungal azole, is promising as salvage therapy in zygomycosis refractory to amphotericin B formulations, but it has not been evaluated as primary therapy for invasive mold infections.^{210,218}

Fusarium species²¹⁹⁻²²¹ and *Scedosporium* species became increasingly more important causes of invasive fungal infections—related mortality in leukemia and in allogeneic HSCT recipients.^{216,222,223} The likelihood of infection by a *Fusarium* species is substantially increased by the presence of disseminated cutaneous lesions and isolation of a mold from blood culture.²²⁰ Therapy for invasive fusariosis generally involves voriconazole,²²⁴ posaconazole,²¹² or a lipid formulation of amphotericin B.²²⁵ *Scedosporium* species are resistant to amphotericin B; therapy generally involves itraconazole, voriconazole, or posaconazole. An Infectious Diseases consultation is advised in all cases of invasive mold infections and particularly in diseases by uncommon and resistant molds.

Early Diagnosis of Invasive Mold Infections

Invasive fungal pathogens have increased and remain a major concern. Computed tomography scanning of the chest may facilitate early detection of aspergillosis and other filamentous fungi.^{226,227} A CT scan may show peripheral or subpleural nodules inapparent on plain chest radiographs. The “halo sign” is a characteristic early chest CT feature of angioinvasive organisms. The hazy alveolar infiltrates surrounding the central nodule or region of consolidation appear to correspond to regions of hemorrhage and are highly suggestive of invasive mold disease, aspergillosis being the most common. The panel recommends

a chest CT scan in patients with 10 to 14 days of neutropenia and with persistent or recurrent fever of unknown origin that is unresponsive to empiric antibacterial agents. A chest CT scan may be considered earlier in patients with multiple prior cycles of potentially cytotoxic chemotherapy and in those receiving systemic corticosteroid therapy.

Studies differ regarding whether serum galactomannan is a useful surveillance tool in asymptomatic patients at high risk for mold infections and in patients with persistent neutropenic fever of unknown etiology. In one study, prospective serial monitoring of galactomannan antigenemia in allogeneic HSCT recipients yielded positive and negative predictive values of 94.4% and 98.8%, respectively, and antigenemia preceded radiographic findings by more than 1 week in 80% of cases of invasive aspergillosis.²²⁸ In another study, the sensitivity was only 64.5% in cases of definite invasive aspergillosis.¹⁷³ The positive predictive value (PPV) was poor when serum galactomannan was used as a surveillance tool in patients with persistent neutropenic fever (PPV=7.1%) and in HSCT (mostly autologous) recipients (PPV=10%); the negative predictive value was 100% in both groups.

Odabasi and colleagues evaluated the beta-glucan assay (GlucateLL assay, Associates of Cape Cod) as an early diagnostic marker for invasive fungal infections in patients with acute leukemia or MDS receiving antifungal prophylaxis.¹⁶⁷ At least one serum sample was positive at a median of 10 days before the clinical diagnosis in all patients with a proven or probable invasive fungal infection, including candidiasis, fusariosis, trichosporonosis, and aspergillosis. The negative predictive value was 100%, and the specificity of the test was 90% for a single positive test result and at least 96% for 2 or more sequential positive results. The experience of the beta-glucan assay in HSCT recipients is limited¹⁶⁸ and requires additional study.

Although valuable as diagnostic adjuncts to support a diagnosis of a probable invasive aspergillosis in patients with compatible host factors as well as clinical and radiologic findings²²⁹ (see section on Pulmonary Infiltrates), the value of these laboratory markers as surveillance tools for invasive fungal infections is controversial. Use of surveillance markers as a trigger for additional diagnostic evaluation or to modify antifungal therapy is at an exploratory level,¹¹⁵ and more research is required. Currently, the database is inadequate to recommend any of these methods as a surveillance tool in asymptomatic immunocompromised patients or in patients with neutropenic fever alone.

Prevention of Infectious Diseases

Infection prophylaxis in cancer patients generally involves broad spectrum antimicrobial therapy directed against the most common infecting pathogens (including bacterial, viral, and fungal) in high-risk patients.

Antibacterial Prophylaxis During Neutropenia

Patients with cancer and chemotherapy-induced neutropenia are at risk for severe bacterial infections. Fluoroquinolones are the most commonly used prophylactic antibacterial agents in adults with chemotherapy-induced neutropenia. In a meta-analysis that evaluated 18 trials (n=1408 patients) in which fluoroquinolones were compared to either placebo or TMP/SMX, fluoroquinolone recipients had about 80% fewer Gram-negative infections than those without prophylaxis, leading to an overall reduction in total infections.²³⁰ The reduction in fever was small, and in blinded trials, was not significant. Fluoroquinolone prophylaxis did not affect mortality in this meta-analysis.

The rate of Gram-positive infections and fungal infections was not significantly affected by fluoroquinolone prophylaxis in this meta-analysis.²³⁰ This is an important consideration given the occurrence of

an increased rate of Gram-positive infections in some trials of fluoroquinolone prophylaxis.²³¹ Viridans group streptococcal bacteremia breakthroughs have been associated with ciprofloxacin prophylaxis,^{23,62} an important consideration given the potential for substantial morbidity and mortality associated with this pathogen in neutropenic patients.

Although the IDSA guidelines on management of neutropenic fever recognize the evidence that antibacterial prophylaxis in high-risk neutropenic patients reduced the frequency of Gram-negative infections, the IDSA advises against prophylaxis.²³² This recommendation is based on the concern for emergence of antibiotic-resistant bacteria and a review of previous studies that showed lack of a survival benefit associated with antibacterial prophylaxis, despite decreases in Gram-negative bacterial infections.

Recently published studies have provided additional insight into the benefits and limitations of prophylaxis among neutropenic patients with varying degrees of risk for serious infectious complications. Gafter-Gvili and colleagues²³³ conducted a meta-analysis of 95 randomized, controlled trials comparing antibiotic prophylaxis with either placebo or no intervention or with another antibiotic in afebrile neutropenic patients. Antibiotic prophylaxis significantly decreased the risk for death when compared with placebo or no treatment. The survival benefit was more substantial when the analysis was limited to fluoroquinolones. Fluoroquinolone prophylaxis reduced the risk for all-cause mortality as well as infection-related mortality, fever, clinically documented infections, and microbiologically documented infections. Most of the trials involved hospitalized patients with hematologic malignancies, and data were inadequate to assess the relationship between duration and degree of neutropenia and relative risk of mortality. There was no significant increase in fluoroquinolone-resistant bacterial infections, although the length of observation may have been too short to detect the emergence of resistant bacteria. The panel recognizes the

substantial limitations associated with meta-analyses. However, the panel believes that the benefit of prophylaxis in patients with hematologic malignancies on overall survival outweighs detriments related to adverse effects and development of resistance.

Two recent large randomized, placebo-controlled studies showed the benefit of levofloxacin prophylaxis in neutropenic patients at different levels of risk of infectious complications.^{234,235} Levofloxacin has similar activity against Gram-negative pathogens compared to ciprofloxacin and ofloxacin; however, levofloxacin has improved activity against certain Gram-positive pathogens, including streptococci. Bucaneve and colleagues²³⁵ evaluated levofloxacin prophylaxis in adult patients with cancer in whom chemotherapy-induced neutropenia (less than 1000 neutrophils/mcL) was expected to occur for more than 7 days. This protocol intentionally excluded patients anticipated to have a short duration of neutropenia who would generally be candidates for outpatient management of neutropenic fever. Levofloxacin recipients had a lower rate of microbiologically documented infections, bacteremias, and single-agent Gram-negative bacteremias than did placebo recipients. The effects of prophylaxis were also similar between patients with acute leukemia and those with solid tumors or lymphoma. Mortality and tolerability were similar in the 2 groups.

Cullen and colleagues²³⁴ evaluated levofloxacin prophylaxis after chemotherapy for solid tumors and lymphomas for patients anticipated to have brief durations of neutropenia and typically categorized as low risk. The primary outcome was the incidence of clinically documented febrile episodes (temperature more than 38°C) attributed to infection. Secondary outcomes included the incidence of all probable infections, severe infections, and hospitalization. A total of 1565 patients underwent randomization, 87% with solid tumors and 13% with lymphoma. During the entire chemotherapy course, 10.8% of levofloxacin recipients had at least one febrile episode compared with

15.2% of placebo recipients ($P=.01$). Hospitalization was required for the treatment of infection (suspected and documented) in 15.7% of patients in the levofloxacin group and 21.6% of patients in the placebo group ($P=.004$). The incidence of severe infections, infection-related mortality, and overall mortality were similar in both groups.

Thus, the main advantage of levofloxacin prophylaxis in intermediate and higher risk patients with chemotherapy-induced neutropenia was a reduction in clinically significant bacterial infections, including Gram-negative rod bacteremia.²³⁵ In contrast, the main advantage of prophylaxis in lower risk neutropenic patients was a small, but statistically significant, reduction in fever and hospitalization for neutropenic fever.²³⁴ Neither study conducted a systematic long-term evaluation of antimicrobial resistance. The NCCN panel considers that reduction in the incidence of significant infections is a more clinically meaningful endpoint than reduction in the incidence of neutropenic fever. Using the primary endpoint of prevention of neutropenic fever in the study by Cullen and colleagues,²³⁴ 1000 hypothetical low-risk patients would have to receive prophylaxis during each cycle of chemotherapy-induced neutropenia to benefit only 44 patients.

An important consideration for low-risk patients with short durations of neutropenia is whether fluoroquinolone prophylaxis is of greater benefit than the option of outpatient fluoroquinolone treatment for fever and neutropenia, should it occur. Both the NCCN and IDSA²³² recommend oral fluoroquinolone-based regimens as outpatient empiric therapy for neutropenic fever in adults who meet criteria for low risk of complications (see [FEV-14](#)). Use of fluoroquinolone prophylaxis may preclude their later use as empiric therapy for neutropenic fever in the same patient. The modest difference in rates of hospitalization for suspected infection in levofloxacin compared to placebo recipients (15.7% versus 21.6%, respectively) in the study by Cullen and

colleagues²³⁴ may be offset by exclusion of outpatient oral empiric therapy in patients receiving fluoroquinolone prophylaxis.

The decision whether to use antibacterial prophylaxis and the selection of the specific agent requires a balance between expected benefit and risk. The concept of risk applies to immediate adverse effects of the drug (for example, rash, GI intolerance), the potential for selection for resistant pathogens that can harm the individual receiving prophylaxis, and the risk of resistant organisms to a specific population of patients (for example, those being treated at a cancer center). The recent link between fluoroquinolone use and severe *C.difficile* as well as MRSA infections provides an additional cautionary note regarding excess use of fluoroquinolones.^{142,143,236,237}

The panel advises that fluoroquinolone prophylaxis (levofloxacin is preferred) be considered in patients with expected duration of neutropenia (ANC less than 1000/mcL) for more than 7 days. Trimethoprim-sulfamethoxazole should be used in patients at risk for *P.jirovecii* (formerly *P.carinii*) such as childhood acute lymphoblastic leukemia (see section on “Prophylaxis against *P.jirovecii*”). Among patients with neutropenia who are at lower risk of infectious complications (a category that includes most patients with solid tumor malignancies), the main benefit of antibacterial prophylaxis relates to a reduction in fever rather than in documented infections. In patients with neutropenia expected to last less than 7 days who are not receiving immunosuppressive regimens (for example, systemic corticosteroids), the panel suggests no antibiotic prophylaxis.

Prophylaxis Against Pneumococcal Infection

Prophylaxis against pneumococcal infection is advised in patients who have undergone splenectomy or who are functionally asplenic and in allogeneic HSCT recipients. Most cases of pneumococcal sepsis occur within the first 2 years after splenectomy; however, a third of cases may

occur up to 5 years after, and cases of fulminant sepsis have been reported more than 20 years after splenectomy. Lifelong prophylactic antibiotics have been recommended in patients who have had a splenectomy and particularly in the first 2 years after surgery, in children up to age 16 years, and in patients with other immune impairment.^{238,239} However, the need for long-term antibiotic prophylaxis makes compliance extremely difficult, and resistance to penicillin is a growing concern. Penicillin prophylaxis is a reasonable approach for at least the first 5 years after splenectomy. Some experts think that prophylaxis should be continued in patients with persistent immune impairment caused by the underlying hematologic malignancy or by chemotherapy. Alternatively, patients may be provided with supplies of penicillin or amoxicillin to be taken for fever or for other early signs of sepsis. It should be emphasized that neither immunizations nor antibiotic prophylaxis will prevent all instances of overwhelming sepsis.

Allogeneic HSCT recipients are at increased risk for pneumococcal sepsis due to functional asplenia and impaired B-cell immunity. Pneumococcal sepsis is most common in the late transplant period, between 3 months to years after HSCT. Immunosuppressive therapy for GVHD delays reconstitution of B-cell immunity and significantly increases the risk of post-transplant pneumococcal sepsis.^{34,240}

The NCCN panel advises that penicillin prophylaxis be initiated at 3 months after HSCT and be continued until at least 1 year after transplant. Prophylaxis should be continued in patients with chronic GVHD until immunosuppressive therapy has been discontinued. Post-transplant pneumococcal infection is generally community-acquired, and the frequency of resistance to antibiotics reflects regional antibiotic susceptibility patterns. In some areas, as many as 35% of pneumococcal isolates have intermediate- or high-level resistance to penicillin, and cross-resistance to other classes of antibiotics is common. Breakthrough pneumococcal sepsis in HSCT recipients

receiving penicillin prophylaxis is well described. Thus, in areas with a significant frequency of penicillin-resistant pneumococcal isolates, alternative agents should be considered based on local susceptibility patterns. Daily TMP/SMX used as prophylaxis for PCP is likely to be protective against pneumococcal disease. Vaccination with the polysaccharide pneumococcal vaccine is also strongly recommended at 1 year after cessation of immunosuppression in HSCT patients, or before a planned splenectomy, with revaccination after 5 years.

Antifungal Prophylaxis

Antifungal prophylaxis should not be used routinely in all patients with neutropenia. The rationale for antifungal prophylaxis is to prevent fungal infections in a targeted group of high-risk patients, especially those with longer durations of neutropenia or with GVHD after allogeneic HSCT. In neutropenic allogeneic HSCT recipients, 2 double-blind, placebo-controlled trials have shown that prophylactic fluconazole controlled yeast colonization as well as decreased the rate of mucosal candidiasis and invasive *Candida* infections.^{241,242} A decrease in mortality was noted in the study by Slavin and colleagues,²⁴² in which most of the patients were allograft recipients. Fluconazole conferred significant long-term improvement in survival, possibly by decreasing *Candida* antigen-induced GI tract GVHD.²⁴³

Fluconazole prophylaxis decreased fungal colonization, invasive infection, and fungal infection-related mortality in nontransplant patients with leukemia and in autologous transplant recipients in a placebo-controlled trial.²⁴⁴ However, only 30% of the patients received growth factors, and the median duration of neutropenia was 14 to 16 days.²⁴⁴ The benefit of fluconazole prophylaxis was greatest in autologous transplant recipients not receiving colony-stimulating growth factor support and in patients with leukemia receiving mucotoxic regimens consisting of cytarabine plus anthracycline. Therefore, no antifungal prophylaxis can be considered (category 2B) in autologous HSCT

recipients who receive growth factor support and who do not have significant mucositis. Other studies of nontransplant patients with acute leukemia showed no significant benefit of fluconazole.^{245,246}

The panel recognizes that there is strong evidence for the use of fluconazole as prophylaxis in allogeneic neutropenic HSCT recipients (category 1). However, as a consequence of broad fluconazole prophylaxis in allogeneic HSCT patients, *Candida glabrata* has emerged as an important cause of candidemia in this population, because it is less susceptible to fluconazole than *C. albicans*.²⁴⁷

Low-dose amphotericin B product or itraconazole have also been studied in high-risk patients and shown to provide protection against invasive molds, although they have provided no survival benefit in randomized studies with fluconazole.^{248,249} Itraconazole, however, may be associated with hepatic toxicity and GI intolerance.²⁵⁰ Itraconazole is contraindicated in persons with a decreased cardiac ejection fraction based on its negative inotropic properties. It can also increase cyclophosphamide metabolites, which in turn are associated with hyperbilirubinemia and nephrotoxicity during the early transplant period.²⁵¹ This finding reinforces a note of caution about itraconazole (and by extension, voriconazole and posaconazole), a potent inhibitor of the cytochrome P450 3A4 isoenzyme, with regard to potential serious drug-drug interactions. Based on the toxicity of amphotericin B products and the availability of safer and equally effective alternative agents, amphotericin B products were considered a category 2B recommendation for prophylaxis. If an amphotericin B product is used, a lipid formulation is generally preferred because of less infusional and renal toxicity compared to conventional amphotericin B. This recommendation is made more strongly for patients at high risk for renal failure, such as those with pre-existing renal disease, HSCT recipients and co-administration of other nephrotoxic agents.^{100,102}

The echinocandin, micafungin is approved as prophylaxis in HSCT recipients with neutropenia (category 1). In a randomized, double-blind trial of autologous and allogeneic HSCT recipients, micafungin was superior to fluconazole based on pre-specified criteria that included absence of a breakthrough fungal infection and the absence of modifying the antifungal regimen empirically due to neutropenic fever.¹⁰⁸ The duration of study drug encompassed the neutropenic period, but not the period after neutrophil recovery where GVHD would be expected to occur. The frequency of breakthrough candidemia was similar in both arms, but there was a trend to fewer episodes of invasive aspergillosis in allogeneic HSCT recipients receiving micafungin. Survival and drug-related toxicity were similar in both arms.

Voriconazole (compared with fluconazole) is being evaluated in an ongoing randomized study, but its potent anti-mold activity and good tolerability have promoted its widespread use. The panel recognizes that the multicenter randomized trial has not yet been completed but cautiously considers voriconazole (category 2B) an untested option for prophylaxis based on its efficacy in treatment trials for invasive aspergillosis.¹³⁹

Posaconazole is currently only available in an oral formulation and needs to be taken with food for adequate absorption. Posaconazole is effective as primary therapy for oropharyngeal candidiasis²⁵² but has not been evaluated as primary therapy for invasive fungal infections. Prophylaxis with posaconazole led to fewer invasive fungal infections and less overall mortality compared to fluconazole or itraconazole in neutropenic patients with acute myelogenous leukemia (AML) or MDS in a randomized trial.¹¹⁰ The NCCN panel recommends posaconazole (category 1) as the drug of choice as prophylaxis in neutropenic patients with AML and MDS (see [INF-3](#)). Posaconazole as prophylaxis has not been evaluated during the neutropenic period following conditioning in allogeneic HSCT recipients, and thus the safety of this

approach is unknown. Ingestion of a meal (ideally high-fat) or liquid nutritional supplement with each posaconazole dose is essential for achieving adequate posaconazole serum levels; patients who are unable to tolerate such oral intake should not receive this drug for prophylaxis.

The panel advises that prophylaxis with posaconazole, itraconazole, and voriconazole be avoided in patients receiving vinca alkaloid-based regimens (such as vincristine in acute lymphoblastic leukemia) because of the potential of these azoles to inhibit the cytochrome P450 3A4 isoenzyme, reducing clearance of vinca alkaloids. Severe vinca alkaloid-induced neurotoxicity has occurred when co-administered with itraconazole,²⁵³ data on pairing vinca alkaloids with posaconazole and voriconazole are lacking. Although the package inserts of voriconazole and posaconazole advise caution if co-administered with vinca alkaloids and consideration of dose-reducing the vinca alkaloid, there are no data on the level of dose reduction required. Prophylaxis with fluconazole (which is a less potent inhibitor of cytochrome P450 3A4 than the mold-active azoles), an echinocandin, or an amphotericin B formulation should be considered in these patients as a safer alternative to the mold-active azoles.

Patients with chronic severe neutropenia (ANC less than 500/mcL) due to the underlying disease (such as aplastic anemia) are at substantial risk for invasive aspergillosis.²⁵⁴ Although this population has not been evaluated in prophylactic antifungal trials, some panel members advise the use of a prophylactic mold-active agent (for example, posaconazole or voriconazole) in such patients.

In patients with acute leukemia and autologous HSCT recipients, antifungal prophylaxis is administered until neutrophil recovery. Antifungal prophylaxis should be considered until at least day 75 after allogeneic HSCT (see [INF-3](#)). Although many centers reasonably use antifungal prophylaxis in non-neutropenic allogeneic HSCT recipients

with GVHD, this practice only recently was evaluated in a properly designed study that focused specifically on this patient group. Posaconazole was compared with fluconazole as prophylaxis in allogeneic HSCT recipients with severe GVHD requiring intensive immunosuppressive therapy in a prospective, randomized, double-blind study.²⁵⁵ The inclusion criteria included either grade II to IV GVHD, chronic extensive GVHD, or receiving intensive immunosuppressive therapy consisting of either high-dose corticosteroids, antithymocyte globulin, or a combination of 2 or more immunosuppressive agents or types of treatment. Prophylaxis with posaconazole led to a reduction in the incidence of invasive aspergillosis, the total number of invasive fungal infections while on treatment, and the number of deaths attributed to fungal infection. Posaconazole is recommended (category 1) as prophylaxis in patients with GVHD receiving intensive immunosuppressive therapy, as defined by the inclusion criteria in this trial. Prophylactic posaconazole can be considered in all patients with GVHD receiving immunosuppressive therapy, although the benefit/risk ratio of mold-active prophylaxis in patients receiving less intensive immunosuppressive regimens has not been established.

The panel recommends secondary prophylaxis with an appropriate antifungal agent in patients with prior chronic disseminated candidiasis²⁵⁶ or with invasive filamentous fungal infection²⁵⁷ during subsequent cycles of chemotherapy or HSCT. In patients with invasive aspergillosis before HSCT, antifungal therapy for more than a month and resolution of radiologic abnormalities correlate with a lower likelihood of post-transplant recurrence of infection.²⁵⁸ Secondary prophylaxis with a mold-active agent is advised for the entire period of immunosuppression. Secondary prophylaxis is generally administered for the duration of immunosuppression.

Antiviral Prophylaxis and Preemptive Antiviral Therapy

Herpes Simplex Virus

Herpes simplex virus is an important pathogen in patients who develop neutropenia and mucositis. These HSV infections are primarily reactivation of latent virus. The presence of latent HSV can be determined by pretreatment HSV serology. Reactivation and infection with HSV occur in 60% to 80% of HSCT recipients and in unprophylaxed patients with acute leukemia undergoing induction or re-induction therapy who are seropositive for HSV.^{259,260} Among allogeneic HSCT recipients, HSV disease is most likely to occur within the first month, but may occur in later stages during intense immunosuppression. Although disseminated HSV infection is uncommon, the reactivation infection is frequently associated with increased mucosal damage, resulting in increased pain, limitation of the patient's ability to maintain oral hydration and nutrition, and an increased risk of bacterial and fungal superinfections.

Antiviral prophylaxis (acyclovir, valacyclovir, or famciclovir) against HSV is advised in HSV-seropositive patients receiving chemotherapy for acute leukemia, in all allogeneic HSCT recipients, and in some autologous HSCT recipients at high risk for mucositis during the neutropenic period.¹⁴ A longer period of prophylaxis should be considered in allogeneic HSCT recipients with GVHD or with frequent HSV reactivations before transplantation.¹⁴

Herpes simplex virus and herpes zoster infections are common in alemtuzumab recipients. Antiviral prophylaxis is advised until at least 2 months after completion of therapy or until CD4 counts are 200/mcL or more, whichever occurs later.

Prophylaxis against HSV should be considered in other patients at intermediate risk for HSV reactivation including those with hematologic malignancies with prolonged neutropenia or those receiving high-dose

corticosteroids or T-cell depleting agents (such as, fludarabine). Once a patient has had an HSV reactivation infection requiring treatment, the panel recommends HSV prophylaxis for that patient during all future episodes of neutropenia induced by cytotoxic therapy.

Varicella Zoster Virus

Impaired cellular immunity is the principal risk factor for VZV disease. In allogeneic HSCT recipients with a history of VZV infection without antiviral prophylaxis, about 30% have VZV disease after reactivation. In patients with a history of chicken pox, acyclovir (800 mg oral twice daily)—administered from 1 to 2 months until 1 year after allogeneic HSCT—significantly decreased the incidence of VZV disease compared to placebo (5% versus 26%, respectively).²⁶¹ The frequency of VZV disease in the post-prophylactic period was similar in the 2 groups and predominantly occurred in patients who required systemic immunosuppression. This prolonged course of acyclovir prophylaxis is likely to also prevent HSV reactivations. The panel recommends acyclovir prophylaxis against VZV from the 1st to 12th month after allogeneic HSCT in patients seropositive for VZV pretransplant and recommends considering extending prophylaxis in patients who continue to receive systemic immunosuppressive therapy. Agents used as HSV prophylaxis are also active against VZV, although higher doses may be optimal for VZV prophylaxis (see [FEV-C](#)).

Other patients at increased risk for VZV and HSV reactivation include autologous HSCT recipients (first year) and those receiving T-cell depleting agents (for example, alemtuzumab, fludarabine, calcineurin inhibitors) and bortezomib (a proteasomal inhibitor).^{262,263} Prophylaxis with acyclovir, valacyclovir, or famciclovir should be protective and can be considered in these settings. Among alemtuzumab recipients, antiviral prophylaxis is recommended by the FDA until 2 months after the drug is stopped or until the CD4 count is 200/mcL or more, whichever occurs later.

Cytomegalovirus

In allogeneic HSCT recipients at risk for CMV reactivation, the following preventative approaches have been evaluated:²⁶⁴ 1) prophylaxis: antiviral agents are administered to all allogeneic HSCT recipients if either the donor or recipient is CMV seropositive; and 2) pre-emptive therapy: initiation of antiviral agents after detection of asymptomatic CMV infection by active surveillance. Antiviral agents potentially active against CMV have substantial toxicity with long-term use. Ganciclovir is associated with marrow suppression that may increase the risk of common and opportunistic infections. Foscarnet can cause nephrotoxicity but is generally well tolerated. Cidofovir (a second-line anti-CMV agent) is associated with substantial nephrotoxicity. Acyclovir and valacyclovir have an excellent safety profile but are only weakly active against CMV.

In 2 randomized studies, prophylaxis with acyclovir was associated with increased survival in allogeneic HSCT recipients, but the rates of CMV reactivation and disease were fairly high.^{265,266} Ljungman and colleagues²⁶⁷ compared oral valacyclovir (a valine esterified analogue of acyclovir with high oral bioavailability) with acyclovir as prophylaxis in allogeneic HSCT recipients in whom either the donor or recipient was CMV seropositive. All patients received initial intravenous acyclovir until day 28 after transplantation or until discharge, and then either oral valacyclovir or acyclovir until week 18 after transplantation. Valacyclovir was more effective than acyclovir in preventing CMV reactivation (28% versus 40%, respectively); no difference was observed in CMV disease, adverse events, or overall survival. Thus, acyclovir and valacyclovir are acceptable agents for CMV prophylaxis, but surveillance and pre-emptive therapy with ganciclovir or foscarnet are still necessary.

Highly sensitive methods for early CMV diagnosis include detection of the CMV pp65 antigen from peripheral blood leukocytes and of CMV DNA by PCR. Triggers for pre-emptive antiviral therapy are either a

single positive CMV antigenemia or 2 consecutive positive PCR results. Foscarnet and ganciclovir had similar efficacy as pre-emptive CMV therapies in allogeneic HSCT recipients, but ganciclovir was associated with significantly more premature discontinuation because of either neutropenia or thrombocytopenia.²⁶⁸ Oral valganciclovir used as pre-emptive anti-CMV therapy was shown to have acceptable oral bioavailability (including, in patients with grades I and II GI GVHD); was safe and effective in controlling CMV reactivation.²⁶⁹⁻²⁷² Thus, valganciclovir is a highly acceptable oral option for pre-emptive therapy for CMV in the absence of substantial GI GVHD.

Late CMV disease, defined as occurring after day 100 of HSCT, remains a persistent problem in the era of CMV prophylaxis and pre-emptive therapy. In one series, 92% of patients with late CMV pneumonia had chronic GVHD or had received T cell-depleted transplants.²⁷³ T-cell reconstitution results—at 3 months after allogeneic HSCT—appear to be useful in risk stratification for late CMV disease. At 3 months after HSCT, CD4 T-cell counts less than 50/mcL, total lymphocyte counts less than 100/mcL, undetectable CMV-specific T-cell responses, and GVHD were associated with late CMV disease or death in CMV-seropositive allogeneic HSCT recipients.²⁷⁴ A CD4+ count less than 100/mcL predicted delayed recovery of CMV-specific immunity at 3 months after allogeneic HSCT.²⁷⁵ In a case-control study, CMV disease was significantly delayed in nonmyeloablative compared with standard ablative allogeneic transplantation (median time, 132 versus 52 days, respectively); the overall 1-year incidence was similar between the 2 groups.²⁷⁶ Tetramer technology allows quantification of CMV antigen-specific CD4+ and CD8+ cells as a marker for reconstitution of CMV-specific cellular immunity; it may more precisely stratify the risk for CMV disease and need for CMV surveillance.²⁷⁷

Based on the available data that predict risk of CMV disease, the NCCN panel recommends CMV surveillance for at least 6 months after

allogeneic HSCT. Additional surveillance should be strongly considered during chronic GVHD requiring immunosuppressive therapy and until the CD4+ count is 100/mcL or more. Note that the CD4 count will be reduced by systemic corticosteroids and by lymphocyte-depleting agents. The majority of cases of late CMV disease occur within the first year of transplant and less than 5% occur after the second year.^{273,274} Therefore, the value of CMV surveillance beyond 2 years after HSCT is unknown but can be considered in patients with significant chronic GVHD.

Cytomegalovirus reactivation is common among alemtuzumab recipients and occurs most frequently between 3 to 6 weeks after initiation of therapy when T-cell counts reach a nadir. The NCCN panel recommends surveillance for CMV reactivation using PCR or antigen-based methods and monitoring at least weekly. The panel recommends pre-emptive therapy with ganciclovir, foscarnet, or valganciclovir in alemtuzumab recipients from the time of initiation until at least 2 months after completion of alemtuzumab therapy or until the CD4 count is 100/mcL or more, whichever occurs later (see [INF-6](#)).

Hepatitis B Virus

Reactivation of latent hepatitis B virus (HBV) may occur in the setting of significant immunosuppression (for example, HSCT). HBV carriers with lymphoid malignancies, especially those treated with anthracycline-based regimens, have a high risk of HBV reactivation.²⁷⁸ Rare cases of liver failure and death associated with HBV reactivation have occurred in patients receiving rituximab-containing regimens (www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Rituxan). Fulminant hepatitis and mortality may occur following HBV reactivation in immunocompromised patients. Thus, it is prudent in these settings to assess for the potential of prior HBV infection, especially in individuals who have spent significant time in HBV endemic areas or have risk factors for blood-borne exposure.

A positive hepatitis B surface antigen (HBsAg) is associated with active infection (or a window period before the development of protective immunity). False-negative HBsAg results may occur in chronic liver disease.²⁷⁹ A positive hepatitis B surface antibody (HBsAb) is generally equated with protective immunity, although reactivated HBV disease may occur in the setting of significant immunosuppression in HBsAb-positive individuals.²⁸⁰

In patients undergoing intensive immunosuppressive therapy, evaluation of HBV surface antigen, core antibody, and surface antibody should be considered at baseline. Evaluation of HBV and hepatitis C virus infection should be routine in HSCT recipients and donors. In HBsAg-positive individuals, baseline quantitative PCR for HBV DNA should be obtained. Based on limited data, antiviral therapy (for example, lamivudine) should be strongly considered in patients with active HBV infection undergoing HSCT or other intensive immunosuppression.^{278,281, 282} Donors who have not been exposed to HBV should be considered for HBV vaccination before stem cell collection when the recipient is HBsAg-positive.

Vaccination

Both the CDC and the European Bone Marrow Transplant group have published guidelines on vaccination of HSCT recipients.^{35,283} The ACIP has recently published general recommendations on immunization that include immunocompromised patients.²⁸⁴ We discuss general principles regarding vaccination in patients with cancer, with a focus on influenza.

Live attenuated viral vaccines have the potential to cause disease in immunocompromised patients. Vaccines that are not live attenuated organisms can be safely administered to the immunocompromised. However, the immunogenicity of the vaccines may be attenuated in immunocompromised patients. The potential for protection conferred by antigen-derived vaccines, even if incomplete, is better than no protection if the vaccine is withheld. Persons receiving chemotherapy or

radiation therapy for malignancies should not receive live attenuated vaccines for at least 3 months after therapy has been stopped and the patient is presumed to be immunocompetent.²⁸⁴ Certain live viral vaccines can be safely administered to household members of severely immunocompromised patients (for example, measles, mumps, and rubella [MMR]), whereas others can not (for example, small pox vaccine) because of the potential risk of transmission. The package insert for the vaccine should be reviewed before administration.

Ideally, patients should be vaccinated at least 2 weeks before receiving cytotoxic or immunosuppressive therapy; however, this timing is often not feasible in patients with cancer. Administering vaccines on the same day as cytotoxic therapy is not advised, because proliferative lymphocytic responses are required for protective immunity.

Immunization between cytotoxic chemotherapy courses is likely to be associated with higher response rates than during chemotherapy administration.^{285,286} Patients should be considered unprotected if they were vaccinated less than 2 weeks before starting cytotoxic or immunosuppressive therapy or while receiving these agents. These patients should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored.²⁸⁴

Pneumococcal, meningococcal, and Hib vaccines should be administered at least 2 weeks before elective splenectomy.²⁸⁴

Influenza infections cause significant morbidity and mortality in cancer patients. Among bone marrow transplant recipients, influenza accounts for 11% to 42% of all community-acquired viral respiratory infections.²⁸⁷⁻²⁸⁹ An increased incidence and duration of influenza infections have also been observed in immunosuppressed cancer patients when compared to healthy controls.^{290,291} During community outbreaks, influenza infections may represent a significant proportion of episodes of febrile neutropenia.²⁹² Influenza infections in severely immunocompromised cancer patients are often associated with

hospitalizations, delays in potentially life-saving chemotherapy, and occasionally, death.²⁹⁰⁻²⁹² As a result, annual vaccination against influenza with the inactivated influenza virus is currently recommended for all individuals at increased risk from immunosuppressive disease in several countries, including the United States, Canada, and United Kingdom.²⁹³⁻²⁹⁵ The United States and Canadian guidelines also include health care workers and household contacts in their target group for annual immunization, because they can transmit influenza to high-risk patients.^{293,294}

The intranasal attenuated influenza vaccine (FluMist) should be avoided in patients with immunosuppression, because FluMist contains live attenuated influenza viruses still capable of replication, which could theoretically lead to infection in immunocompromised individuals.²⁹⁶ As a result, the CDC recommends that persons with known or suspected immunodeficiency diseases or those who are receiving immunosuppressive therapies should not be immunized with the live influenza vaccine.²⁹⁶ In addition, because no data are available assessing the risk for person-to-person transmission of FluMist from vaccine recipients to immunosuppressed contacts, the CDC also recommends that inactivated influenza vaccine should be used in household contacts, health-care workers, and others who have close contact with immunocompromised patients.²⁹⁶

Prophylaxis for *Pneumocystis jirovecii* (formerly *Pneumocystis carinii*)

Trimethoprim/sulfamethoxazole prophylaxis for *P.jirovecii* is highly effective.²⁹⁷ Studies have documented the efficacy of this prophylactic therapy in patients with acute lymphocytic leukemia, and similar results have been found in bone marrow transplant recipients. TMP/SMX also has the potential advantage of protecting against other infectious complications (such as common bacterial infections, listeriosis, nocardiosis, and toxoplasmosis) that afflict patients with severe T-cell

impairment. The more difficult questions include: (1) What prophylactic regimen should be used in patients who are truly intolerant of TMP/SMX? and (2) Besides acute leukemia patients, which other patients warrant *P.jirovecii* prophylaxis? TMP/SMX is preferred; TMP/SMX desensitization can be considered in patients who are intolerant to TMP/SMX. Daily dapsone and aerosolized pentamidine are thought to be effective alternatives to TMP/SMX, although data suggest aerosolized pentamidine may be inferior when used prophylactically in allogeneic transplant recipients.²⁹⁸ Atovaquone appears to be equivalent to dapsone in HIV patients who cannot tolerate TMP/SMX. Thus, atovaquone is another alternative for oncology patients who require prophylaxis.²⁹⁹

Prophylaxis against PCP should be used in allogeneic transplant recipients, alemtuzumab recipients (<http://www.fda.gov/cder/foi/label/2007/103948s5070lbl.pdf>), and patients with acute lymphocytic leukemia (category 1). Prophylaxis against PCP is also advised in patients receiving concomitant temozolomide and radiotherapy and should be continued until recovery from lymphocytopenia (see Warnings) (<http://www.fda.gov/cder/foi/label/2006/021029s012lbl.pdf>).³⁵ Some panel members advise prophylaxis against PCP (category 2B) for the following patients: 1) patients receiving fludarabine therapy and other T-cell depleting agents (for example, cladribine [2-CdA]); 2) autologous hematopoietic cell transplant recipients; and 3) patients with neoplastic diseases receiving intensive corticosteroid treatment (for example, the equivalent of 20 mg or more of prednisone daily for 4 weeks or more).³⁰⁰

Protected Environments

Although well-designed clinical trials have not validated the use of high-efficiency particulate air (HEPA) filtration, the CDC recommends that allogeneic HSCT recipients be placed in rooms with HEPA filters.¹⁴ It is

also reasonable to use HEPA filtration in nontransplant patients with prolonged neutropenia. The principal benefit of HEPA filtration is likely to be related to prevention of mold infections. In a retrospective analysis, HEPA filters were protective in highly immunocompromised patients with hematologic malignancies in the setting of an outbreak of aspergillosis.³⁰¹ The value of laminar air flow in preventing infections is unclear and is not generally recommended.

Summary

Previous NCCN guidelines related to infectious complications of cancer were primarily focused on fever and neutropenia. However, the guidelines were revised in 2007 to address prevention and treatment of infections in both neutropenic and non-neutropenic immunocompromised patients with cancer. These NCCN guidelines on “Prevention and Treatment of Cancer-Related Infections,” replace the previous “Fever and Neutropenia” guidelines.

Substantial progress has been made in preventing and treating infectious complications of neutropenia and immunosuppressive therapy in patients with cancer. It is essential to know the patient's quantitative and qualitative immune defects and to stratify the risk for specific pathogens in the context of the history, physical examination, radiologic, and laboratory data. The development of antipseudomonal beta-lactam agents and the routine use of empiric antibacterial therapy at the onset of neutropenic fever reduced mortality from bacterial infections.³⁰² More patients were treated with potent cytotoxic regimens (for example, for acute leukemia) and received allogeneic stem cell transplants; opportunistic viral and fungal infections became an important cause of mortality in these patients. In addition, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and

demand careful hand-washing by all health care professionals who come into contact with immunocompromised patients.

Disclosures for the NCCN Prevention and Treatment of Cancer-Related Infections Guideline Panel

At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers' bureau participation. Members of the panel indicated that they have received support from the following: Amgen; Astellas Pharma; Berlex Laboratories; BioCryst Pharmaceuticals; BioPharma; Chimerix Inc.; Cubist Pharmaceuticals; Elan Corp.; Enzon Pharmaceuticals; Genzyme Pharmaceuticals; Merck & Co., Inc.; Pfizer, Inc.; Roche; Schering Plough Corp.; ViraCor Laboratories; ViroPharma Incorporated; and Wyeth. Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.

References

1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. *N Engl J Med* 1993;328:1323-1332.
2. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. *Am J Med* 1986;80[suppl 5c]:13-20.
3. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002;34:730-751.
4. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime vs imipenem. *J Clin Oncol* 1995;13:165-176.
5. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy: International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. *N Engl J Med* 1999;341:312-318.
6. Rolston KV, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. *Infect Dis Clin North Am* 1996;10(2):223-237.
7. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. *Lancet* 1992;339:1092-1096.
8. Hidalgo M, Hornedo J, Lumberras C. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever, a prospective randomized clinical trial. *Cancer* 1999;85:213-219.
9. Aquino VM, Herrera L, Sandler ES, et al. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. *Cancer* 2000;88:1710-1714.
10. Talcott JA, Whalen A, Clark J, et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients, based on a validated prediction rule. *J Clin Oncol* 1994;12:107-114.
11. Talcott J, Siegel R, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. *J Clin Oncol* 1992;10:316-322.
12. Talcott J, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neutropenia. *Arch Intern Med* 1988;148:2561-2568.
13. Rolston KV. Outpatient management of febrile, neutropenic patients. *Infections in Medicine* 1995;12:5.
14. Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. *Hematology (Am Soc Hematol Educ Program)* 2001:392-421.
15. Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). *Clin Exp Immunol* 1992;89:374-377.
16. Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. *Ann Intern Med* 1982;96:47-50.
17. DiNubile MJ. Fever and neutropenia: still a challenge. *Contemp Intern Med* 1995;7(1):35-37, 41-45.
18. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. *Ann Intern Med* 1984;100:345-351.
19. Wade JC. Management of infection in patients with acute leukemia. *Hematol Oncol Clin North Am* 1993;7:293-315.

20. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med* 1966;64:328-340.
21. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. *Eur J Clin Microbiol Infect Dis* 1996;15:291-296.
22. Engelhard D, Elishoov H, Or R, et al. Cytosine arabinoside as a major risk factor for *Streptococcus viridans* septicemia following bone marrow transplantation: a 5-year prospective study. *Bone Marrow Transplant* 1995;16:565-570.
23. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. *Am J Med* 1994;97:256-264.
24. Rossetti F, Cesaro S, Putti MC, Zanesco L. High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. *Pediatr Hematol Oncol* 1995;12:387-392.
25. Bow EJ, Loewen R, Cheang MS, et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. *J Clin Oncol* 1997;15:2254-2261.
26. Kalhs P, Kier P, Lechner K. Functional asplenia after bone marrow transplantation [letter]. *Ann Intern Med* 1990;113:805-806.
27. Anaissie E, Kontoyiannis DP, Kantarjian H, et al. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. *Ann Intern Med* 1992;117:466-469.
28. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]. *Blood* 1993;82:1695-1700.
29. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. *Leuk Lymphoma* 2002;43:1755-1762.
30. Buhles WC Jr, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. *Rev Infect Dis* 1988 Jul-Aug;10 Suppl 3:S495-506.
31. Sandherr M, Einsele H, Hebart H, et al; Infectious Diseases Working Party, German Society for Hematology and Oncology. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). *Ann Oncol* 2006;17(7):1051-1059. Epub 2006 Jan 12.
32. Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* 2002;8:281-289.
33. Winston DJ, Schiffman G, Wang DC, et al. Pneumococcal infections after human bone-marrow transplantation. *Ann Intern Med* 1979;91:835-841.
34. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. *Blood* 2000;95:3683-3686.
35. Dykewicz CA; CDC; IDSA; ASBM. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2001;33:139-144. Epub 2001 Jun 14.
36. Meijer E, Dekker AW, Rozenberg-Arska M, et al. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. *Clin Infect Dis* 2002;35:703-712.

37. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. *Blood* 2002;100:4358-4366.
38. Donawitz GR, Harman C, Pope T. The role of the chest roentgenogram in febrile neutropenic patients. *Arch Intern Med* 1991;151:701-704.
39. Gaur AH, Flynn PM, Giannini MA, et al. Difference in time to detection: a simple method to differentiate catheter-related from non-catheter-related bloodstream infection in immunocompromised pediatric patients. *Clin Infect Dis* 2003;37:469-475.
40. Siegman-Igra Y, Anglim AM, Shapiro DE, et al. Diagnosis of vascular catheter-related bloodstream infection: A meta-analysis. *J Clin Microbiol* 1997;35:928-936.
41. Englund JA, Sullivan CJ, Jordan MC, et al. Respiratory syncytial virus infection in immunocompromised adults. *Ann Intern Med* 1988;109:203-208.
42. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. *J Infect Dis* 1992;165:987-993.
43. Oblon D, Ramphal R. A randomized trial of cefepime vs ceftazidime as initial therapy for patients with prolonged fever and neutropenia after intensive chemotherapy (abstract). *Proc Ann Mtg Am Assoc Cancer Res* 1993;34:A1362.
44. De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial. *Ann Intern Med* 1994;120:834-844.
45. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem vs combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. *Antimicrob Agents Chemother* 1996;40:1108-1115.
46. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. *Clin Infect Dis* 2006;43:447-459.
47. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. *Lancet Infect Dis* 2007;7(5):338-348.
48. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2006;57(2):176-189. Epub 2005 Dec 12.
49. Flaherty JP, Waitley D. Multicenter randomized trial of ciprofloxacin plus azlocillin vs ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. *Am J Med* 1989;87[suppl 5A]:278S-282S.
50. Cometta A, Zinner S, de Bock R, et al. Piperacillin/tazobactam plus amikacin vs ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer: The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. *Antimicrob Agents Chemother* 1995;39:445-452.
51. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime/amikacin vs ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. *Clin Infect Dis* 1997;24:41-51.
52. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. *Antimicrob Agents Chemother* 1999;43:1549-1555.
53. European Organization for Research and Treatment of Cancer (EORTC), International Antimicrobial Therapy Cooperative Group, and the National Cancer Institute of Canada - Clinical Trials Group:

Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. *J Infect Dis* 1991;163:951-958.

54. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. *N Engl J Med* 1988;319:1053-1058.

55. Granowetter L, Wells H, Lange BJ. Ceftazidime with or without vancomycin vs. cephalothin, carbenicillin and gentamicin as the initial therapy of the febrile neutropenic pediatric cancer patient. *Pediatr Infect Dis J* 1988;7:165-170.

56. Brown AE, Kiehn TE, Armstrong D. Bacterial resistance in the patient with neoplastic disease. *Infect Dis Clin Pract* 1995;4[suppl 3]:S136-144.

57. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. *MMWR* 2002;51:565-567.

58. Centers for Disease Control and Prevention: Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). *Morb Mortal Wkly Rep* 1995;44(RR-12):1-13.

59. Wade JC, Schimpff SC, Newman KA, et al. Staphylococcus epidermidis: An increasing but frequently unrecognized cause of infection in granulocytopenic patients. *Ann Intern Med* 1982;97:503-508.

60. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer: Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer: A trial of oral penicillin V or placebo combined with pefloxacin. *JAMA* 1994;272:1183-1189.

61. Arning M, Wolf HH, Aul C, et al. Infection prophylaxis in neutropenic patients with acute leukemia—a randomized, comparative study with

ofloxacin, ciprofloxacin and cotrimoxazole/colistin. *J Antimicrob Chemother* 1990;26[suppl D]:137-142.

62. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. *Clin Infect Dis* 1992;14:1201-1207.

63. Kerr KG, Armitage HT, McWhinney PH. Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. *Support Care Cancer* 1999;7:28-30.

64. McWhinney PH, Patel S, Whiley RA, et al. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. *Antimicrob Agents Chemother* 1993;37(11):2493-2495.

65. Tunkell AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. *Clin Infect Dis* 2002;34:1524-1529.

66. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. *Clin Infect Dis* 2003;37:382-389.

67. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. *Clin Microbiol Infect* 2006;12:212-216.

68. Erjavec Z, de Vries-Hospers HG, Laseur M, et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. *J Antimicrob Chemother* 2000;45:843-849.

69. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. *Ann Intern Med* 2003;138:135-142.

70. Linden PK, Moellering RC Jr, Wood CA, et al. Synercid Emergency-Use Study Group. Treatment of vancomycin-resistant Enterococcus

faecium infections with quinupristin/dalfopristin. *Clin Infect Dis* 2001;33:1816-1823.

71. Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. *Ann Oncol* 2003;14:795-801.

72. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. *Clin Infect Dis* 2006;42:597-607.

73. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia. *Chest* 2003;124(5):1789-1797.

74. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. *Expert Opin Investig Drugs* 2003;12:379-399.

75. Bozdogan B, Esel D, Whitener C, et al. Antibacterial susceptibility of a vancomycin-resistant *Staphylococcus aureus* strain isolated at the Hershey Medical Center. *J Antimicrob Chemother* 2003;52:864-868.

76. Fowler VG, Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N Engl J Med* 2006;355:653-665.

77. Raad II, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant *Enterococcus faecium* infections. *J Antimicrob Chemother* 2004;53:646-649.

78. Poutsika DD, Skiffington S, Miller KB, et al. Daptomycin in the treatment of vancomycin-resistant *Enterococcus faecium* bacteremia in neutropenic patients. *J Infect* 2007;54(6):567-571. Epub 2006 Dec 26.

79. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004;32:858-873.

80. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002;288:862-871.

81. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998;26:645-650.

82. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999;27:723-732.

83. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. *N Engl J Med* 2003;348:727-734.

84. Abraham E, Laterre PF, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. *N Engl J Med* 2005;353(13):1332-1341.

85. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001;344:699-709.

86. Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: a gLocal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. *Lancet* 2007;369(9564):836-843.

87. Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in neutropenic cancer patients: observations from two decades of epidemiologic and clinical trials. *Clin Infect Dis* 1997;25:247-259.

88. Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile

patients with neutropenia during cancer chemotherapy. *N Engl J Med* 1999;341:305-311.

89. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. *Cancer* 1993;7:3640-3646.

90. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. *Cancer* 1999;86:126-134.

91. Malik IA, Kahn WA, Karim M, et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. *Am J Med* 1995;98:224-231.

92. Klastersky J. Supportive Care in Cancer. Abstracts of the 14th MASCC International Symposium 2001;10(4).

93. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. *J Pediatr* 1996;128:847-849.

94. Karthaus M, Wolf HH, Kampfe D, et al. Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. *Chemotherapy* 1998;44:343-354.

95. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. *Am J Med* 1982;72:101-111.

96. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. *Clin Infect Dis* 2004;39:S38-S43.

97. Marr KA, Seidel K, White TC, et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. *J Infect Dis* 2000;181(1):309-316.

98. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *N Engl J Med* 1999;340:764-771.

99. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". *Clin Infect Dis* 2003;37:415-425. Epub 2003 Jul 22.

100. Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. *Kidney Int* 2001;60(4):1452-1459.

101. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. *Clin Infect Dis* 2001;32(5):686-693. Epub 2001 Feb 21.

102. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. *Clin Infect Dis* 1999;29(6):1402-1407.

103. Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. *Am J Med* 2000;108:282-289.

104. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. *Eur J Cancer* 1996;32A:814-820.

105. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. *Ann Intern Med* 2001;135:412-422.

106. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J Med* 2002;346:225-234.

107. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients

with persistent fever and neutropenia. *N Engl J Med* 2004;351(14):1391-1402.

108. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. *Clin Infect Dis* 2004;39(10):1407-1416.

109. van Burik JA. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. *Curr Opin Infect Dis* 2005;18(6):479-483.

110. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med* 2007;356:348-359.

111. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. *Clin Infect Dis* 2007;44(3):402-409. Epub 2007 Jan 2.

112. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the *Aspergillus* galactomannan enzyme immunoassay. *Clin Infect Dis* 2005;40:1762-1769.

113. Foy PC, van Burik JA, Weisdorf DJ. Galactomannan antigen enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2007;13(4):440-443. Epub 2007 Feb 1.

114. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. *Clin Infect Dis* 2006;42:1417-1727.

115. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. *Clin Infect Dis* 2005;41:1242-1250.

116. Elting LS, Rubenstein EB, Rolston K, et al. Time to clinical response: An outcome of antibiotic therapy of febrile neutropenia with

implications for quality and cost of care. *J Clin Oncol* 2000;18:3699-3706.

117. Serody JS, Berry MM, Albritton K, et al. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. *Bone Marrow Transplant* 2000;26:533-538.

118. Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. *Am J Med* 1979;67:194-200.

119. Mugge A, Daniel WG, Frank G, et al. Echocardiography in infective endocarditis: Reassessment of the prognostic implications of vegetation size determined by transthoracic and transesophageal approach. *J Am Coll Cardiol* 1989;14:631-638.

120. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis* 2000;30:633-638.

121. Daniel WG, Mugge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. *N Engl J Med* 1991;324:795-800.

122. Rosen AB, Fowler VG, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine duration of therapy for intravascular catheter associated *Staphylococcus aureus* bacteremia. *Ann Intern Med* 1999;130:810-820.

123. Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis: diagnosis, antimicrobial therapy, and management of complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. *Circulation* 2005;111:e394-e434e.

124. Wade JC, Newton B, McLaren C, et al. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: A double-blind trial. *Ann Intern Med* 1982;96:265-269.
125. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J Clin Oncol* 2006;24:3187-3205.
126. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol* 2000;18:3038-3051.
127. Rubenstein EB, Rolston KVI. Risk-adjusted management of the febrile neutropenic cancer patient. In: Rolston KVI, Rubenstein EB, eds. *Textbook of Febrile Neutropenia*. Martin Dunitz: London 2001:167-187.
128. Uys A, Rapoport BL, Anderson R. Febrile neutropenia: A prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. *Support Care Cancer* 2004;12:555-560.
129. Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. *J Clin Oncol* 2006;24:4129-4134.
130. Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. *Arch Intern Med* 1992;152:283-291.
131. Rubin M, Hathorn JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. *Cancer Invest* 1988;6:167-184.
132. Kohn L, Corrigan J, Donaldson M, eds. *Committee on Quality of Health Care in America: To err is human: building a safer health system*. Institute of Medicine Report. National Academy Press: Washington, D.C., 2000.
133. Kerr KG, Armitage HT, McWhinney PH. Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy. *Support Care Cancer* 1999;7:28-30.
134. Giamarellou H, Bassaris HP, Petrikos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. *Antimicrob Agents Chemother* 2000;44:3264-3271.
135. Paganini H, Rodriguez-Brieschke T, Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. *Cancer* 2001;91:1563-1567.
136. Baglin TP, Gray JJ, Marcus RE, et al. Antibiotic resistant fever associated with herpes simplex virus infection in neutropenic cancer patients with haematological malignancy. *J Clin Pathol* 1989;42:1255-1258.
137. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic subjects. *Clin Infect Dis* 2003;36:1221-1228.
138. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary care cancer center in the era of Aspergillus-active antifungal therapy: a case control observational study of 27 recent cases. *J Infect Dis* 2005;191:1350-1360.
139. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 2002;347:408-415.
140. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. *Crit Care Med* 1999;27:1066-1072.

141. Gorschluter M, Glasmacher A, Hahn C, et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001;33:786-791.
142. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-2441.
143. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449.
144. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586-1590.
145. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5(9):549-557.
146. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145(10):758-764.
147. Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007;45(2):222-227. Epub 2007 Jun 4.
148. Song HK, Kreisel D, Canter R, et al. Changing presentation and management of neutropenic enterocolitis. Arch Surg 1998;133:979-982.
149. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group. N Engl J Med 1999;340(1):1-8.
150. Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999;281(3):261-267.
151. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282(6):554-560.
152. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 2005;143(8):570-580.
153. Pittet D, Walder B, Tramèr MR. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. ICHE 2002;23:748-756.
154. Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006;43(4):474-484. Epub 2006 Jul 11.
155. O'Grady NP, Alexander M, Dellinger EP, et al; Healthcare Infection Control Practices Advisory Committee. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002;23(12):759-769.
156. Blot F, Nitenberg G, Chachaty E, et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 1999;354(9184):1071-1077.
157. Raad I, Hanna HA, Alakech B, et al. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004;140(1):18-25.
158. Krause R, Auner HW, Gorkiewicz G, et al. Detection of catheter-related bloodstream infections by the differential-time-to-positivity method and gram stain-acridine orange leukocyte cytospin test in neutropenic patients after hematopoietic stem cell transplantation. J Clin Microbiol 2004;42(10):4835-4837.
159. Abdelkefi A, Achour W, Ben Othman T, et al. Difference in time to positivity is useful for the diagnosis of catheter-related bloodstream infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;35(4):397-401.

160. Blot F, Schmidt E, Nitenberg G, Tancrede C, et al. Earlier positivity of central-venous- versus peripheral-blood cultures is highly predictive of catheter-related sepsis. *J Clin Microbiol* 1998;36(1):105-109.
161. La Quaglia MP, Caldwell C, Lucas A, et al. A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. *J Pediatr Surg* 1994;29:742-745.
162. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia. *Clin Infect Dis* 2007;44:S27-S72.
163. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and health-care associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388-416.
164. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. *Clin Infect Dis* 2007;44(3):373-379. Epub 2006 Dec 29.
165. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group [see comments]. *N Engl J Med* 1990;323:1451-1457.
166. Nguyen Q, Estey E, Raad I, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. *Clin Infect Dis* 2001;32:539-545.
167. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clin Infect Dis* 2004;39:199-205. Epub 2004 Jun 28.
168. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-->3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin Infect Dis* 2005;41:654-659.
169. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. *Chest* 2007;131:1173-1180.
170. Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. *Transpl Infect Dis* 2003;5:158-166.
171. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. *Lancet Infect Dis* 2004;4:349-357.
172. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. *J Infect Dis* 2004;190:641-649. Epub 2004 Jul 1.
173. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. *J Clin Oncol* 2002;20:1898-1906.
174. Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. *J Clin Microbiol* 2004;42:4744-4748.
175. Sulahian A, Touratier S, Ribaud P. False positive test for *Aspergillus* antigenemia related to concomitant administration of piperacillin and tazobactam. *N Engl J Med* 2003;349:2366-2367.
176. Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-d-glucan in patients receiving intravenous amoxicillin-clavulanic acid. *N Engl J Med* 2006;354:2834-2835.
177. Ogawa M, Hori H, Niiguchi S, et al. False-positive plasma (1-->3)-beta-D-glucan test following immunoglobulin product replacement in an adult bone marrow recipient. *Int J Hematol* 2004;80:97-98.

178. Masur H, Gill VJ, Ognibene FP, et al. Diagnosis of Pneumocystis pneumonia by induced sputum technique in patients without the acquired immunodeficiency syndrome. *Ann Intern Med* 1988;109:755-756.
179. Shelhamer JH, Toews GB, Masur H, et al. NIH conference. Respiratory disease in the immunosuppressed patient. *Ann Intern Med* 1992;117:415-431.
180. Levine SJ. An approach to the diagnosis of pulmonary infections in immunosuppressed patients. *Semin Respir Infect* 1992;7:81-95.
181. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. *Transplantation* 2007;83(10):1330-1336.
182. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. *J Clin Microbiol* 2007;45(6):1759-1765.
183. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004 Nov 1;39(9):1267-1284. Epub 2004 Oct 6.
184. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. *Clin Infect Dis* 1999;29:239-244.
185. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute [see comments]. *N Engl J Med* 1994;331:1325-1330.
186. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. *Lancet* 2005;366:1435-1442.
187. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. *N Engl J Med* 2002;347:2020-2029.
188. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. *Lancet* 2007;369(9572):1519-1527.
189. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clin Infect Dis* 2007;45(7):883-893. Epub 2007 Aug 29.
190. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. *N Engl J Med* 2007;356(24):2472-2482.
191. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. *Blood* 2005;106:2641-2645.
192. Denning DW. Therapeutic outcome in invasive aspergillosis. *Clin Infect Dis* 1996;23:608-615.
193. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. *Clin Infect Dis* 2002;35:359-366. Epub 2002 Jul 25.
194. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. *Clin Infect Dis* 2005;40:Suppl 6:S392-S400.
195. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). *Clin Infect Dis* 2007;44(10):1289-1297. Epub 2007 Apr 9.

196. Maertens J, Raad I, Petrikos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. *Clin Infect Dis* 2004;39:1563-1571. Epub 2004 Nov 9.
197. Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox^{-/-} mouse model of chronic granulomatous disease. *Antimicrob Agents Chemother* 2006;50:422-427.
198. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. *Antimicrob Agents Chemother* 2002;46:2564-2568.
199. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. *J Infect Dis* 2003;187:1834-1843.
200. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. *Antimicrob Agents Chemother* 2003;47:1452-1455.
201. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive aspergillosis. *Clin Microbiol Infect* 2004;10:925-928.
202. Sivak O, Bartlett K, Risovic V, et al. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. *J Pharm Sci* 2004;93:1382-1389.
203. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. *J Antimicrob Chemother* 2003;52:656-662.
204. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. *Cancer* 2003;97:1025-1032.
205. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. *Cancer* 2003;98:292-299.
206. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. *Clin Infect Dis* 2004;39:797-802. Epub 2004 Aug 27.
207. Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. *Cancer* 2006;107:2888-2897.
208. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. *J Infect* 2006;53(5):337-349. Epub 2006 May 6.
209. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. *Clin Infect Dis* 2006;42(12):1726-1734. Epub 2006 May 8.
210. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. *Antimicrob Agents Chemother* 2006;50:126-133.
211. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system infections. *J Antimicrob Chemother* 2005;56:745-755.
212. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. *Clin Infect Dis* 2006;42:1398-1403.
213. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or

intolerant of conventional therapy: an externally controlled trial. *Clin Infect Dis* 2007;44(1):2-12. Epub 2006 Nov 28.

214. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. *Clin Infect Dis* 2004;39:743-746. Epub 2004 Aug 13.

215. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. *N Engl J Med* 2004;350(9):950-952.

216. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2002;34:909-917.

217. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. *Clin Infect Dis* 2000;30:851-856.

218. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. *Clin Infect Dis* 2006 Apr 1;42(7):e61-65. Epub 2006 Feb 21. Erratum in: *Clin Infect Dis* 2006;43(10):1376.

219. Nucci M, Marr KA, Queiroz-Telles F, et al. *Fusarium* infection in hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2004;38:1237-1242. Epub 2004 Apr 15.

220. Boutati EI, Anaissie EJ. *Fusarium*, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. *Blood* 1997;90:999-1008.

221. Kontoyiannis DP, Bodey GP, Hanna H, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. *Leuk Lymphoma* 2004;45:139-141.

222. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. *Clin Microbiol Infect* 2004;10 Suppl 1:48-66.

223. Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. *Semin Respir Infect* 2002;17:113-120.

224. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. *Clin Infect Dis* 2003;36:1122-1131.

225. Perfect JR. Treatment of non-*Aspergillus* moulds in immunocompromised patients, with amphotericin B lipid complex. *Clin Infect Dis* 2005;40:Suppl 6:S401-408.

226. Kuhlman JE, Fishman EK, Burch PA, et al. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. *Chest* 1987;92:95-99.

227. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. *J Clin Oncol* 1997;15:139-147.

228. Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. *J Infect Dis* 2002;186:1297-1306.

229. Ascoglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin Infect Dis* 2002;34:7-14.

230. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. *J Clin Oncol* 1998;16:1179-1187.

231. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. *Am J Med* 1988;84:847-854.

232. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002;34:730-751.
233. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. *Ann Intern Med* 2005;142:979-995.
234. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. *N Engl J Med* 2005;353:988-998.
235. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. *N Engl J Med* 2005;353:977-987.
236. Bartlett JG, Perl TM. The new *Clostridium difficile* – what does it mean? *N Engl J Med* 2005;353:2503-2505.
237. Cook PP, Catrou P, Gooch M, Holbert D. Effect of reduction in ciprofloxacin use on prevalence of methicillin-resistant *Staphylococcus aureus* rates within individual units of a tertiary care hospital. *J Hosp Infect* 2006;64(4):348-351. Epub 2006 Oct 12.
238. British Committee for Standards in Haematology Guideline 2001; update of guidelines initially published in 1996: <http://www.bmj.com/cgi/eletters/312/7028/430#EL1>
239. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. *BMJ* 1996;312:430-434.
240. Youssef S, Rodriguez G, Rolston KV, et al. *Streptococcus pneumoniae* infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. *Medicine (Baltimore)* 2007;86(2):69-77.
241. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation [see comments]. *N Engl J Med* 1992;326:845-851.
242. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. *J Infect Dis* 1995;171:1545-1552.
243. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. *Blood* 2000;96:2055-2061.
244. Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group [In Process Citation]. *Clin Infect Dis* 1999;28:331-340.
245. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial [see comments]. *Ann Intern Med* 1993;118:495-503.
246. Kern W, Behre G, Rudolf T, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. *Cancer* 1998;83:291-301.
247. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of *Candida glabrata* and *Candida albicans* fungemia in immunocompromised patients with cancer. *Am J Med* 2002;112(5):380-385.
248. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant

recipients. A multicenter, randomized trial. *Ann Intern Med* 2003;138:705-713.

249. Koh LP, Kurup A, Goh YT, et al. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. *Am J Hematol* 2002;71(4):260-267.

250. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in allogeneic stem cell transplant patients. *Blood* 2004;103(4):1527-1533.

251. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is impacted by azole antifungals. *Blood* 2004;103(4):1557-1559.

252. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. *Clin Infect Dis* 2006;42:1179-1186.

253. Böhme A, Just-Nübling G, Bergmann L, et al. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. *J Antimicrob Chemother* 1996;38(6):953-961.

254. Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of *Aspergillus* as a major cause of death. *Medicine (Baltimore)* 1992;71:24-43.

255. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med* 2007;356:335-347.

256. Walsh TJ, Whitcomb PO, Revankar SG, et al. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. *Cancer* 1995;76:2357-2362.

257. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. *Clin Infect Dis* 1998;26:1098-1103.

258. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. *Biol Blood Marrow Transplant* 2004;10:494-503.

259. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. *J Infect Dis* 1980;142:338-346.

260. Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. *Ann Intern Med* 1983;99:773-776.

261. Boeckh M, Kim HW, Flowers MED, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation – a randomized double-blind placebo-controlled study. *Blood* 2006;107:1800-1805.

262. Tong Y, Qian J, Li Y, et al. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. *Am J Hematol* 2007;82(5):403-404.

263. Varettoni M, Vassallo C, Borroni G, et al. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. *Ann Hematol* 2007;86:301-302.

264. Prentice HG, Kho P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. *Bone Marrow Transplant* 1997;19:135-142.

265. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. *Lancet* 1994;343:749-753.

266. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. *N Engl J Med* 1988;318:70-75.

267. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valgancyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. *Blood* 2002;99:3050-3056.
268. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. *Blood* 2002;99:1159-1164.
269. Winston DJ, Baden LR, Gabriel DA, et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. *Biol Blood Marrow Transplant* 2006;12:635-640.
270. Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2006;37:851-856.
271. van der Heiden PL, Kalpoe JS, Barge RM, et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. *Bone Marrow Transplant* 2006;37:693-698.
272. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. *Blood* 2006;107:3002-3008.
273. Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. *Clin Infect Dis* 1999;28(3):618-623.
274. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. *Blood* 2003;101:407-414.
275. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. *Blood* 2003;102(8):3060-3067. Epub 2003 Jul 3.
276. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. *Blood* 2002;99:1978-1985.
277. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. *Blood* 2001;98:1358-1364.
278. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis Bs-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. *J Clin Oncol* 2004;22;927-934.
279. Bréchet C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. *N Engl J Med* 1985;312(5):270-276.
280. Dhédin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. *Transplantation* 1998;66(5):616-619.
281. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. *Hepatology* 2002;36(3):702-709.
282. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. *Br J Haematol* 2001;115(1):58-62.

283. Ljungman P, Engelhard D, de la Cámara R, et al; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. *Bone Marrow Transplant* 2005;35(8):737-746.

284. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2006;55(RR15):1-48.

285. Ortals DW, Liebhaber H, Presant CA, et al. Influenza immunization of adult patients with malignant diseases. *Ann Intern Med* 1977;87(5):552-557.

286. Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. *J Oncol Pharm Pract* 2006;12(3):143-154.

287. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. *Clin Infect Dis* 1996;22:778-782.

288. Ljungman P. Respiratory virus infections in stem cell transplant patients: The European experience. *Biol Blood Marrow Transplant* 2001;[7 suppl]:5S-7S.

289. Bowden RA. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience. *Am J Med* 1997;102:27-30.

290. Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. *Cancer* 1977;39:350-353.

291. Kempe A, Hall CB, MacDonald NE, et al. Influenza in children with cancer. *Journal of Pediatrics* 1989;115:33-39.

292. Elting LS, Whimbey E, Lo W, et al. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. *Support Care Cancer* 1995;3:198-202.

293. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the advisory Committee on Immunization Practices (ACIP). *MMWR* 2003;52 (RR-8):1-34.

294. Health Canada. Statement on influenza vaccination for the 2003-2004 season: an Advisory Committee Statement (ACS) from the National Advisory Committee on Immunization (NACI). *Canada Communicable Disease Report*. 2003;29 (ACS-4):1-20.

295. Department of Health, UK. Summary of flu immunisation policy. Key points about flu immunisation policy in England. (http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/Flu/Flugeneralinformation/DH_4001688) (Accessed November 30, 2007).

296. Harper SA, Fukuda K, Cox NJ, et al; Centers for Disease Control and Prevention. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2003;52(RR-13):1-8.

297. Hughes WT, Rivera GK, Schell MJ, et al. Successful intermittent chemoprophylaxis for *Pneumocystis carinii* pneumonitis. *N Engl J Med* 1987;316:1627-1632.

298. Vasconcelles MJ, Bernardo MV, King C, et al. Aerosolized pentamidine as *Pneumocystis* prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. *Biol Blood Marrow Transplant* 2000;6(1):35-43.

299. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. *N Engl J Med* 1998;339:1889-1895.

300. Sepkowitz KA. *Pneumocystis carinii* pneumonia among patients with neoplastic disease. *Semin Respir Infect* 1992;7(2):114-121.

301. Hahn T, Cummings KM, Michalek AM, et al. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. *Infect Control Hosp Epidemiol* 2002;23:525-531.

302. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. *N Engl J Med* 1971;284:1061-1065.